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ABSTRACT 
Xiaomeng Wan: Poly(2-oxazoline) micellar formulation for cancer therapy 
 (Under the direction of Alexander Kabanov) 
Most nanoparticles have a fairly low threshold for incorporation of such drugs. Previously, 
we have reported a nanosized polymeric micelles (PM) formulation based on highly defined 
amphiphilic triblock copolymers of poly(2-oxazoline)s (POx), poly(2-methyl-2-oxazoline-block-
2-butyl-2-oxazoline-block-2-methyl-2-oxazoline) (P(MeOx-b-BuOx-b-MeOx)), that have greatly 
enhanced the solubility of single and multiple drug combinations. [1, 2] In particular, the POx-based 
PM of paclitaxel (PTX) with unprecedentedly high drug loading of nearly 45 % wt. and 
controllable ~30 to 40 nm size displayed reduced toxicity and superior efficacy in early and late 
stage breast cancer models compared to clinically approved Taxol and Abraxane. [3] 
The co-delivery of drugs in a single nanofomulation remains a principal challenge since 
poor solubility and differential pharmacokinetics (PK) severely restricts the selection of drugs that 
can be translated into successful combination treatments. Critical to success is optimizing the 
relative doses of the drugs to obtain synergistic effects on tumors [4]. Here, we propose that co-
loading of PTX and hydrophobic cisplatin prodrug at synergistic drugs ratios in the POx-based 
drug delivery platform significantly improve the PK profile and efficacy in both ovarian and breast 
cancer.  
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We also propose that co-loading of etoposide (ETO) and platinate at synergistic drugs 
ratios in the POx-based drug delivery platform with “worm-like” shape micelles can safely and 
efficiently treat both SCLC and NSCLC lung cancer. 
In summary, tri-block POx copolymer is a viable and promising platform for various 
chemotherapeutic agents, singly and multiply, delivery in cancer therapy.   
iv 
V 
 
 
To my parents Jing Cheng and Limin Wan, my beloved grandmother, Shuzhen Li, and my cutest 
cat Tippi. 
  
v 
VI 
 
 
ACKNOWLEDGMENTS 
First of all, I would like to express my sincere gratitude to my advisor Prof. Alexander 
Kabanov for his who offered me this great educational opportunity in his lab and constant support 
throughout my PhD journey, for his priceless guidance, patience, motivation, and extraordinary 
wisdom. He is an exceptional and remarkable mentor I am so blessed to have, and I will be forever 
thankful to his inspiration, mentorship in not only research but other aspect in life.   
I would also like to thank my committee members, Prof. Leaf Huang, Prof. William 
Zamboni, Dr. Carey Anders and Prof. Elena Batrakova for their precious encouragement, 
guidance, support and help throughout the years. In addition, I would like to thank Dr. Marina 
Solkosky for her continual understanding, support and tremendous help in both my research 
studies and overcoming life issues in the years. I would like to extend my special appreciation to 
Dr. Rainer Jordan, Dr. Robert Luxenhofer, Dr. Yuanzeng Min, Dr. Andrew Wang, Dr. Zibo Li, 
Dr. Hui Wang, Dr. Herdis Bludau, Mr. Andrew Keith and former lab members Dr. Zhijian (Jimmy) 
for their collaboration and as my external advisors.  
Moreover, I want to express my gratitude to UNC Eshelman School of Pharmacy and 
UNMC School of Pharmacy for allowing me pursuing higher education. I wouldn’t have 
successfully completed my graduate research projects without support, company and friendship 
from my lab mates. Ms. Yuling Zhao, Mr. Youngee Seo, Dr. Yi Zhao, Dr. Dongfen Yuan, Mr. 
Duhyeong Hwang, Mr. Matt Haney, Dr. Dasha Filonova, Dr. Vivek Mahajan, Dr. Hemant 
Vishwasrao, Dr. Soo Kim, Dr. Si Qin, Ms. Jubina Bregu, Mr. Nazar Filonov, and Ms. Shu Li, 
vi 
VII 
 
along with all past and present members of Kabanov Lab. I also want to thank my friends from 
other labs for their kind help throughout my study: Dr. Lei Miao, Dr. Hao Cai, Dr. Junghyun (Jay) 
Kim, Ms. Naihan Chen, Dr. Qiaoxi Li, Dr. Yu Mi and Dr. Feifei Yang.  
My thesis work involves interdisciplinary efforts which is not possible to be conducted by 
myself. I want to express my sincere thanks to all the core facility managers who have kindly 
allowed me to use their instruments and trained me to use them with confidence. Dr. Bob Bagnell 
and Ms. Victoria (Vichy) Madden for their help with my confocal microscopy experiments; Dr. 
Wallace Ambrose and Dr. Amar S. Kumbhar for helping me with TEM and AFM to characterize 
my nanoparticles; Dr. Michael Jay, and Dr. Zibo Li for kindly letting me use their gamma counters 
for my pharmacokinetic analysis; Dr. Hong Yuan, Mr. Jonathan Frank, and Mr. Joseph Merrill for 
their help with my IVIS imaging and PET imaging in my projects. 
Last but not least, I would particularly thank my parents, Limin Wan and Jing Cheng, and 
my dearest cat Tippi for their unconditional support and love all along the journey. I cannot go this 
far without their understanding, patience, standing by my side, faith and love. 
 
 
 
  
vii 
VIII 
 
 
TABLE OF CONTENTS 
LIST OF TABLES ..................................................................................................................xii 
LIST OF FIGURES ............................................................................................................... xiv 
LIST OF ABBREVIATIONS AND SYMBOLS .................................................................. xvii 
CHAPTER 1  INTRODUCTION ......................................................................................... 1 
1.1 Clinical Sate of Polymeric Micelle (PM) on Cancer Treatment .......................................... 2 
1.1.1 Taxane-based chemotherapy (paclitaxel and docetaxel)........................................................... 2 
1.1.1 Platinum-based chemotherapy (cisplatin and oxaliplatin) ........................................................ 6 
1.1.2 Doxorubicin-based chemotherapy ........................................................................................... 7 
1.1.3 Other compounds based chemotherapy ................................................................................... 7 
1.2 Polymeric micelles in anticancer therapy ............................................................................. 9 
1.2.1 High drug loading capacity ..................................................................................................... 9 
1.2.2 Controlled release ................................................................................................................. 10 
1.2.3 Biodistribution and pharmacokinetics profile ........................................................................ 10 
1.3 Polymeric micelles for multi-drug delivery in cancer ........................................................ 12 
1.3.1 Combination index (CI) ........................................................................................................ 12 
1.3.2 Concurrent multiple drug delivery ........................................................................................ 13 
1.3.3 Sequential multiple drug delivery.......................................................................................... 13 
1.4 The influence of nanoparticle shape on cancer drug delivery ........................................... 15 
1.4.1 Circulation ............................................................................................................................ 15 
1.4.2 Biodistribution and target delivery ........................................................................................ 16 
viii 
IX 
 
1.4.3 Cellular uptake ..................................................................................................................... 16 
1.4.4 Anticancer efficacy and cytotoxicity ..................................................................................... 17 
1.5 Conclusion ........................................................................................................................... 18 
CHAPTER 2 : A HIGH CAPACITY POLYMERIC MICELLE OF PACLITAXEL: 
IMPLICATION OF HIGH DOSE DRUG THERAPY TO SAFETY AND IN VIVO 
ANTI-CANCER ACTIVITY 1................................................................................................ 21 
2.1 Summary ............................................................................................................................. 21 
2.2 Introduction ........................................................................................................................ 22 
2.3 Materials and Methods ....................................................................................................... 25 
2.3.1 Materials .............................................................................................................................. 25 
2.3.2 Preparation of POx/PTX polymeric micelles ......................................................................... 25 
2.3.3 In vitro complement activation, hemolysis, blood coagulation and cytotoxicity ..................... 27 
2.3.4 Serum albumin quenching studies ......................................................................................... 27 
2.3.5 Serum binding studies ........................................................................................................... 28 
2.3.6 In vivo studies ....................................................................................................................... 29 
2.3.7 PK and biodistribution studies .............................................................................................. 31 
2.3.8 PK and data analysis ............................................................................................................. 32 
2.4 Results ................................................................................................................................. 33 
2.4.1 Characterization of PTX-loaded POx micelles ...................................................................... 33 
2.4.2 Serum binding studies ........................................................................................................... 33 
2.4.3 MTD and toxicology profiles of POx/PTX in nude or healthy mice ....................................... 34 
2.4.4 Drug PK and biodistribution of POx/PTX compared to Taxol ............................................... 37 
2.4.5 Antitumor efficacy and tumor accumulation of POx/PTX ..................................................... 40 
2.5 Discussion ............................................................................................................................ 42 
CHAPTER 3 : CO-DELIVERY OF PACLITAXEL AND CISPLATIN IN HIGH 
CAPACITY POLY(2-OXAZOLINE) POLYMERIC MICELLES IMPROVES 
TREATMENT OF OVARIAN AND BREAST CANCER 1 .................................................. 71 
3.1 Summary ............................................................................................................................. 71 
ix 
X 
 
3.2 Introduction ........................................................................................................................ 72 
3.3 Materials and Methods ....................................................................................................... 74 
3.3.1 Materials .............................................................................................................................. 74 
3.3.2 Synthesis of 64Cu-DOTA-POx .............................................................................................. 74 
3.3.3 Synthesis and characterization of hydrophobic platinum (IV) prodrugs (CPs) ........................ 75 
3.3.4 Preparation and characterization of POx PM ......................................................................... 75 
3.3.5 In vitro drug release .............................................................................................................. 76 
3.3.6 In vitro cytotoxicity assays.................................................................................................... 77 
3.3.7 Pharmacokinetics (PK) and tumor accumulation ................................................................... 77 
3.3.8 Efficacy and tumor accumulation studies .............................................................................. 78 
3.3.9 Statistical Analysis ............................................................................................................... 80 
3.4 Results ................................................................................................................................. 81 
3.4.1 Synthesis of CPs ................................................................................................................... 81 
3.4.2 Preparation and characterization of PTX and CP loaded POx PM .......................................... 81 
3.4.3 Drug co-loading in the PM slows down drug release compared to single-drug PM ................ 82 
3.4.4 Drug combination micelles exhibit synergy in ovarian cancer cells ....................................... 83 
3.4.5 PK and tumor accumulation in A2780/CisR ovarian tumor bearing mice............................... 84 
3.4.6 In vivo efficacy ..................................................................................................................... 86 
3.5 Discussion ............................................................................................................................ 90 
CHAPTER 4 : DRUG COMBINATION SYNERGY IN WORM-LIKE 
POLYMERIC MICELLES IMPROVES TREATMENT OUTCOME FOR SMALL 
CELL AND NON-SMALL CELL LUNG CANCER 1 ........................................................ 115 
4.1 Summary ........................................................................................................................... 115 
4.2 Introduction ...................................................................................................................... 116 
4.3 Materials and Methods ..................................................................................................... 118 
4.3.1 Materials ............................................................................................................................ 118 
4.3.2 Synthesis and characterization of hydrophobic platinum (IV) prodrugs (CPs) ...................... 118 
x 
XI 
 
4.3.3 Preparation and characterization of drug loaded POx PM .................................................... 119 
4.3.4 In vitro drug release ............................................................................................................ 120 
4.3.5 Serum binding studies ......................................................................................................... 120 
4.3.6 In vitro cytotoxicity and combination index (CI) analysis .................................................... 121 
4.3.7 In vitro cell uptake .............................................................................................................. 122 
4.3.8 Maximum Tolerable Dose (MTD) determination ................................................................ 122 
4.3.9 Toxicology studies .............................................................................................................. 123 
4.3.10 PK and tumor accumulation .............................................................................................. 123 
4.3.11 In vivo tumor growth inhibition ......................................................................................... 124 
4.3.12 Tumor sections histology .................................................................................................. 125 
4.3.13 Statistical Analysis ........................................................................................................... 126 
4.4 Results ............................................................................................................................... 127 
4.4.1 Synthesis of CPs ................................................................................................................. 127 
4.4.2 Preparation and characterization of drug-loaded micelles .................................................... 127 
4.4.3 Drug release and serum binding are decreased in co-loaded C6CP/ETO PM ........................ 130 
4.4.4 Combination C6CP/ETO PM display high activity drug synergy in cancer cells................... 132 
4.4.5 Combination C6CP/ETO PM increase drug accumulation in cancer cells ............................. 133 
4.4.6 Toxicology studies MTD and toxicology profiles of co-loaded C6CP/ETO PM ................... 133 
4.4.7 Combination C6CP/ETO PM have improved PK in tumor-bearing mice .............................. 134 
4.4.8 Combination C6CP/ETO PM have superior anti-tumor activity in vivo ................................ 135 
4.4.9 Combination C6CP/ETO PM increase DNA damage and apoptosis in tumors ...................... 137 
4.5 Discussion .......................................................................................................................... 138 
CHAPTER 5  SUMMARY AND FUTURE DIRECTIONS ............................................ 177 
REFERENCES ..................................................................................................................... 179 
 
xi 
XII 
 
LIST OF TABLES 
TABLE 1.1 POLYMERIC MICELLES IN CLINICAL STUDIES. ..................................................................19 
TABLE 2.1 DRUG CONCENTRATION, LOADING EFFICIENCY (LE), LOADING 
CAPACITY (LC), DRUG LOADED MICELLE SIZE AND PDI OF POX/PTX 
FORMULATIONS. ...............................................................................................................................47 
TABLE 2.2 SIZE AND PDI OF TWO POX/PTX FORMULATIONS BEFORE AND AFTER 
LYOPHILIZATION. ............................................................................................................................48 
TABLE 2.3 SPE COLUMN SEPARATION OF POX/PTX 50/40. ....................................................................49 
TABLE 2.4 SPE COLUMN SEPARATION OF PTX DISSOLVED IN ETOH/WATER.................................50 
TABLE 2.5 SPE COLUMN SEPARATION OF SERUM SAMPLES INCUBATED WITH 
POX/PTX 50/40, POX/PTX 50/20, OR TAXOL AND FREE PTX FOR 1H AND 4H.........................51 
TABLE 2.6  SUMMARY OF CYTOTOXICITY TO LIVER HEP G2 AND KIDNEY LLC-PK1 
CELLS. ..................................................................................................................................................52 
TABLE 2.7 MONITORING OF ANIMAL WEIGHT AND BEHAVIOR TO DETERMINE THE 
MAXIMUM TOLERATED DOSE. ......................................................................................................53 
TABLE 2.8 CLINICAL CHEMISTRY PARAMETERS OF BALB/C MICE RECEIVING 
SALINE, POX AND POX/PTX AND TAXOL. ....................................................................................54 
TABLE 2.9 PK PARAMETERS OF PTX FOR PLASMA AND ORGANS IN TUMOR-FREE 
NUDE MICE. ........................................................................................................................................55 
TABLE 2.10 PK PARAMETERS OF PTX FOR PLASMA AND ORGANS IN TUMOR 
BEARING MICE. .................................................................................................................................56 
TABLE 3.1 CHARACTERISTICS OF C6CP/ETO PMA. ..................................................................................95 
TABLE 3.2 PK PARAMETERS OF C6CP AND PTX IN PLASMA AND TUMOR AFTER 
ADMINISTERING PM IN A2780/CISR TUMOR BEARING MICE. ................................................97 
TABLE 3.3 PK PARAMETERS OF C8CP AND PTX IN PLASMA AND TUMOR AFTER 
ADMINISTERING PM IN A2780/CISR TUMOR BEARING MICE. ................................................98 
TABLE 3.4 PK PARAMETERS OF POX POLYMER IN PLASMA AND TUMOR IN 
A2780/CISR TUMOR BEARING MICE. ............................................................................................99 
TABLE 3.5 COMPARISON OF PK PARAMETERS OF DRUGS IN PM IN PLASMA AND 
TUMOR IN A2780/CISR TUMOR BEARING MICE. ...................................................................... 100 
xii 
XIII 
 
TABLE 3.6 STATISTICAL COMPARISONS OF TUMOR GROWTH BETWEEN GROUPS. 
(BY ONE-WAY ANOVA WITH HOLM-SIDAK POST-HOC TEST FOR MULTIPLE 
COMPARISONS AT A SIGNIFICANCE LEVELS OF P < 0.05 (*, P < 0.05, **, P < 0.01, 
***, P < 0.001) ..................................................................................................................................... 101 
TABLE 3.7 STATISTICAL COMPARISONS OF ANIMAL SURVIVAL BY LOG-RANK 
(MANTEL-COX) TEST. ..................................................................................................................... 103 
TABLE 4.1 CHARACTERISTICS OF ETO LOADED PM.A ......................................................................... 142 
TABLE 4.2 CHARACTERISTICS OF C4CP LOADED PM. ......................................................................... 143 
TABLE 4.3 CHARACTERISTICS OF C6CP LOADED PM. ......................................................................... 143 
TABLE 4.4 CHARACTERISTICS OF C8CP LOADED PM. ......................................................................... 144 
TABLE 4.5 CHARACTERISTICS OF C10CP LOADED PM. ........................................................................ 144 
TABLE 4.6 CHARACTERISTICS OF C6CP/ETO PM.A ................................................................................ 145 
TABLE 4.7 SERUM BINDING OF DRUGS IN PM. ....................................................................................... 146 
TABLE 4.8 CYTOTOXICITY OF THE SINGLE DRUG AND CO-LOADED DRUG PM IN 
SCLC H69AR AND NSCLC 344SQ/LUC. CELL LINES. ................................................................. 147 
TABLE 4.9 IC50 VALUES OF SINGLE CP PM AND FREE DRUG IN SCLC H69AR AND 
NSCLC 344SQ/LUC. CELL LINES. .................................................................................................. 148 
TABLE 4.10 CLINICAL CHEMISTRY PARAMETERS OF H69AR TUMOR BEARING 
FEMALE NU/NU MICE. .................................................................................................................... 149 
TABLE 4.11 PK PARAMETERS OF ETO AND C6CP IN PLASMA AND TUMOR IN H69AR 
TUMOR BEARING MICE. (N=3)...................................................................................................... 150 
TABLE 4.12 STATISTICAL COMPARISONS OF TUMOR GROWTH BETWEEN GROUPS. ................ 152 
TABLE 4.13 STATISTICAL COMPARISONS OF ANIMAL SURVIVAL BY LOG-RANK 
(MANTEL-COX) TEST. ..................................................................................................................... 154 
CHAPTER I   
xiv xiii 
XIV 
 
LIST OF FIGURES 
FIGURE 1.1 SCHEMATIC EXAMPLES OF VARIOUS SHAPES OF NANOPARTICLES. .........................20 
FIGURE 2.1 STANDARD OPERATING PROCEDURE (SOP) FOR SMALL SCALE (1-5 MG) 
MICELLE PRODUCTION...................................................................................................................58 
FIGURE 2.2 CONSTRUCTION AND PHYSICOCHEMICAL PROPERTIES OF PTX 
NANOFORMULATIONS. ....................................................................................................................59 
FIGURE 2.3 CHARACTERIZATION OF POX/PTX FORMULATION. ........................................................60 
FIGURE 2.4 IN VITRO TOXICITY EVALUATION. ......................................................................................61 
FIGURE 2.5 MTD IN TUMOR BEARING NUDE MICE AND TOXICOLOGY PROFILES. .......................62 
FIGURE 2.6 TISSUE BIODISTRIBUTION AND PET/CT IMAGES OF TUMOR BEARING 
(A2780 XENOGRAFT) NUDE MICE OBTAINED AFTER I.V. INJECTION OF 
FORMULATIONS CONTAINING 0.2 MCI 64CU-POX. ...................................................................63 
FIGURE 2.7 QUENCHING OF BSA FLUORESCENCE BY MICELLAR PTX.............................................64 
FIGURE 2.8 PHARMACOKINETICS, BIODISTRIBUTION AND TUMOR INHIBITION IN 
A2780 HUMAN OVARIAN TUMOR BEARING MICE. ....................................................................65 
FIGURE 2.9 PK AND BIODISTRIBUTION IN TUMOR FREE NUDE MICE. ..............................................66 
FIGURE 2.10 PHARMACOKINETICS IN A2780 HUMAN OVARIAN TUMOR BEARING 
MICE. ....................................................................................................................................................67 
FIGURE 2.11 BIODISTRIBUTION OF POX AND PTX IN A2780 XENOGRAFT MICE. ............................68 
FIGURE 2.12 ANTITUMOR EFFICACY OF PTX FORMULATIONS IN A2780 TUMORS OF 
SMALL SIZE. .......................................................................................................................................69 
FIGURE 2.13 ANTITUMOR EFFICACY OF VARIOUS PTX FORMULATIONS IN 
DIFFERENT TUMORS. .......................................................................................................................70 
FIGURE 3.1 STRUCTURE OF CP AND THEIR REDUCTION TO FREE CISPLATIN............................. 104 
FIGURE 3.2 1H-NMR OF CISPLATIN PRODRUGS (CPS). ......................................................................... 105 
FIGURE 3.3 ELECTROSPRAY IONIZATION MASS SPECTRA (ESI-MS) ANALYSIS OF 
CPS. ..................................................................................................................................................... 107 
xiv 
XV 
 
FIGURE 3.4 PHYSICOCHEMICAL CHARACTERIZATION OF PTX/CP PM. ......................................... 108 
FIGURE 3.5 DRUG RELEASE PROFILES OF PTX AND CP FROM SINGLE AND 
COMBINATION DRUG PM CONTAINING PTX AND (A, B) C6CP, (C) C8CP AND 
(D) C10CP. .......................................................................................................................................... 109 
FIGURE 3.6  IN VITRO CYTOTOXICITY OF PTX/CP PM IN A2780/CISR HUMAN 
OVARIAN CANCER CELL LINES. ................................................................................................. 110 
FIGURE 3.7  IN VITRO CYTOTOXICITY OF SINGLE AND COMBINATION DRUG PM IN 
(A, B) A2780/CISR AND (C) A2780 CELL LINES. ........................................................................... 111 
FIGURE 3.8  IN VITRO CYTOTOXICITY OF PTX/CP PM IN A2780 HUMAN OVARIAN 
CANCER CELL LINE........................................................................................................................ 112 
FIGURE 3.9  PHARMACOKINETICS AND BIODISTRIBUTION IN A2780/CISR HUMAN 
OVARIAN TUMOR BEARING MICE. ............................................................................................. 113 
FIGURE 3.10  ANTI-TUMOR EFFECTS OF THE SINGLE AND COMBINATION DRUG 
POLYMERIC MICELLES. ................................................................................................................ 114 
FIGURE 4.1 SCHEME OF CO-DELIVERY OF ETOPOSIDE AND CISPLATIN PRODRUG 
VIA POLY (2-OXAZOLINE) CO-POLYMERIC MICELLE. .......................................................... 156 
FIGURE 4.2 PREPARATION OF BINARY PM CONTAINING ETO AND CPS......................................... 157 
FIGURE 4.3 CHARACTERIZATIONS OF C6CP/ETO PM FORMULATIONS. ......................................... 158 
FIGURE 4.4 SOLUBILIZATION OF ETO LOADED POX PM. ................................................................... 159 
FIGURE 4.5 CHARACTERIZATION OF SINGLE CPS LOADED MICELLE. .......................................... 160 
FIGURE 4.6 TYPICAL AFM IMAGES AND PARTICLE AREA HISTOGRAMS FOR EMPTY 
POX PM AND DRUG LOADED MICELLES, C6CP/ETO PM (4/8/10). ......................................... 161 
FIGURE 4.7 AFM SIZE MEASUREMENT FOR EMPTY POX PM. ............................................................ 162 
FIGURE 4.8 AFM SIZE MEASUREMENT FOR DRUG CO-LOADED C6CP/ETO PM (4/8/10). .............. 163 
FIGURE 4.9 AFM POPULATION ANALYSIS FOR DRUG CO-LOADED C6CP/ETO PM 
(4/8/10). ................................................................................................................................................ 164 
FIGURE 4.10 POPULATION SEPARATION BY CIRCULARITY OF PARTICLES IN AFM 
IMAGES FOR DRUG CO-LOADED C6CP/ETO PM (4/8/10). ........................................................ 165 
xv 
XVI 
 
FIGURE 4.11 POPULATION SEPARATION BY CIRCULARITY OF PARTICLES IN AFM 
IMAGES FOR DRUG CO-LOADED C6CP/ETO PM (4/8/10). ........................................................ 166 
FIGURE 4.12 DRUG RELEASE PROFILES FOR SINGLE AND CO-LOADED DRUG PM...................... 167 
FIGURE 4.13 CYTOTOXICITY, SYNERGY AND DRUG UPTAKE FOR SINGLE AND CO-
LOADED DRUG PM IN (A, B) SCLC H69AR AND (C-F) NSCLC 344SQ/LUC. CELL 
LINES. ................................................................................................................................................. 168 
FIGURE 4.14 IN VITRO CYTOTOXICITY OF SINGLE CPS LOADED MICELLES. .............................. 169 
FIGURE 4.15 HISTOLOGICAL EXAMINATION KIDNEY AND TUMOR TISSUES BY 
HEMOTOXYLIN & EOSIN (H&E) STAINING. .............................................................................. 170 
FIGURE 4.16 PK AND TUMOR ACCUMULATION OF C6CP AND ETO IN H69AR SCLC 
BEARING MICE. ............................................................................................................................... 171 
FIGURE 4.17 BIODISTRIBUTION AFTER SINGLE I.V. INJECTION OF VARIOUS POX 
MICELLE FORMULATIONS AT 1HR P.I. (N=3) ........................................................................... 172 
FIGURE 4.18 ANTI-TUMOR EFFECTS OF THE SINGLE AND CO-LOADED DRUG PM IN 
NCSLC AND SCLC ANIMAL MODELS. ......................................................................................... 173 
FIGURE 4.19 EFFICACY OF VARIOUS DRUG FORMULATIONS IN 344SQ-LUC LUNG 
CANCER MODEL. ............................................................................................................................. 174 
FIGURE 4.20 KAPLAN-MEIER SURVIVAL PLOT SHOWING ANTI-TUMOR EFFECTS OF 
THE SINGLE AND CO-LOADED DRUG PM IN 344SQ/LUC. NCSLC ANIMAL 
MODEL. .............................................................................................................................................. 175 
FIGURE 4.21 KAPLAN-MEIER SURVIVAL PLOT IN VARIOUS TREATMENT GROUPS. ................... 176 
xvi 
  xvii 
LIST OF ABBREVIATIONS AND SYMBOLS 
ABC accelerated blood clearance 
ACN acetonitrile 
AFM atomic force microscope 
ALP alkaline phosphatase 
ALT alanine aminotransferase 
AML acute myeloid leukemia 
ASCO American Society of Clinical Oncology 
Asp aspartic acid 
AUC area under the curve 
BC breast cancer 
BD biodistribution 
BMS Bristol-Myer Squibb 
BSA bovine serum albumin 
BUN blood urea nitrogen 
CI combination index 
CLSM confocal laser scanning microscopy 
Cmax maximum concentration 
CMC critical micelle concentration 
CNT carbon nanotube 
CP cisplatin prodrug 
CrEL Cremophor EL  
ii 
  xviii 
DAPI 4',6-diamidino-2-phenylindole 
DC drug concentration 
Deff effective diameter 
DLS dynamic light scattering 
DMEM Dulbecco’s Modified Eagle Medium 
DMF dimethylformamide 
DMSO dimethyl sulfoxide 
DMPC 1,2-dimyristoyl-sn-glycero-3-phosphocholine 
DNA deoxyribonucleic acid 
DOPA 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine 
DOPC 1,2-dioleoyl-sn-glycero-3-phosphocholine 
DOTA tetraazacyclododecane-1,4,7,10-tetraacetic acid 
DOX doxorubicin 
DSPE 1,2-distearoyl-sn-glycero-3-phosphoethanolamine 
DTX docetaxel 
ECM extracellular matrix 
EDC 1-ethyl-3-[3-(dimethylamino)propyl] carbodiimide 
EDTA ethylenediaminetetraacetic acid 
EP/PE etoposide and platinum drug combination  
EPR enhanced permeability and retention 
ER estrogen receptor 
ETO etoposide 
  xix 
EtOH ethanol 
FBS fetal bovine serum 
FDA Food and Drug Administration 
GEM genetically engineered mouse 
GPC gel permeation chromatography 
h hours 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
H&E hematoxylin & eosin 
HPLC high-performance liquid chromatography 
ICP-MS inductively coupled plasma mass spectrometry 
IC50 half maximal inhibitory concentration 
ID injected dosage 
i.p. intraperitoneal 
i.v. intravenous 
IVIS international veterinary information service 
LC loading capacity 
LE loading efficiency 
MBC metastatic breast cancer 
MDR multiple drug resistance 
MeOH methanol 
mg milligram 
min minute 
i  
  xx 
mL milliliter 
Mn number-average molecular weight 
mPEG-PLA methoxy poly(ethylene glycol)-b-poly(lactide) 
MP1U mouse phase 1 unit 
MS mass spectrum 
MTD maximum tolerated dose 
MTT 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide 
MW molecular weight 
Mw weight-average molecular weight 
NCI National Cancer Institute 
NIH National Institute of Health 
ng nanogram 
NMR nuclear magnetic resonance 
NSCLC non-small cell lung cancer 
OC ovarian cancer 
OST orthotopic syngeneic transplant 
PBS phosphate buffered saline 
pBuOx poly(2-butyl-2-oxazoline) 
PCL poly-carprolactone 
PDI polydispersity index 
PDLLA Poly(D,L-lactic acid) 
PEG poly(ethylene glycol)  
xx 
  xxi 
PEG-PLA methoxy poly(ethylene glycol)-block-poly(D,L-lactic acid) 
PEI polyethylenimine 
PFS  the randomization to relapse or death 
P-gp P-glycoprotein 
PK pharmacokinetics 
PLA poly(D,L-lactic acid) 
PLGA poly(lactic-co-glycolic acid) 
PLL poly(L-Lysine) 
PM polymeric micelle 
pMeOx poly(2-methyl-2-oxazoline) 
POx poly(2-oxazoline)s 
PRINT particle replication in non-wetting templates 
Pt platinum 
PTX paclitaxel 
q4d x 4 every 4 days injection for 4 injections in total 
Ref. reference 
RES reticuloendothelial system 
RT room temperature 
s.c. subcutaneous 
SCID severe combined immune-deficiency 
SCLC small cell lung cancer 
SEC size exclusion chromatography 
i 
  xxii 
SEM standard error of the mean 
SNHS N-hydroxysulfonosuccinimide 
SPARC secreted protein acidic and rich in cysteine 
SPE solid phase extraction 
t1/2 half-life 
TEM transmission electron microscopy 
TFA trifluoroacetic acid 
THF tetrahydrofuran 
TIC tumor initiating cells 
TNBC triple negative breast cancer 
TV tumor volume 
µg microgram 
µL microliter 
USP United States Pharmacopeia 
Vd volume of distribution 
Vdss steady state volume of distribution 
VEGF vascular endothelial growth factor 
vs. versus 
WOR wortmannin 
17-AAG 17-allylamino-17-demethoxygeldanamycin 
 
  
xxii 
  1 
 
CHAPTER 1  INTRODUCTION 
Most drug candidates in pre-clinical development display poor solubility, bioavailability, 
suboptimal pharmacokinetics and biodistribution profiles and systemic toxicity and can be 
administrated only through non-patient-centric administration routs. Finding the solution that 
gives a particular drug the desired bioavailability, safety and efficacy profile is still a major 
challenge. 
Nano formulations address these challenges by developing efficient encapsulation and 
solubilization techniques for the drug candidates and improve bioavailability, PK and 
biodistribution and reduce systemic toxicity through: 1) safe delivery of the loaded carrier to the 
target organ and/or cell in the body, and 2) on-site triggered release of the payload.  
The field of nanomedicine and drug delivery has undergone explosive development over 
the last decade. Micelles, self-assembling nano-sized colloidal particles with a hydrophobic core 
and hydrophilic shell have being successfully used as pharmaceutical carriers for water-insoluble 
drugs and demonstrate a series of attractive properties as drug carriers. Their development along 
with other nano-particulate drug carriers such as liposomes, drug-polymer conjugates and 
degradable nanoparticles was reported as early as 1980s and early 1990s.  Block copolymer 
micelles were developed as solubilizes and/or drug carriers depending on their drug retention 
properties in vivo. Indeed, the formulation of hydrophobic drugs in these micelle systems has 
been shown to provide up to a 30,000 fold increase in the water solubility of some compounds.[5] 
Formulation of drugs in block copolymer micelles: drug loading and release. [5] However, by the 
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new millennium the focus has evolved from solubilization of the hydrophobic drugs to 
developing drug delivery tools which provide sustained release of the incorporated cargo, 
improve metabolic stability, circulation time in the blood stream and enhance accumulation of 
the cargo in the target site through passive targeting (enhanced permeability effect). Later, the 
focus has shifted to design of new polymers and materials specifically tailored for the drug 
delivery purposes, such as high capacity carriers, carries for several drug candidates and carriers 
for charged drug candidates. To address PK and biodistribution issues the attention shifted 
towards targeted carriers, stimuli responsive materials, which release the cargo in response to 
environmental clues in the targeted environment and alternative routes of administration. 
However, following repeating administration, the issue of acquired resistance arises and presents 
a major drawback to successful clinical treatment. Overcoming drug resistance through the 
selection of the carrier has being additional approach to overcoming drug development 
challenges.  In this chapter, we discuss resent developments of different aspects of overcoming 
drug development challenges with polymeric micelles.  
1.1  Clinical Sate of Polymeric Micelle (PM) on Cancer Treatment 
Various chemical compounds loaded polymeric micelles are currently in clinical use and 
Phase I, II, III and IV clinical studies. [6, 7] Among all the anti-cancer agents, paclitaxel, docetaxel 
and cisplatin are the most loaded drugs. In this section, we discussed the current polymeric 
micelle formulations in market and being investigated in clinical studies for cancer therapies. 
(Table 1.1) 
1.1.1 Taxane-based chemotherapy (paclitaxel and docetaxel)  
Genexolâ PM 
This PEG and poly(D,L-lactic acid) (PDLLA) based micellar paclitaxel formulation was 
first approved use in South Korea by Samyang Biopharm, and has been approve by FDA 
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recently. [8] The paclitaxel loading capacity in Genexolâ PM is more than 10%, 10-fold 
increasing, compared to Taxolâ with only 1% paclitaxel loading capacity. The pharmacokinetic 
studies demonstrated a similar AUC with free PTX, however, a 3-fold higher Cmax in tumor, 
liver, spleen, lung and kidney. [9] Clinical studies determined Genexolâ PM with a MTD 390 
mg/m2 every 3 weeks or 120 mg/m2 every week, and in the Phase II studies, it was proved to be 
safer and more effective with high response rates in patients in advanced pancreatic cancer and 
breast cancer. [10] Moreover, Genexolâ PM showed significant activity in combined use with 
cisplatin in non-small cell lung cancer patients. However, this formulation lacks good stability 
when present in the circulation and fast extracted from the polymeric micelle core, which 
compromised the antitumor efficacy. [11-13] 
Nanoxelâ M 
Another PM formulation produced by Samyang Biopharm and approved clinical use in 
South Korea is Nanoxelâ M. [14-17] Nanoxelâ M was originally developed to find an alternative 
for Taxotere, a conventional docetaxel formulation and is composed of mPEG-b-PDLLA block 
copolymers using the solid dispersion method. The PMs have an average diameter of 25 nm with 
around 10% loading capacity. It has completed a phase I trial for advanced solid tumors and a 
Phase II trial in patients with metastatic head and neck cancer and a Phase III trial in patients 
with bladder cancer are now recruiting in South Korea.  
Paclicalâ 
Paclical/Apealea is a vitamin A derivative XR17, an excipient technology of a Swedish 
company Oasmiaã, based micellar paclitaxel formulation for the treatment of lung, breast and 
ovarian cancer. [18, 19] The MTD of Paclicalâ was determined as a one-hour intravenous infusion 
at its recommended dose of 250 mg/m2. [18] In the recent Phase III studies, compared to Taxol in 
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combination with carboplatin, Paclicalâ combined with carboplatin, where paclitaxel in 
combination with platinum containing compound has emerged as a first line treatment in patients 
with ovarian cancer, showed an extended PFS (the period from randomization to relapse or 
death). [18] 
NK-105 
NK-105 is a PTX-loaded micellar formulation based on PEG-b-poly(aspartate) block 
copolymer. The average diameter of NK-105 PM is 85 nm with 23% (w/w) of loading capacity. 
[20] Phase I study showed NK-105 with a 15-fold higher plasma AUC, compared to PTX. It was 
demonstrated with modest tolerate and activity against advanced gastric cancer in a Phase II 
clinical trial. [21] However, in a recent Phase III clinical trial compared with PTX that the 
statistical noninferiority of PFS (progression-free survival) could not be achieved, suggesting a 
promising PM formulation failed to provide greater efficacy in clinical trials. [13] 
BIND-014 
BIND-014 is a DTX formulation, currently under development by BIND therapeutics. It 
is a targeted PEG- poly(D,L-lactide-co-glycolide) (PLGA) micelles using an RNA aptamer 
accurin as targeting moiety that binds to the extracellular domain of the prostate-specific 
membrane antigen (PSMA) on the surface of prostate cancer cells. [22-24] BIND-014 has been 
shown to have enhanced cellular uptake compared to their non-targeted counterparts in vitro and 
in vivo. The micelles have a particle size about 90 nm and drug loading close to 11%. The 
BIND-014 was selected through a combinatorial screening optimization of formulation regarding 
size, targeting group density, PEG shell and PLGA core MW, surface charge, drug loading, 
initial release rate, as well as encapsulation process.[25] After validation for PK, tolerability, 
tumor accumulation and efficacy, the best candidate formulation was selected (namely BIND-
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014). It was evaluated in NSCLC and mCRPC. Currently BIND therapeutics released 
preliminary data from a Phase II trial at the 26th the European Organization for Research and 
Treatment of Cancer, the National Cancer Institute and the American Association for Cancer 
Research (EORTC-NCI-AACR) meeting. 
The clinical results indicated that BIND-014 was well tolerated and had promising anti- 
tumor activity in 40 patients with advanced or metastatic NSCLC at a dose of 60 mg/m 2 q3w. 
This dose, lower than conventional Taxotere®, also showed activity in patients with KRAS 
mutant tumors, which normally poorly respond to Taxotere® treatment. Five patients (13%, 
N=40) achieved a PR with a median PFS of 2.7 months and 2 of 9 confirmed KRAS mutant 
patients experienced an objective response (22%) with median PFS of 2.7 months. In addition, 
BIND-014 treated patients experienced substantially reduced toxicities such as neutropenia, 
anemia, neuropathy, and alopecia commonly associated with Taxotere®. 
CriPecâ doxetaxel 
CriPecâ doxetaxel is developed to overcome the side effects of Taxotere.[26] DTX is 
covalently conjugated to cross-linked polymeric micelles (DTX-CCL-PMs) with mPEG-b-
poly(HPMAm-Lacn) block copolymer, with an average diameter of 66 nm and a 12% (w/w) 
DTX loading. As a result of a cross-linked conjugation of drug to the polymer, CriPecâ 
doxetaxel was proved with better in vivo stability and elevated circulation time in blood. 
Significant reduced side effect and superior anticancer efficacy in mice have been observed 
compared to Taxotere. The tumor accumulation was greatly enhanced by the cross-linking. 
CriPec doxetaxel is under a Phase I clinical trial in Belgium in patients with solid tumors. [27] 
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1.1.1 Platinum-based chemotherapy (cisplatin and oxaliplatin)  
NC-6004 (Nanoplatinä) 
NC-6004 was first reported in 2003 that originally developed by Prof. Kazunori 
Kataoka’s group at University of Tokyo. It is a cisplatin incorporated via polymer-metal 
complex-formation, PEG-b-poly(Glu) copolymeric micellar formulation, with an average size of 
28 nm in diameter with high drug loading (39%). [28] The in vivo study of NC-6004 showed 
prolonged circulation and a 20-fold higher tumor accumulation. The common neurotoxicity and 
nephrotoxicity caused by cisplatin were found significant lower in the NC-6004 treated patients. 
[28-31] The most significant antitumor activity for NC-6004 was proved in colon cancer that it led 
to tumor regression in mice. [28] In clinical study, NC-6004 provides sustained release of 
platinum with a 230-fold increase in plasma T1/2 and 8.5-fold increase in AUC. The phase II 
study suggested the MTD to be identified as 120 mg/m2. A Phase I/II clinical trial of NC-6004 
combined with gemcitabine (GEM) was conducted in patients with pancreatic cancer, with a 
relatively well tolerated and exhibited modest antitumor efficacy. [32] 
NC-4016 
Similar as NC-6004 (Nanoplatinä), NC-4016 uses the same polymer as in Nanoplatinä, 
however, it encapsulates a platinum derivation dichloro(1,2-diaminocyclohexane)platinum(II) 
(DACH-Pt), which overcomes the acute toxicity and acquired resistance caused by cisplatin. [33] 
NC-4016 PM has an average size of 40 nm with an extreme high platinum loading of 75% 
(w/w). It has great stability that no drug releases in water and 60% released after 96 h of 
incubation with phosphate buffered saline at 37°C, and as a result in vivo, NC-406 elevates the 
levels of platinum in the circulation and prolongs the circulation time.[34] NC-4016 resulted in 
  7 
better antitumor efficacy and 25-fold higher accumulation in tumor, compared to oxaliplatin free 
drug.  
1.1.2 Doxorubicin-based chemotherapy  
NK-911 
NK-911 is a DOX-loaded polumeric micelle formulation composed of PEG-b-poly(Asp) 
block copolymers with DOX conjugated to the core block (poly(Asp)) with an average diameter 
of 40 nm. A Phase I study showed a moderate response in patients with metastatic pancreatic 
cancer. [35] However, the plasma clearance of NK-911 was demonstrated 400-fold higher 
compared with Doxil®, suggesting that the NK-911 has lower stability in the bloodstream.  
SP1049C 
SP1049C is a DOX-loaded micelle formulation based on the class of Pluronic® 
polymers, which is the first Pluronic-based polymeric micelle formulation of DOX entering 
clinical trials. [36, 37] SP1049C PM has been demonstrated with higher antitumor effects compared 
with free drug. [36, 37] SP1049C has successfully completed Phase I and II clinical trials, obtained 
a SPA on a single approvable Phase III trial in refractory upper GI adenocarcinoma and has 
obtained an orphan drug designation in adenocarcinoma of the esophagus from US FDA. [38] In 
late 2016 patent rights to SP1049C, which expire in 2028, were acquired by Canadian SoftKemo 
Pharma Corp. to complete the final development of the novel anticancer therapeutic now code 
named SKC1049.  
1.1.3 Other compounds based chemotherapy 
NK-012 
NK-012 is polymeric prodrug of SN-38, where the compound 7-ethyl-10-hydroxy-
camptothecin (SN-38) covalently conjugated to the PEG-b-poly(L-glutamic acid) block 
copolymer. The self-assembly polymeric micelle results in an average size of 20 nm with 20% 
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(w/w) of drug loading. [39] In several Phase I/II clinical trials, NK-012 showed promising 
antitumor activity in patients with advanced solid tumors.[40, 41] The safety and efficacy of NK012 
for advanced and metastatic triple negative breast cancer treatment in a Phase II study 
demonstrated efficacious and presented a satisfactory safety profile, as well as, for colorecal 
cancer treatment in combination with 5-fluorouracil in a Phase I study. [41] 
NC-6300 
The formulation NC6300 consists of epirubicin covalently conjugated to the carboxylic 
acid groups of PEG-b-poly(aspartate) block copolymers via an acid-labile hydrazone bond. NC-
6300 PM has an average size of 40-80 nm in diameter with 14.7% (w/w). [42-48] In pre-clinical 
studies, NC-6300 showed a prolonged blood circulation with preferential accumulation in human 
liver and breast cancer xenograft model. [45] It also showed extended antitumor effects with 
reduced epirubicin cardiotoxicity in mice bearing Hep3B liver orthotopic tumors. [47] A Phase I 
trial is underway in Japan in patients with advanced solid tumors since 2013 to evaluate 
tolerability and the recommended dose. [7, 49]  
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1.2  Polymeric micelles in anticancer therapy 
Block copolymer micelles (PM) encapsulating anticancer compounds have been 
developed for around 40 years and have been widely used as a drug delivery platform for cancer 
therapy. [13, 14, 50, 51] At low concentration, the amphiphilic polymers exist as monomers, but self-
assembly micelles are formed when the concentration increases. [52] The concentration at which 
the micelles are formed is critical micelle concentration (CMC). Compared to low MW 
excipients, amphiphilic copolymers usually have a much lower CMC. [53]  
Polymeric micelles have several advantages over other nanosized drug delivery systems, 
such as 1) small size enabling effective EPR accumulation (diameter = 10-200nm), 2) high 
structural stability, 3) high drug loading, 4) low toxicity, 5) incorporation of various chemical 
species, 6) agents can be formulated in a non-covalent way, 7) biodegradability, and 8) simple 
manufacturing. [54] In this section, we summarize the outstanding features of polymeric micelle 
nanoformulation mainly in the following aspects.   
1.2.1 High drug loading capacity 
The polymeric micelles are originally designed for enhancing the solubility of 
hydrophobic agents. Consequently, incorporation of these agents in micelles avoid the toxic side 
effect causing by the conventional solubilizing adjuvants, such as Cremophor EL. [55-57]  
The drug loading capacity (LC), loading efficiency (LE) and drug loading (DL) are 
usually used for the quantification of drug loading. They are calculated using following 
equations (a)-(b): where Mdrug and Mexcipient are the weight amounts of the loaded (solubilized) 
drug and polymer excipient in the dispersion, while Mdrug added is the weight amount of the drug 
initially added to the dispersion. 
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LC = Mdrug/ (Mdrug + Mexcipient) ´ 100%,                                                                     (a) 
LE = Mdrug/ (Mdrug added) ´ 100%,                                                                               (b) 
PMs are optimized formulations having high drug to polymer ratios enabling 
solubilization of drugs up to 10000-fold higher their aqueous solubility. [8, 20, 58] As discussed in 
the previous section, the PMs under clinical trial exhibits high drug loading capacity 10% to 75% 
(w/w). (Table 1.1) Notably, the poly (2-oxazoline) (POx) tri-block co-polymer platform used in 
cancer therapy developed by our lab exhibits extreme high loading capacities of various 
hydrophobic drugs, such as PTX, ETO and 17-AAG. [2, 3] However, a major challenge with PM 
is the design of the formulation act as true drug carriers but not only as solubilizers, or in another 
way, the in vivo stability as nanoparticle in blood circulation. [59] 
1.2.2 Controlled release 
Drug release from micelles mostly depends on the rate of micelle stability, drug 
diffusion, and the rate of biodegradation of the copolymers. [60] The concern of the micelles with 
poor stability reflect on the fast release post intravenous administration. However, for those 
micelles as considered carriers (good stability), a controlled-pattern of release have been 
observed in many studies. [61] Moreover, the drug concentration in micelles, the length of the 
hydrophobic polymer, the molecular weight and the physicochemical characteristics of the drug 
and the localization of the drug within the micelles. [12]  
1.2.3 Biodistribution and pharmacokinetics profile 
In vivo, the administration of free chemotherapeutic drugs presents a low therapeutic 
value, mainly due to the poor pharmacokinetics (PK) profile of the drugs. [62, 63] The PK and 
biodistribution of the drug are significantly influenced by the physicochemical properties of 
polymeric micelles. The PMs with good stability, exhibit improved PK profiles, specifically, 
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higher plasma AUC and Cmax, prolonged blood circulation time, and tumor accumulation, with 
reduced in vivo off-site distribution and side effect/toxicity in both preclinical and clinical 
studies. As a result of the improved PK profile, 2/3 of the PM in clinical trials described in 
previous section present better antitumor efficacy. [13]  
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1.3  Polymeric micelles for multi-drug delivery in cancer 
In this section, we summarize recent research on polymeric micelles for multi-drug 
delivery in cancer therapy. Tumors are micro-environmentally diverse due to the variety of 
expression rate of biomarkers, proliferation profile and vasculature distribution. Other factors 
like age, sex, genetics vary the tumor heterogeneity as well. [64-68] Clinically, the strategy of 
combining anticancer drugs with various antitumor mechanism would possibly overcome tumor 
heterogeneity, thus improve the efficacy of oncology. [69] Delivery of multiple drugs in one 
vehicle raises the hopes for antitumor efficacy and also with reduced toxicity. However, multi-
drug delivery has several considerations, such as, synergistic effect, concurrent or sequential 
delivery, pharmacokinetics and biodistribution, toxicity and safety, and anticancer efficacy. [70] 
In sequential drug delivery, polymeric micelles participate in pretreatment strategies that “prime” 
solid tumors and enhance the penetration of secondarily administered anticancer agent or 
nanocarrier. The improved delivery of multiple poorly water-soluble anticancer agents by 
polymeric micelles via concurrent or sequential regimens offers novel and interesting strategies 
for drug combinations in cancer treatment. [70] 
1.3.1 Combination index (CI) 
To evaluate and quantify the multiple drug effect, the Chou-Talalay method was 
developed, based on the median-effect equation, derived from the mass-action law principle. [71-
73] Briefly, for each level of growth inhibition Fa the CI values for binary drug combinations are 
calculated according to the following equation: CI = (D)1/(Dx)1 + (D)2/(Dx)2, where (D)1 and (D)2 
are the concentrations of each drug in the combination resulting in Fa x 100% growth inhibition, 
and (Dx)1 and (Dx)2 are the concentrations of the drugs alone resulting in Fa x 100% growth 
inhibition. CI values for drug combinations are plotted as a function of Fa. [71] Generally, the CI 
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values between Fa = 0.2 and Fa = 0.8 are considered valid. CI values less than 1 or more than 1 
demonstrate synergism or antagonism of drug combinations, respectively. [74] 
1.3.2 Concurrent multiple drug delivery  
Poorly water-soluble anticancer agents can be loaded chemically or physically into 
polymeric micelles for concurrent multi-drug delivery. [75-78] The chemically conjugation include 
1) mixed prodrug polymeric micelles, 2) PEG-b-poly(aspartic acid), 3) covalent linkage and 
hydrophobic interaction. [70]  Physically trapped could be realized by 1) hydrophobic interaction, 
2) multiple drug solubilization, 3) PEG-b-PLA.  
Multi-drug polymeric micelles may release physically loaded drugs by disassembling in 
blood or by diffusion mostly with similar rate (concurrent delivery). [77] Briefly, Bae et al. has 
reported a PEG-b-poly(Asp-Hyd) block copolymer micellar formulation incorporate DOX with 
wortmannin (WOR) or GDM-OH. The multi-drug micelles exhibit lower IC50 on breast cancer 
cell and higher antitumor efficacy on breast cancer model on mice. [79] Shin et al. reported a 3-in-
1 of PTX, rapamycin and 17-AAG co-loaded PEG-b-PLA micelles. [77] The micelles show 
significant better in vivo efficacy in non-small cell lung cancer and breast cancer xenograft 
models. [76] Many more studies have shown multi-drug co delivery in PEG-PLGA, poly (2-
oxazoline) (POx), PEG-b-poly(carbonate-co-lactic acid) (PEG-b-(CB-co-LA)), PEG-b-PCl, 
PEG-DSPE/TPGS and PEG-b-PGlu-b-PPhe) block copolymers. These results exhibit concurrent 
multi-drug delivery enhance antitumor efficacy with reduced toxicity. [2, 80-86] 
1.3.3 Sequential multiple drug delivery 
Sequential drug delivery is performed in cancer treatment due to the risk of drug 
overlapping and incompatibility in the injection mixtures. An enhanced tumor penetration and 
enhanced antitumor efficacy would be achieved as the second drug being delivered, with the goal 
of increasing the intratumoral drug delivery. For example, Au et al. studied a tumor priming 
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effect of an iv. pretreatment inducing apoptosis by a compound, such as PTX, on the purpose of 
reducing tumor cell density and expanding interstitial space, following with a second drug of 
enhanced intratumoral uptake. [87, 88]  
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1.4  The influence of nanoparticle shape on cancer drug delivery 
According to previous studies, the antitumor efficacy of nanoparticle is not only 
influenced by the particle size, the shape of nanoparticle is also a crucial element influencing 
both cell uptake and pharmacokinetics. However, most formulations for anticancer therapy are in 
the spherical form. Various non-spherical nanoparticle platforms have been explored in several 
studies exhibiting beneficial properties compared to spherical shapes. In this section of 
introduction, we summarize the influence of nanoparticle shape on biocirculation, 
pharmacokinetics, cellular uptake and anticancer efficacy by comparing spherical and non-
spherical nanoparticles. A list of nanoparticle shapes in recent studies in anticancer therapy is 
summarized in Fig. 1.1. [89] 
1.4.1 Circulation 
The anticancer therapeutic efficacy of nanoparticles is highly influenced by the 
circulation/half-life of anticancer drug. Anticancer drugs with low molecular weight, degradable 
and hydrophobic properties, are mostly fast eliminated from the circulation and have short half-
life.[90] In most studies, spherical nanoparticles have been designed for its easy preparation 
process.[91, 92] Poly (ethylene glycol) (PEG) have been commonly used for enhancing circulation 
time by the stealth property.[93] In previous studies, Dishcher et al. demonstrated the prolonged 
circulation time of filamentous or worm-like micelles of about 1 week in rodents. [94] Not only in 
his study, the circulation time of filomicelles have been shown with a significant extension up to 
1 mouth. [94, 95] The enhancement could possibly be explained by the derivation from fluid-
polymer interactions. [94, 96, 97] In the Weissenberg number (Equation 1, describing the extension 
of a polymer in flow), filomicelles with lengths > 1µm and long relaxation times (tR > 1), are 
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affected under rapid blood flow and spleen filtration (nflow > 5 µms-1). [98] Other studies of 
nanorods shaped formulation also demonstrated prolonged circulation time. [99] 
                                       (Equation 1) 
1.4.2 Biodistribution and target delivery  
Biodistribution plays a crucial role in determining anticancer drug delivery and 
therapeutic efficacy. To maximize therapeutic efficacy, anticancer drugs should be delivered to 
the targeting biological site with minimal of-site distribution. A study done by Christian et al. 
has demonstrated high accumulation of filamentous micelles in mouse xenograft tumors. [92] The 
higher distribution in tumor site of filomicelles has also been supported by other studies. [100, 101] 
These founds of high concentration in tumors of worm-like micelles suggest a promise in 
reducing dose with high anticancer efficacy. [102, 103] Tumor targeting accumulation has been 
observed in other shapes of nanoparticles as well. CNT (carbon nanotubes), nanorods and 
elliptical disks nanoformulaitons have been observed with higher accumulation in mice bearing 
orthotopic tumors. [104-109] 
1.4.3 Cellular uptake 
The cellular uptake is also influenced by the shape of nanoparticles. Studies have 
demonstrated filomicelles/worm-like micelles are negligibly uptake by macrophages because of 
hydrodynamic shearing in vivo. [110] This inhibition on phagocytosis has been also observed in 
other non-spherical nanoparticles, for example, a polystyrene nanodisks were shown accumulate 
in phospholipid bilayers resulting in low cellular uptake. [111] However, many other studies have 
shown enhanced cellular uptake. For example, a worm-like micelles formulation, coated with 
biotin, is able to internalize through biotin-receptor endocytosis. [112] Ellipsoid and gold nanorod 
have been observed with higher macrophage uptake.[113, 114] A nanoneedle-like formulation has 
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been studied with enhanced ability to cross the endothelial cell membrane and deliver siRNA 
into the cytoplasm, resulting in higher cellular uptake. [115] Overall, previous studies support an 
enhanced cellular uptake of non-spherical nanoparticles, however, the reason has not been 
clearly explored. [89] 
1.4.4 Anticancer efficacy and cytotoxicity 
There’s no clear evidence on the relationship between the nanoparticle shape and 
cytotoxicity, with conflicting reports from literatures. [116-119] However, clear evidences from 
literature demonstrate non-spherical nanoparticles have higher MTD (maximum tolerated 
dosage), antitumor efficacy in mice tumor models.[92, 120, 121] For example, DOX loaded worm-
like micelles via pH-sensitive bonds have been found to have higher cytotoxicity on MCF-7 cells 
and in vivo antitumor efficacy on tumor model. [122, 123] Moreover, gold nanorods and 
nanoneedle-like nanoparticles have been reported with higher anticancer efficacy in literature as 
well. [115, 124] By using PRINT technique (Particle Replication in Non-Wetting Templates), 
DeSimone et al. have demonstrated cylindrical shape PLGA nanoparticles successfully deliver 
docetaxel to SKOV-3 ovarian xenograft mice tumor. [125]  
  18 
1.5  Conclusion 
With decades of research directed towards understanding the polymeric micelle, we can 
now take advantage of this phenomenon to develop anti-cancer drug encapsulated formulation 
for their delivery. We summarized the current clinical applications of polymeric micelles on 
cancer therapy and more PM formulations appear to be encouragingly applicable in the near 
future. By combining various rational polymers and drugs with different shapes in order to 
optimize thermodynamic and kinetic stability, enhancing drug loading capacity and enabling 
possible targeting. One possible next step could be combination therapy with various mechanism 
of anti-cancer treatments.  
On the other hand, our understanding on the fundamental principles of polymeric micelle 
encapsulating hydrophobic anti-cancer drugs is still limited. Currently it is difficult to predict the 
loading capacity from the structure and properties of the drug and polymer, and how stable the 
micelles can be in a given environment due to the complexity of the system. These can be 
hopefully achieved by in situ simulations with the rapid advancement of computing power.  
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Table 1.1 Polymeric micelles in clinical studies.  
Polymeric micelle Block copolymer Drug Size (nm) LC (w/w) Indication Clinical phase Company Ref. 
Genexol®-PM PEG-b-p(D,L-lactide) Paclitaxel 20-50 11.5% 
Breast, lung and 
ovarian cancer Approved 
Samyang Biopharm, 
South Korea 
[8, 10, 126-
128] 
Nanoxel®-M mPEG-b-p(D,L-lactide) Docetaxel 10-50 11.2% 
Breast, non-
small cell lung, 
prostate, ovarian 
cancer 
Approved Samyang Biopharm, South Korea [14-17] 
Paclical® Vitamin A derivatives XR-17 Paclitaxel 20-60 N/A Ovarian cancer 
III 
(completed) 
Oasmia 
Pharmaceutical AB, 
Sweden 
[18, 19] 
NK-105 PEG-b-p(Asp-4-phenyl-1-butanol) Paclitaxel 85 23% 
Advanced 
stomach and 
breast cancer 
III NanoCarrier/Nippon Kayaku, Japan 
[20, 21, 
129-134] 
NC-6004 
(Nanoplatinä) PEG-b-p(Glu) Cisplatin 16-30 39% 
Pancreatic, lung, 
bladder, bile 
duct and head 
and neck cancer 
III 
NanoCarrier, 
Japan/Orient 
EuroPharma 
(co-development) 
[135, 136] 
NK-911 PEG-b-p(Asp-DOX) Doxorubicin 40 50% Pancreatic and colorectal cancer II 
Nippon Kayaku, 
Japan [35, 58] 
NK-012 PEG-b-p(Glu-SN-38) SN-38 20 20% 
Breast, lung and 
colorectal cancer II 
Nippon Kayaku, 
Japan [126, 137] 
SP1049C Pluronics® Doxorubicin 30 8.20% 
Advanced 
adenocarcinoma 
of esophagus, 
gastroesophageal 
junction and 
stomach cancer 
III Supratek Pharma Inc. [138, 139] 
BIND-014 
PEG-p(D,L-lactide-
b-glycolide) (PLGA), 
with Accurin that 
targets PSMA 
Docetaxel 95 11% Solid tumors II Bind Therapeutics [140, 141] 
NC-6300 PEG-b-p(Asp-hydrazone) Epirubicin 40-80 14.7% Solid tumors I 
NanoCarrier, 
Japan/Kowa (co-
development) 
[42-48] 
NC-4016 PEG-b-p(Glu) DACH-Pt 40 32% Solid tumors and lymphoma I NanoCarrier, Japan 
[33, 34, 
142] 
CriPec® 
doxetaxel 
mPEG5000-b-
p(HPMAm-Lacn) Docetaxel 66 12% Solid tumors I 
Cristal Therapeutics, 
The Netherlands 
[26, 57, 
143] 
25  
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Figure 1.1 Schematic examples of various shapes of nanoparticles. 
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CHAPTER 2 : A HIGH CAPACITY POLYMERIC MICELLE OF PACLITAXEL: 
IMPLICATION OF HIGH DOSE DRUG THERAPY TO SAFETY AND IN VIVO ANTI-
CANCER ACTIVITY 1 
2.1  Summary 
The poor solubility of paclitaxel (PTX), the commercially most successful anticancer 
drug, has long been hampering the development of suitable formulations. Here, we present 
translational evaluation of a nanoformulation of PTX, which is characterized by a facile 
preparation, extraordinary high drug loading of 50% wt. and PTX solubility of up to 45 g/L, 
excellent shelf stability and controllable, sub-100 nm size. We observe favorable in vitro and in 
vivo safety profiles and a higher maximum tolerated dose compared to clinically approved 
formulations. Pharmacokinetic analysis reveals that the higher dose administered leads to a 
higher exposure of the tumor to PTX. As a result, we observed improved therapeutic outcome in 
orthotopic tumor models including particularly faithful and aggressive “T11” mouse claudin-low 
breast cancer orthotopic, syngeneic transplants. The promising preclinical data on the presented 
PTX nanoformulation showcase the need to investigate new excipients and is a robust basis to 
translate into clinical trials. 
 
 
 
 
 
 
 
 
1 
This chapter under collaboration with former student Dr. Zhijian He, and previously appeared as an article in press. 
Z.H. and X.W. performed together characterization of particles and in vivo animal studies of POx/PTX formulation 
and analyzed experimental data.   
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2.2  Introduction 
Paclitaxel (PTX) [144] is a powerful antineoplastic agent against metastatic breast cancer, 
non-small cell lung cancer, advanced ovarian cancer, head and neck cancer and other 
malignancies.[145] By interfering with tubulin polymerization, thus perturbing microtubule 
dynamics, PTX leads to chromosome missegregation on multipolar spindles.[146] Apart from 
excellent potency, PTX is characterized by an extremely low solubility in aqueous media (<1 
mg/L),[147] thereby demanding delivery vehicles for parenteral administration. Three 
formulations are currently clinically approved, two of which by the FDA. Both are blockbusters 
and make PTX the best-selling chemotherapeutic in history.[146] 
The first clinical formulation of PTX was Taxol. It is characterized by very low drug 
loading (1% wt.), thus, the amount of the excipient, Cremophor EL/ethanol, necessary to deliver 
effective doses of PTX is substantial. Excipient plasma concentration can reach 0.4% (v/v) and 
persist above 0.1% (v/v) for over 24 hours.[148] Cremophor EL causes severe allergic, 
hypersensitivity, anaphylactic reactions and nephro- and neurotoxicity in animals and humans, 
which significantly limits dosing and requires clinical intervention.[55, 149] 
The clinical demand for alternative formulations led to the development of Abraxane, a 
nanoparticle formulation (hydrodynamic diameter ≈ 130 nm) comprising human serum albumin 
and ca. 10% wt. PTX. Evidenced advantages of Abraxane vs. Taxol such as increased antitumor 
activity and tumor accumulation in several mice xenograft models, significantly higher 
maximum tolerated doses (MTD) in human, as well as approximately 74% increase of response 
rates in metastatic breast cancer patients ultimately led to the clinical approval of this new 
formulation.[150] However, its clinical trials also revealed an increased peripheral neuropathy as 
compared to Taxol.[151] Moreover, a recent randomized phase III clinical trial of weekly Taxol 
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compared to weekly Abraxane in combination with Bevacizumab as first-line therapy for locally 
recurrent or metastatic breast cancer indicates that Abraxane offers no benefits to progression-
free survival compared to Taxol, while inducing greater hematologic toxicity and sensory 
neuropathy.[152] Thus, there clearly remains a clinical demand for a formulation of PTX with 
improved safety profile and therapeutic outcome. 
Besides other approaches, polymeric micelles were investigated to formulate PTX[9, 20, 
21]For example, Genexol-PM,[9] a formulation comprising a block copolymer of poly (ethylene 
glycol) (PEG) and poly(DL-lactide) (PLA) is clinically approved in South Korea. NK105, a 
formulation of PTX using a block copolymer of PEG and modified poly(aspartate) recently 
successfully completed a phase II clinical study.[21] However, even these developmental 
formulations only in part overcome the common limitations of PTX formulations. The MTD of 
Genexol-PM identified as 50 and 60 mg/kg in non-tumor bearing female SPF C3H/HeNcrj mice 
and nude mice respectively is only 2-3x higher compared to Taxol.[9] NK105 could be safely 
administered at 100 mg/kg in balb/c female nude mice but only at a rather low concentration 
(0.12 mg/mL), requiring prolonged intervals of administration.[20] A superior dosage form, which 
exhibits high drug loading, desirable pharmacokinetics (PK) and tumor accumulation, and low 
toxicity while increasing therapeutic efficacy, remains elusive. 
Here we present self-assembled nano-sized polymeric micelle formulation based on 
amphiphilic poly(2-oxazoline) (POx) block copolymers with unique polysoap structure[1, 2] 
fulfilling unmet needs in formulation of PTX. This nanoformulation of PTX exhibit a facile 
preparation and unprecedentedly high drug loading of 50 % wt., with excellent shelf stability as 
well as controllable sub-100 nm size. In addition, absolute drug concentrations of 45 g/L could 
be achieved in an injectable formulation. Favorable in vitro and in vivo safety profiles and a 
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much higher maximum tolerated dose compared to clinically approved formulations were 
observed. Pharmacokinetic analysis revealed higher exposure of the tumor to PTX as compared 
to Taxol. Subsequently, we observed improved therapeutic outcome in orthotopic tumor models 
including particularly faithful and aggressive “T11” mouse claudin-low breast cancer orthotopic, 
syngeneic transplants. 
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2.3  Materials and Methods 
2.3.1 Materials 
Two batches of amphiphilic triblock copolymers P(MeOx33-b-BuOx26-b-MeOx45), Mn 
= 10.0 kg/mol, Đ (Mw/Mn) = 1.14 and P(MeOx47-b-BuOx21-b-MeOx36), Mn = 9.9 kg/mol, Đ 
(Mw/ Mn) = 1.19 were synthesized as described in the previous study[2]. PTX was purchased from 
LC Laboratories (Woburn, MA). All other materials were from Fisher Scientific Inc. (Fairlawn, 
NJ) and all reagents were HPLC grade. The A2780 cells were originally obtained from Sigma-
Aldrich. Cells were cultured in DMEM medium (Gibco 11965-092) supplemented with 10% 
FBS and 1% pen-strep. 
2.3.2 Preparation of POx/PTX polymeric micelles 
POx/PTX micelles were prepared by a thin film method (Fig. 2.1). Briefly, pre-
determined amounts of POx and PTX (stock solution 10-20 g/L in ethanol) were dissolved in 
ethanol (5-10 g/L) and mixed, followed by complete removal of volatiles. We tested and 
optimized small (1-5mg scale, air flow at 40 °C) and large scale (200 mg scale, rotary 
evaporator) production methods to control the thin film formation process (Fig. 2.1). Appropriate 
amounts of deionized (DI) water or normal saline were used to rehydrate the dried thin-film 
under heating at 50-60 C for up to 20 min in order to obtain drug loaded polymeric micelles. The 
resulting micelle formulation was stored as aqueous solution in refrigerator for up to 2 weeks or 
as lyophilized powder. 
The drug concentrations in POx micelles were measured by reverse-phase HPLC method 
with a Nucleosil C18 - 5µm column (250 mm ´ 4.6 mm) in an Agilent 1200 HPLC equipment. 
Each sample was diluted 20 times in mobile phase (ACN/water; 55/45, v/ v) and 20 mL diluted 
sample was injected into the HPLC. The retention times of PTX was approximately 5.0 min and 
detection wavelength was 227 nm while the flow rate was 1.0 mL/min and column temperature 
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was 30 °C. A standard curve range from 5 mg/ mL to 200 mg/mL was used to calibrate the 
quantity of PTX. 
The drug loading capacity (LC), loading efficiency (LE) and drug loading (DL) were 
calculated using following equations (a)-(b): where Mdrug and Mexcipient are the weight amounts of 
the loaded (solubilized) drug and polymer excipient in the dispersion, while Mdrug added is the 
weight amount of the drug initially added to the dispersion. 
LC = Mdrug/ (Mdrug + Mexcipient) ´ 100%,                                                                                                        
(a) 
LE = Mdrug/ (Mdrug added) ´ 100%,                                                                                                     
(b) 
A Nano-ZS (Malvern Instruments Inc., UK) DLS equipment was used to measure size 
distribution of POx micelles. Briefly, each sample was diluted 50 times with DI H2O or 10 mM 
NaCl to yield 1 g/L final polymer concentration before the measurement. The hydrodynamic 
diameters of POx/PTX micelles was determined by intensity-mean z-averaged particle size 
(effective diameter) and the polydispersity index (PDI) from cumulate analysis. Results were 
obtained from the average of three independent micelle samples. 
The morphology of POx/PTX micelles was studied using a LEO EM910 TEM operating 
at 80 kV (Carl Zeiss SMT Inc., Peabody, MA). Digital images were obtained using a Gatan 
Orius SC1000 CCD Digital Camera in combination with Digital Micrograph 3.11.0 software 
(Gatan Inc., Pleasanton, CA). One drop of each diluted POx/ PTX micelle solution (dilute 500 or 
1000 times using DI H2O) was deposited on a copper grid/carbon film for 5 min and excess 
solution was wicked off using fine filter paper. Then one drop of staining solution (1% uranyl 
acetate) was added and allow to contact for 10 s prior to the TEM imaging. The drug release 
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studies for POx/PTX micelles were performed using membrane dialysis method against 
phosphate buffered saline (PBS, pH 7.4) at 37 C. Briefly, POx/PTX micelles were diluted in PBS 
to achieve approximately 100 mg/mL of PTX final concentration. Subsequently, 100 mL of the 
diluted micelle solutions were added into floatable Slide-A-Lyzer MINI dialysis devices (100 
mL capacity, 3.5 kDa MWCO; Thermo Scientific) and suspended in 20 mL PBS in compliance 
with the sink conditions. Three devices were used for every time point. At each time point the 
samples were withdrawn from dialysis device and quantified by HPLC to obtain remaining drug 
amount of sample. Drug release profiles were constructed by plotting the amount of PTX drug 
released from POx/PTX micelles over time. 
2.3.3 In vitro complement activation, hemolysis, blood coagulation and cytotoxicity 
These studies were carried out following the protocols established and published by the 
Nanotechnology Characterization laboratory (http://ncl.cancer.gov/working_assay-cascade.asp). 
2.3.4 Serum albumin quenching studies 
Fluorescence emission spectra were obtained using a PelkinElmer LS 55 Fluorescence 
spectrometer equipped with a thermostatted cell holder, a Xenon Flash lamp, a Monk-Gillieson 
type monochromator, and a variable slit system. Emission spectra were recorded in phosphate 
buffered saline (PBS: 140 mM NaCl, 1.9 mM NaH2PO4, 8.1 mM Na2HPO4, pH 7.4) from 300 to 
440 nm (data shown up to 410 nm) after excitation at 295 nm. Both excitation and emission slits 
were set at 10 nm. BSA stock solution of 2.5 µM was freshly prepared by dissolving bovine 
serum albumin in 150 mM PBS. To ensure proper mixing all samples were gently mixed by 
using a laboratory vortex. The samples were then incubated for 30 min at 25 °C before 
measuring the fluorescence. Fluorescence emission spectra of tryptophan residues were 
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measured at different sample concentrations. Presented data represents average of triplicate 
samples.  
2.3.5 Serum binding studies 
Reverse-phase Thermo Scientific™ SOLA™ HRP solid phase extraction (SPE) 
cartridges were used for separation and determination of micellar (encapsulated) and non-
micellar (free) paclitaxel (PTX) in serum based upon the selective retention of micellar 
(encapsulated) PTX and non-micellar (protein bound) PTX on the cartridge. The former 
exhibited no retention, while the latter was retained on the stationary phase and eluted only with 
acidified methanol. 
Sample preparation was performed as follows. The formulations and PTX solutions (100 
µL POx/PTX 50/40, 50/20, 50/10, Taxol and free PTX (dissolved in small amount of EtOH) 
comprising 3H labeled PTX (2.5 µCi/mg PTX) were added to 2 mL of fetal bovine serum (FBS), 
incubated at 37 °C, and 200 µL samples were collected from the mixture solution at 1hr and 4hr. 
Each 200 µL serum sample was added to 200 µL of POx solution (2 mg/ml) in phosphate 
buffered saline, pH 7.4.  
To separate micellar and non-micellar (free) paclitaxel the following procedure was used: 
(A1) Column conditioning: Add 0.5 mL methanol (to waste)  
(A2) Equilibrate: Add 0.5 mL water (to waste)  
For the next steps, collect the effluent of A3 and A4 as this contains the micellar 
paclitaxel fraction. This fraction requires further clean up, described below.  
(A3) Application: load pre-treated sample (collect)  
(A4) Wash 1: 2 × 0.25 mL POx in phosphate buffered saline (2 mg/ml), pH 7.4 added 
sequentially (collect)  
(A5) Wash 2: 2 × 1 mL water / methanol (90:10 v/v) added sequentially (to waste)  
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(A6) Elution: 0.5 mL methanol + 0.1% formic acid (collect)  
2.3.6 In vivo studies 
All animal procedures were performed in compliance with federal animal welfare 
regulations, and protocols were approved by the Institutional Animal Care and Use committee. 
All animals used in PK, biodistribution, MTD, toxicology and efficacy studies were allowed to 
acclimate for at least 72 h in the animal facilities before experiments. Animals were exposed to a 
12 h light/dark cycle and received food and water ad libitum throughout the studies. Dosages of 
POx/PTX micelle formulations or commercial drugs Taxol and Abraxane are expressed as the 
quantity of PTX administered.  
2.3.6.1 MTD studies 
MTDs for Taxol, Abraxane and POx/PTX micelles were determined in a dose escalation 
method in female nude mice (tumor-free 6-8 weeks of age). Animals (n=3 per group) received 
i.v. injections of POx/PTX micelles (20, 40, 60, 90, 120, 150, 175 and 200 mg/kg), Taxol (20, 
25, and 30 mg/kg), Abraxane (30, 60, 90 and 120 mg/kg), and saline as a control (q4d x 4). Mice 
survival and changes in body weight were observed daily over two weeks in all groups. The 
highest dose that did not cause toxicity (as defined by a median body weight loss of 15 % of the 
control or abnormal behavior including hunched posture and rough coat) was defined as MTD. 
Changes in histopathology such as inflammation, or presence of necrotic cells were used to 
assess cytotoxicity occurring after treatment.  
Healthy Balb/c mice received POx alone, POx/PTX and Taxol at MTD dose. The 
following day mice were sacrificed and blood were withdrawn and a comprehensive blood 
chemistry panel were performed. Major organs including heart, liver, kidney, spleen, lung and 
brain were harvest, fixed in formalin, and subjected to pathological analysis by H&E staining. In 
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addition, tumor bearing animals were sacrificed two weeks post fourth injection and organs were 
harvested according to the same procedures as healthy mice. 
2.3.6.2 Efficacy and POx/PTX tumor accumulation studies 
A2780 ovarian cancer xenograft model 
Female athymic nude mice (6-8 weeks) were subcutaneously inoculated in the right flank 
with 8 x 106 human A2780 ovarian cancer cells (Sigma Aldrich) resuspended in 50% growth 
medium and 50% Matrigel. Two sets of experiments were performed: early stage tumor 
treatment starting after tumor sizes reached ca. 100-200 mm3; or late stage tumor treatment when 
tumor sizes reached ca. 400 mm3. Animals were randomized into groups of seven mice such that 
the mean tumor volumes were similar between groups and then administered with following 
formulations: 1) Normal saline; 2) Taxol (20 mg/kg PTX at determined MTD dose); 3) Abraxane 
(45 and 90 mg/kg PTX at determined ½MTD and MTD doses); 4) PTX loaded micelles (75 and 
150 mg/kg at determined ½MTD and MTD doses). The formulations were administered via tail 
vein following q4d x 4 regimen (on the days 0, 4, 8, 12). Tumor growth was monitored twice 
weekly for 15 weeks or earlier end-points defined by tumor volume (> 2000 mm3), animal 
weight loss (> 15%), or animals becoming moribund. Tumor length (L), width (W) were 
measured and tumor volume (TV) was calculated as TV =1/2 ´ L ´ W2. Survival and body 
weight were monitored daily. Tumors were removed at the end of the observation and subjected 
to histopathological examination.  
Orthotopic model of LCC6-MDR human TNBC 
The LCC6-MDR cells (obtained from Dr. R. Clarke, Georgetown University Medical 
School, Washington DC) expressing high levels of P-glycoprotein (P-gp) were originated from 
LCC6-WT cells stably transfected with a retrovirus vectored mdr1 gene 36. The parent LCC6-
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WT cells were derived from estrogen receptor (ER)-negative, aggressive and metastatic MDA-
MB-435 cells. The orthotopic model was obtained by directly transplanting LCC6-MDR cells 
into mice mammary fat pad (5 million cells/mouse). 
T11 orthotopic, syngeneic transplant (OST) cancer model 
T11 model mice are assessed using described practices of the Mouse Phase 1 Unit 
(MP1U) of UNC (e.g., tumor regression, large cohort size, etc.). When tumors were noted to be 
approximately 10-50 mm3 in size, animals were treated as described and tumor response was 
assessed by weekly caliper measurements. Data in Fig. 2.6 are normalized to tumor size at the 
time of therapy initiation, with volumes calculated using previously mentioned formula. Tumor-
bearing mice were euthanized at the indicated times for morbidity, tumor ulceration, or tumor 
volume more than 3000 mm3. 
2.3.7 PK and biodistribution studies 
2.3.7.1 Tumor-free mice 
Female Balb/c mice (6-8 weeks of age) were administered a single dose of Taxol (20 
mg/kg) or POx/PTX micelles (150 mg/kg) containing 3H-labelled PTX (5 µCi/mouse) via tail 
vein. At various sampling times (0.083, 0.5, 1, 2, 6, 24, 72, and 168 h post) a group of animals 
(n=3) were euthanized and blood collected from cardiac puncture were analyzed for PTX plasma 
concentration by measuring radioactivity. The tissues (brain, lung, kidney, spleen, liver, and 
heart) were also removed, washed in ice-cold saline, weighted and homogenized in a glass tissue 
homogenizer (TearorTM, BioSpec Products, Inc.), followed by radioactivity level determination 
using a Tricarb 4000 (Packard, Meriden) to quantify tissue distribution.  
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2.3.7.2 Tumor-bearing mice.  
Female nude mice (6-8 weeks of age) were implanted with 8x106 A2780 ovarian cancer 
cells in 50% growth medium and 50% Matrigel (BD Biosciences) by subcutaneous injection. 
When tumors were about 200 mm3 volume, mice were randomized (n=4 per group) such that the 
mean and medium tumor weights were similar between groups. Mice were then administered a 
single dose of above-mentioned formulations. At various time points, blood and tissue samples 
were obtained accordingly. 
2.3.8 PK and data analysis 
PK parameters were assessed with Phoenix WinNonlin (version 6.0) using non-
compartmental analysis. Statistical comparison of efficacy and tumor accumulation data is one-
way ANOVA with Holm-Sidak post-hoc test for multiple comparisons at a significance level of 
p<0.01 (Graphpad Prism, version 5.1.). If groups fail the normality or equal variance test, 
ANOVA on ranks with the Tukey post-hoc test were used for multiple comparisons.  
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2.4  Results 
2.4.1 Characterization of PTX-loaded POx micelles 
The POx/PTX formulation was prepared by a very simple, robust and highly reproducible 
thin film hydration method[1, 2, 153] (Fig. 2.2A and B, Supplementary Fig. 2.1). POx/PTX micelles 
(< 100 nm effective diameter) with drug loading of approx. 50 wt.% spontaneously self-assemble 
during rehydration of the dry film (Fig. 2.1B, Table 2.1).[153] In this work, we concentrated on 
two formulations, comprising 50 g/L excipient and 40 or 20 g/L PTX, subsequently termed 
POx/PTX 50/40 and POx/PTX 50/20, respectively. As opposed to Abraxane, the micelle 
formulations are almost clear solutions with micelles of about 20-80 nm effective diameter and a 
narrow size distribution (Fig. 2.2C,D). These solutions are directly lyophilizable and redispersed 
in desired aqueous buffer, exhibit a neutral ζ-potential and excellent stability (Fig. 2.3; Table 
2.2). In addition, these formulations can be directly injected due to their low viscosity.  
2.4.2 Serum binding studies 
Micelles are dynamic structures that can exchange both the surfactant and the drug with 
the surroundings. Partitioning of the PTX from the micelles to the aqueous media should be very 
low due to low drug solubility (approx. 1 mg/L). However, in the blood the drug can bind with 
the serum proteins. Therefore, we studied interaction of POx/PTX with the bovine serum 
albumin (BSA) by determining the quenching of the fluorescence of albumin tryptophan.[154] 
While the polymer alone had little effect on the BSA tryptophan fluorescence, the POx/PTX 
formulation produced a marked fluorescence quenching, which was increased as the drug 
concentration increased (Fig. 2.7). Importantly, the fluorescence quenching was more 
pronounced at a higher POx/PTX ratio.  
Therefore, the distribution of the drug between the micelles and serum was assessed 
using a solid phase extraction (SPE) column (SOLA™ HRP) that binds protein-bound and 
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unbound drug, but not the micelles. First, we demonstrated that in the absence of serum most of 
the drug (~83-88 %) applied to the column in POx/PTX eluted in the micelle fraction (Table 
2.3). The size of the particles in this fraction was 50 nm by DLS, corroborating the presence of 
intact drug loaded micelles. Only ~9 to 15 % PTX were retained in the column and subsequently 
extracted by the acid-methanol wash. On the contrary, when plain PTX was loaded onto the 
columns, the paclitaxel was almost exclusively found in the fraction corresponding to the acid-
methanol wash (Table 2.4). Next, various POx/PTX formulations were mixed at different ratios 
with 2 ml of the fetal bovine serum (FBS) to mimic the conditions that may realize upon 
injection of the drug in the blood and incubated for either 1h or 4h before the column separation 
(Table 2.5). In this case at the lower drug concentration ([PTX] = 0.27 mg/ml that correspond to 
20 mg/kg PTX dose in the animal studies) only ~62% of PTX eluted with the micelles while the 
rest was bound to the column and was only partially recovered. As the drug (and polymer) 
concentration increased ([PTX] = 2 mg/ml, similar to 150 mg/kg PTX in the animal studies) the 
portion of the drug in the micellar fraction (as well as the overall drug recovery) was also 
increased markedly to > 80%. In contrast, only about 20% of PTX in Taxol formulation was 
eluted in the micellar fraction. Free PTX, without excipient, was found to bind to serum proteins 
almost quantitatively. 
2.4.3 MTD and toxicology profiles of POx/PTX in nude or healthy mice 
We investigated MTD by dose escalation in NCI-Nu/Nu mice in a regimen of every 
fourth day for a total of 4 injections (q4d x 4), which was also employed in subsequent antitumor 
efficacy studies. For the clinically approved formulations our studies confirmed MTDs reported 
in the literature (20 mg/kg for Taxol and 90 mg/kg for Abraxane). 
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It should be noted that we removed endotoxins by heating POx to 200 ºC for 24 h (Fig. 
2.4). We also confirmed the low complement activation previously observed for POx/PTX[1] 
using an alternative protocol (Nanotechnology Characterization Laboratory protocol NCL ITA-
5). Similar to the negative control, the POx polymer itself and POx/PTX do not activate 
complement at ≤ 1.5 mg/mL, being the 2-fold concentration of POx/PTX we would expect in 
animal or patients serum after injection even considering an 7-fold increased PTX dose 
administered compared to Taxol. In contrast Taxol at 1.5 mg/mL (a clinically relevant positive 
control) revealed strong complement activation (Fig. 2.4A).14 POx and POx/PTX formulation are 
not hemolytic and do not induce platelet aggregation (Fig. 2.4B,C). Interestingly, we found 
evidence that POx and POx/PTX formulations can result in prolonged activated partial 
thromboplastin time (APTT) without affecting the thrombin or prothrombin time (PT) (Fig. 
2.4D-F). Such retardation of coagulation could be beneficial to breast cancer patients as it was 
demonstrated that haemostatic alterations and pro-coagulant systems, especially the formation of 
venous thromboembolism (VTE), are frequently observed complications following 
chemotherapy.[155] In vitro cytotoxicity of PTX/POx in hepatic and kidney cells was similar to 
that of Abraxane (Table 2.6). 
POx/PTX treated mice barely showed weight loss and no noticeable changes in behavior 
up to 150 mg/kg dose (Fig. 2.5A). We found that mice administered four times with 175 mg/kg 
micelles lost over 15% body weight. However, a single injection of 200 mg/kg of POx/PTX 
micelles was well tolerated without obvious sign of toxicity. We also tested POx polymer alone 
at equivalent and higher dose (187.5 mg/kg - 500 mg/kg), and no remarkable changes in general 
activity and body weight were observed, showing that relatively high doses of the vehicle are 
well tolerated after repeated injection in vivo (Table 2.7).  
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Thus, the MTD for POx/PTX micelles determined under q4d x 4 regimen was 150 
mg/kg, i.e. more than seven-fold as high as that of Taxol (20 mg PTX/kg) and significantly 
higher than that of Abraxane (90 mg/kg) (Fig. 2.5B). Although it is not straightforward to 
compare MTD in mice or other animals to that in human, the relative MTDs of Taxol, Genexol-
PM, Abraxane and NK105 correlated reasonably well with human MTD or recommended doses 
for these formulations.[10, 129, 156] Therefore, it is reasonable to assume that the present 
nanoformulation could increase MTD also in humans above current possibilities. 
In vivo, safety of POx/PTX was also evaluated in Balb/c by examining clinical chemistry 
parameters for kidney and liver function. There were no significant changes for blood urea 
nitrogen (BUN), alanine amino transferase (ALT), albumin values and other blood chemistry 
parameters with the exception of a slightly increased blood glucose levels for the POx/PTX 
group. Histopathology of major organs of animals two week after four injections (q4d x 4) at 
MTD dose (Fig. 2.5C and Table 2.8) was performed in nude mice.  
Histology reported no toxicity to lung, spleen, brain, and heart for all formulations tested. 
Mild toxic degenerative changes of centrilobular hepatocyte atrophy were evident in samples 
from animals exposed to Abraxane and Taxol (Fig. 2.5C, solid arrow in liver samples). This was 
also observed in POx and POx/PTX samples, albeit markedly attenuated despite the higher PTX 
dose. In saline control, this change was absent. Also, Abraxane and Taxol treated animals 
showed signs of mild toxicity in the kidney with few scattered atrophied tubules with fluid to 
proteinaceous accumulations to occasional casts (Fig. 2.5C dashed arrow in kidney samples). 
Only very little mild and scattered tubular damage was observed in POx/PTX samples (see 
supporting information for a more detailed analysis). Overall, our results confirm the excellent 
biocompatibility profile of POx reported by us and others.[157-168] 
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2.4.4 Drug PK and biodistribution of POx/PTX compared to Taxol 
The PK and biodistribution profiles of POx/PTX 50/40 and 50/20 micelles at MTD (150 
mg/kg) dose in tumor bearing mice (A2780 subcutaneous xenografts) were compared to Taxol 
20 mg/kg. The PK and biodistribution profiles of POx/PTX micelles at MTD dose in healthy 
balb/c mice were compared to Taxol 20 mg/kg (Supplementary Table 2.9 and Fig. 2.9). 
Abraxane was excluded considering expected immunogenicity of human serum albumin in 
balb/c mice. The sum total PTX (encapsulated and released) was measured and reported. PTX 
plasma exposure as measured by AUC of the concentration time curve was 3.2 times for mice 
receiving POx/PTX 50/40 formulation at MTD 150 mg/kg dose vs Taxol MTD 20 mg/kg (Fig. 
2.9). This nonlinear relationship of dose and AUC may be explained by increased clearance (Cl) 
and volume of distribution (Vd) for POx/PTX 50/40 comparing to Taxol. Interestingly, Cmax 
observed for POx/PTX 50/40 was significantly higher and T1/2 were longer (about 2.8 h) in 
contrast to Taxol (about 2.6 h) in these mice. Drug exposure (AUC) of spleen, liver, kidney, 
lung, heart and brain organs in POx/PTX 50:40 group was 6, 3, 8, 9, 12 and 17 folds of the Taxol 
group respectively. Notably, AUC for POx/PTX 50/20 formulation was 2 times of 50/40 
formulation giving the same 150 mg/kg dose, and was 6.8 folds higher than Taxol MTD dose 20 
mg/kg. This increased AUC is possibly due to following: 1) more polymer was used in the 
formulation resulting in much smaller micelles (~20nm) but may contain much higher number of 
nanoparticles; 2) increased number of nanoparticles may saturate mononuclear phagocyte system 
(MPS), a typical route of foreign body removal; 3) higher polymer concentration may retain 
drugs in micelles longer from releasing by maintaining above CMC concentration. However, if 
the MPS would be significantly involved, we would expect much higher drug exposure to organs 
associated with the MPS, such as the liver and spleen. This appears to be not the case. In addition 
to 6.8 folds increase of AUC, POx/PTX 50/20 formulation has similar clearance and volume of 
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distribution to Taxol while drug exposure (AUC) of spleen, liver, kidney, lung, heart and brain 
organs in POx/PTX 50/20 group was 10, 5, 12, 14, 11 and 16 folds of the Taxol group 
respectively. Fig. 2.9B,C,D,E,F depict biodistributions in major organs of each formulation. 
Despite higher AUC, POx/PTX 50/20 showed similar distribution pattern to 50/40 (150 mg/kg) 
but higher liver accumulation at first few hours; Taxol had higher relative liver accumulation but 
other organ distributions are quite similar to POx/PTX 50/20 (20mg/kg).  
In the tumor bearing mice, it is apparent that when administering Taxol, the PTX 
concentration in the blood decreases more rapidly [t½, α= 2.5 h vs. 3.1 h (50/20) and 3.5 h 
(50/40), Table 2.10]. Also, Cmax of Taxol is approx. half of Cmax of POx/PTX 50/40. The plasma 
PTX concentration is approx. one order of magnitude higher for the POx/PTX formulations as 
compared to Taxol formulation (Fig. 2.8A, Fig. 2.10A), resulting in much higher tumor drug 
concentrations (Fig. 2.8B). Please note, since we injected at MTD, a similar relative dose %ID/g 
between POx/PTX and Taxol corresponds to approx. 7 times higher values in the absolute values 
dose (Fig. 2.8A,B). The peak concentrations in the tumors are reached 1 h p.i. for all investigated 
formulations, but Cmax and AUC is considerably higher for both POx/PTX formulations. Similar 
to plasma concentrations, the intratumoral drug concentration is initially 4-6 fold higher for POx 
formulations, the difference reaches two orders of magnitudes after 7 days. The biodistribution 
of PTX is very similar for both POx formulations. At early time points, we observed a moderate 
uptake in spleen, liver, kidney and heart besides tumor uptake. Of all organs, liver exhibited the 
highest uptake (%ID/g) after one hour (Fig. 2.8C). It must be noted that not only in tumor we 
found a higher %ID/g as compared to Taxol but also in sensitive tissue, such as the brain. We do 
not know what the long-term effects of this may be, but our results warrant close examination of 
potential side effects in future preclinical studies. 
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However, after 24 hours and in contrast to Taxol, the tumor-to-organ ratio exceeds unity 
for all organs examined (Fig. 2.8D). Injection of the MTD of Taxol slowed down tumor growth 
and prolonged survival only for approx. 5 days. A single injection of MTD of POx/PTX 
formulations apparently eradicated the tumors in 4 out of 7 animals, no re-growth was observed 
up to 28 days after injection (Fig. 2.8E,F). Although the remaining animals in both groups 
relapsed starting 7 to 19 days after administration, survival was significantly prolonged in both 
cases.  
The biodistribution of the polymeric carrier was followed independently by in vivo 
positron emission tomography (PET, Fig. 2.6) and tissue sampling after necropsy (Fig. 2.11) 
using Cu-64 labeled polymers. The biodistribution of the present amphiphilic POx (10 kg/mol) 
appeared more similar to small hydrophilic POx[144]. When injected without drug and below the 
critical micellar concentration (cmc, polymer present as unimers), the circulation half-live is in 
the order of minutes. Excretion appears almost exclusively via kidneys with negligible liver 
uptake (Fig. 2.12A). The tmax in the kidneys is only approx. 2 min. When injected above the cmc, 
the tmax is shifted to about 10 min and activity associated with the kidneys remains high to about 
60 min (Fig. 2.6B). However, non-specific uptake in other organs remain minimal. 
Also when then polymer is injected as PTX formulation, the kidney concentration is 
maximal at around 10 min and remains constant for at least an hour (Fig. 2.8C,D). After 4 h, 
however, the absolute dose found in the kidney is very low although it constitutes the organ with 
the highest residual activity (Fig. 2.8C,D). More quantitative data from necropsy show that 
polymer %ID/g is highest for plasma and tumor, followed by kidneys for the 50/40 formulation 
(Fig. 2.11). 
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As expected, the polymer with a molar mass well below the excretion limit of the kidney 
(Mn = 10 kg/mol) was readily cleared by the kidney and showed minimal liver uptake, similar to 
previous observation on small (5 kg/mol) hydrophilic POx.[169] 
2.4.5 Antitumor efficacy and tumor accumulation of POx/PTX 
After the preliminary experiment using only a single injection, we evaluated antitumor 
efficacy of POx/PTX in tumor models including A2780 human ovarian cancer xenografts, 
LCC6-MDR multidrug resistant human triple negative breast cancer (TNBC) orthotopic model 
and “T11” mouse claudin-low breast cancer model, an orthotopic syngeneic transplants (OST), 
using a q4d x 4 regimen. 
2.4.5.1 A2780 human ovarian cancer xenografts 
We compared treatment at MTD and ½MTD (for POx/PTX and Abraxane) of small (ca. 
100-200 mm3) and larger tumors (ca. 400 mm3) to mimic early and late stage disease, 
respectively. In small tumors, Taxol delayed tumor growth until the fourth injection after which 
the lesions started to rapidly grow back (Fig. 2.12A,C). In contrast, POx/PTX 50/40 exhibited 
very significant tumor inhibition (p<0.001). After the third dose, all tumors achieved a complete 
response. In the Abraxane MTD group, 3 out of 7 mice in Abraxane group experienced severe 
peripheral neuropathy as evidenced by paralysis and over 15% weight loss that required 
sacrificing the animals (Fig. 2.12D,E). At ½MTD dose of Abraxane, 40% of mice relapsed after 
initial tumor shrinkage. As a result, survival in the Abraxane regimen was the same for MTD and 
½MTD group (Fig. 2.12D). 
For later stage tumors, Taxol did not control tumor (Fig. 2.8A), while POx/PTX 
formulations resulted in complete remission of tumors in all animals at MTD and ½MTD even 
120 days post treatment (Fig. 2.8A,B). This remarkable and complete remission was achieved 
only after four injections of our formulation and in a very aggressive tumor model. The best 
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previous report of complete regression using micellar PTX was done on less aggressive models 
and required much greater number of injections (from 9 to 11).[170] Abraxane at MTD also led to 
complete remission of tumors and survival of all animals, at ½MTD tumors shrunk initially 
significantly but grew back and survival was significantly lower than in POx/PTX and Abraxane 
MTD group (Fig. 2.8B). 
2.4.5.2 Orthotopic model of LCC6-MDR human TNBC[171] 
In this model, the previously established MTDs for POx/PTX 50/40 and Abraxane 
proved to be slightly too high. Thus, experiments were conducted at doses of 80 mg/kg 
(Abraxane) and 120 mg/kg (POx/PTX). These two treatment groups successfully reduced tumor 
growth, POx/PTX more so than Abraxane (Fig. 2.8C). However, Abraxane did not lead to 
increased survival, while POx/PTX extended survival significantly (Fig. 2.8D). 
2.4.5.3 T11 OST breast cancer model 
This very aggressive tumor model represents a recently identified claudin-low subtype of 
TNBC with very poor prognosis.[172] This syngeneic transplant model recapitulates clinical tumor 
types,[173] with this particular line being a good mimic of human claudin-low tumors, and which 
has been extensively used for treatment studies.[174-176] 
Several chemotherapeutic agents including carboplatin, PTX, erlotinib and lapatinib were 
tested in this model as single or two drug combinations but showed no efficacy.[174] The results 
using the POx/PTX 50/40 formulation in A2780 and LCC6-MDR prompted us to test the POx 
nanoformulations in the T11 model. We observed clear trend of tumor inhibition in POx/PTX 
50/40 ½MTD group and significant suppression at MTD dose (p<0.01) (Fig. 2.13E). 
Furthermore, POx/PTX 50/40 at ½MTD dose also exhibited significant trend (p=0.016) 
regarding survival benefit over control groups (Fig. 2.13F).  
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2.5  Discussion 
A very simple formulation approach for a clinically established drug employing an 
amphiphilic polymer results in very significantly improved therapeutic outcomes in several of 
tumor models as compared to clinically applied formulations. This shows the necessity and 
promise for further development of novel excipients. The nanoformulation features a controllable 
and defined size (20 - 80 nm, PDI ~ 0.1), which is particularly desirable for drug delivery. Small 
angle neutron scattering data suggest formation of amorphous nanoparticles with hydrodynamic 
radii < 50 nm.[153] Drug delivery systems in this size range are believed to be particularly useful 
in cancer chemotherapy, due to the “enhanced permeability and retention” (EPR) in tumor tissue 
and because such small sized entities exhibit superior penetration in poorly permeable 
tumors.[177] However, considering our results on serum stability of our formulation, we would not 
expect a major contribution of the EPR effect based on the polymer micelles. 
Notably, polymer design proved to be of major importance in our studies. The 
hydrophilic block is poly(2-methyl-2-oxazoline) (PMeOx), which imposes stealth properties 
similar if not superior to PEG.[178, 179] The hydrophobic block, poly(2-butyl-2-oxazoline) 
(PBuOx) was screened as an ideal environment for solubilizing unprecedentedly high amount of 
PTX with outstanding formulation stability.[1, 2, 180] Moreover, triblock structure proved superior 
as compared to diblock structure.11 In this environment even at very high loading the drug 
remains molecularly dispersed in the micelle having a raspberry-like morphology.[153] We have 
followed some batches of nanoformulations for months and observed no changes at ambient 
conditions.[153] Due to their low viscosity, they can be readily injected as prepared at high 
concentration. Such formulation properties compare very favorably to other PTX formulations in 
clinics and in late stage clinical trials. At maximum loading (POx/PTX 50/45 g/L), the drug 
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release in vitro appears to be slightly faster as compared to lower loading (POx/PTX 50/40 g/L) 
(Fig. 2.3).  
Its unparalleled high drug loading and drug concentration allows for significantly 
decrease of the excipient and injection volume, respectively. This may be a factor for the 
extraordinary high MTD as compared to clinically approved formulations, such as Taxol and 
Abraxane. Due to this favorable safety profile, we hypothesize that the presented 
nanoformulation may result in clinically relevant advantages over current approved formulations, 
allowing high dosage of PTX to be given in order to maximize therapeutic effect.  
Although the POx/PTX formulations are stable for months in solution in the absence of 
an appropriate sink[153], we cannot assume a priori that they are also stable in the presence of 
high protein concentrations and other potential sinks as the blood. We chose a label-free 
approach, and investigated the quenching of albumin tryptophan fluorescence in the presence of 
polymer and POx/PTX formulations. In brief, two important results were obtained. First, the 
polymer leads to minor but noticeable concentration dependent fluorescence quenching, 
indicative of weak polymer-protein interactions. Second, drug formulations lead to a more 
pronounced concentration dependent fluorescence quenching, which was dependent on the 
polymer content of the formulation – higher polymer content decreased fluorescence quenching, 
which we attribute to competitions of the micelles with the serum protein for the drug binding. 
More detailed studies, including fluorescence lifetime measurements are warranted, but we 
conclude from these results that serum albumin represents an excellent sink for PTX from 
POx/PTX formulations and that there is a rapid exchange between the two PTX loci. For the in 
vivo situation, we envision that the PTX can be released from the micelles to serum albumin to 
reach a highly dynamic equilibrium as the polymer unimers are excreted via the kidneys. 
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However, it should be noted that compared Taxol that is known to rapidly exchange PTX to the 
serum,[148] the POx/PTX formulations are more stable in the presence of serum as follows from 
our SPE column experiment. Moreover, as the POx/PTX dose increases to 150 mg/kg the 
amount of the drug associated with the micellar fraction also increases to over 80%. Therefore, at 
least in the initial moment when concentration of the POx/PTX in the blood is very high 
(estimated 2.5 mM PTX compared to ~0.5 mM serum protein [148]) a significant portion of the 
administered drug may still remain in the micelles. This may help explaining the fact that the 
MTD in the case of our formulation is much higher than that of Abraxane. The high value we 
found for protein bound paclitaxel in the case of Taxol is in line with well-known high protein 
bound fraction of approx. 92%-97% in humans. [148] Therefore, it is reasonable to assume that 
compared to in Taxol formulation POx micelles have much better retention of PTX and are more 
stable in the presence of the serum. Moreover, as the ratio of the drug in POx/PTX formulation 
increases the fraction of the drug associated with the POx micelles also increases. 
The biodistribution of radiolabeled polymer indicates that the amphiphilic POx has a 
similarly favorable biodistribution as the purely hydrophilic POx. Remarkable is in particular the 
very low liver uptake of the polymer, which may proof beneficial in repeated treatment regimen. 
PK data of drug loaded polymeric micelles show a strongly elevated drug exposure to tumor 
tissues and consequently a significantly enhanced antitumor activity with significantly prolonged 
survival.  
The benefit in survival in A2780 and LCC6-MDR models over both Taxol and Abraxane 
is remarkable and is very promising for further development. In the case of A2780 we 
investigated tumor growth inhibition and survival for small and large tumor models, In both 
cases, we found that in contrast to Taxol and Abraxane, the tumors were apparently completely 
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eradicated in all animals at MTD and ½ MTD (no regrowth after treatment regimen up to day 80 
treatment initiation) (Fig. 2.12A,B and 2.13A,B). This lead to a highly significant increase in 
animal survival (Fig. 2.12D and 2.13B insert). In the multidrug resistant LCC6-MDR model, 
tumors were not eradicated but shrank initially during treatment, which was not observed in the 
Taxol and Abraxane groups. While Taxol led to no appreciable delay in tumor growth, Abraxane 
slowed it down significantly (Fig. 2.13C). However, no survival benefit was observed for both 
clinically approved formulations, in contrast to the group treated with POx/PTX formulation 
(Fig. 2.13D). It appears that the increased MTD observed for the POx/PTX formulation 
correlates with increased antitumor efficacy. It should be obvious that one can expect a higher 
antitumor efficacy if more drug is administered and delivered to the tumor. However, a critical 
parameter, which will have to be assessed in more detailed toxicity studies is the effects on other 
organs on the long term, but this is clearly outside the scope of this study. 
Also in the T11 model a significant trend of extension in survival was observed. 
However, the therapeutic outcome in this very challenging model is clearly still unsatisfactory. 
Although our results comparing the performance of PTX/POx micelle formulations with Taxol 
and Abraxane are striking, we would like to point out that the latter two formulations of the PTX 
were evaluated in numerous clinical trials and have been commercially available and that the true 
potential of PTX/POx micelle could be revealed only based of the extensive further pre-clinical 
and clinical evaluation. It should be noted that the amphiphilic POx was previously implemented 
in the formulation of various other drugs, some of which show synergism with PTX. The 
resulting nanoformulation exhibited synergism in vitro.[2] In combination with the presented 
results, we hypothesize that treatment option with multiple drugs may benefit in particular by 
using POx formulation in this very challenging model.  
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These promising preclinical data on POx/PTX nanoformulation provide a robust rationale 
for further development. Increased safety may ultimately benefit patient survival and quality-of-
life, which is not provided by Abraxane in comparison to Taxol. 
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Table 2.1 Drug concentration, loading efficiency (LE), loading capacity (LC), drug loaded 
micelle size and PDI of POx/PTX formulations. 
 
POx 
(g/L) 
Final Drug 
conc. (feed) 
(g/L) 
Loading 
Efficiency 
(LE, %) 
Loading 
Capacity 
(LC, %) 
Effective 
Diameter 
(nm) 
PDI 
50 45 (50) 91.6 47.8 76.7 0.162 
50 40 (45) 88.7 44.4 54.7 0.151 
50 20 (20) 100 28.7 23.2 0.155 
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Table 2.2 Size and PDI of two POx/PTX formulations before and after lyophilization.  
 
Formulations Before Lyophilization 
Re-dispersed in 
Water 
Polymer/ 
drug ratio 
POx 
(g/L) 
PTX 
(g/L) 
Effective 
Diameter 
(nm) 
PDI 
Effective 
Diameter 
(nm) 
PDI 
1.25/1 50 40 54.7 0.151 52.3 0.194 
2.5/1 50 20 23.2 0.160 22.3 0.175 
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Table 2.3 SPE column separation of POx/PTX 50/40. 
 
Formulation 
 Concentration, mg/ml PTX recovery, % 
PTX  POx 
Micelle 
fraction 
(A3+A4) 
Acid wash 
(A6) 
Total 
Recovery 
POx/PTX 
50/40 
4 5 86 % 9 % 98 % 
2 2.5 84 % 15 % 99 % 
1.5 1.875 83 % 14 % 98 % 
1 1.25 83 % 13 % 96 % 
0.4 0.5 83 % 13 % 96 % 
0.2 0.25 83 % 13 % 96 % 
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Table 2.4 SPE column separation of PTX dissolved in EtOH/water. 
 
 
 Concentration, 
mg/ml 
PTX recovery, % 
PTX  
“Micelle fraction” 
(A3+A4) 
Acid wash 
(A6) 
Total 
Recovery 
Free PTX 
 
4 4 % 96 % > 99 % 
2 3 % 97 % > 99 % 
1.5 4 % 96 % > 99 % 
1 3 % 97 % > 99 % 
0.4 1 % 99 % > 99 % 
0.2 1%  98 % > 99 % 
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Table 2.5 SPE column separation of serum samples incubated with POx/PTX 50/40, 
POx/PTX 50/20, or Taxol and free PTX for 1h and 4h. 
 
Formulation 
Concentration 
(g/L) 
PTX elution, % 
1h incubationa 4h incubation 
PTX POx 
non-protein 
boundb 
protein 
boundc 
non- 
protein 
boundb 
protein 
boundc 
POx/PTX 
50/40 
0.27 0.33 62.0±2.9 % 33.9±0.4 % 52 % 27 % 
POx/PTX 
50/40 
2.0 2.5 84.1±1.5 % 14.2±0.5 % 74 % 16 % 
POx/PTX 
50/20 
2.0 5.0 81.8±1.8 % 15.6±2.1 % 68 % 15 % 
POx/PTX 
50/10 
2.0 10 80.8±0.6 % 15.1±1.9 % 70 % 16 % 
Taxol 0.27 0 20.3±1.9 % 74.6±4.3 % 7 % 46 % 
PTX 0.27 0 1.4±0.1 % 90.4±0.2 % 1 % 94 % 
a data represents means ± SD (n=3) 
b fractions A3 and A4 as described in the experimental section 
c fractions A6 as described in the experimental section 
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Table 2.6  Summary of cytotoxicity to liver Hep G2 and kidney LLC-PK1 cells. 
 
Formulations 
LLC-PK1 cells 
IC50, µM, 48 h 
Hep G2 cells 
IC50, mM, 48 h 
POx alone > 1000 >5 
POx/PTX 50/40 0.00005 >5 
Taxol 0.03 0.005 
DMSO-PTX 0.0005 0.03 
Abraxane 0.0007 1 
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Table 2.7 Monitoring of animal weight and behavior to determine the maximum tolerated 
dose.  
Animals (tumor-free nude mice (NCI)) received four injections every four days (q4dx4) via tail 
vein injection. 
Formulations 
Dose 
(mg/kg) 
Animal 
death 
Weight loss 
Taxol 
20 0/8 < 5% 
25 3/8 Animal Death 
Abraxane 
90 0/8 Weight gain 
120 4/8 Animal Death 
POx/PTX 
50/40 
Micelles 
80 0/8 Weight gain 
100 0/8 Weight gain 
120 0/8 Weight gain 
150 0/8 Weight gain 
175 5/8 >15% 
Cremophor 
EL 
20 8/8 Animal Death 
25 8/8 Animal Death 
POx 
187.5 0/8 Weight gain 
500 
1000 
0/8 
2/8 
Weight gain 
Animal Death 
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Table 2.8 Clinical chemistry parameters of Balb/c mice receiving saline, POx and POx/PTX 
and Taxol. 
Abbreviations used in the table: ALT, alanine amino transferase; ALP, alkaline phosphatase; BUN, blood 
urea nitrogen. ALT, ALP units in U/L; bilirubin, glucose, creatinine, BUN, phosphate units in mg/dL; total 
protein, albumin, serum globulin units in g/dL. 
 
 
 
 
  
Parameters Normal range 
Formulations 
Saline POx POx/PTX Taxol 
ALT 17 – 77 37.0  38.8  36.3  28.7 
ALP 35 – 222 27.7  15.3  9.0 22.0  
Total bilirubin 0.0 - 0.9 0.3  0.3  0.3  0.3  
Glucose 140 – 263 197.0  199.3  305.3  178.3  
Total protein 3.9 – 6.4 5.1  5.0  5.0  5.3  
Creatinine 0.2 – 0.9 <0.2 <0.2 <0.2 <0.2 
BUN 9 - 33 15.7  14.0 16.3  14.0 
Albumin 2.5 – 4.6 4.0  3.9  4.0  4.3  
Phosphate N/A 9.0  8.9  8.0 8.6  
Serum 
globulin 
N/A 
1.1  1.1  0.9  1.0  
  55 
Table 2.9 PK parameters of PTX for plasma and organs in tumor-free nude mice. 
 
Formulations Parameters 
POx/PTX 
50/20 
POx/PTX 
50/40 
Taxol 
150mg/kg 150mg/kg 20mg/kg 
Plasma 
t1/2, α (h) 2.8 2.8 2.6 
Cmax (ng/g) 250,707.3 222,881.7 73,182.8 
AUClast (h*ng/g) 680,715.5 328,268.7 101,464.0 
Clobs (ml/h/kg) 219.7 455.7 196.1 
Vdobs (ml/kg) 12,020.4 25,432.5 11,869.4 
Spleen 
Cmax (ng/g) 124,770.6 174,751.6 140,079.0 
AUClast (h*ng/g) 759,679.0 435,122.7 423,749.5 
Liver 
Cmax (ng/g) 511,263.4 378,422.3 42,691.0 
AUClast (h*ng/g) 2395,918.0 1384,513.0 93,609.3 
Kidney 
Cmax (ng/g) 311,139.2 375,666.1 13,792.0 
AUClast (h*ng/g) 1138,942.0 766,298.1 36,552.0 
Lung 
Cmax (ng/g) 74,849.1 160,993.4 26,904.0 
AUClast (h*ng/g) 517,888.8 345,669.3 67,963.7 
Heart 
Cmax (ng/g) 163,773.7 194,427.8 25,988.0 
AUClast (h*ng/g) 764,680.8 816,291.3 73,863.4 
Brain 
Cmax (ng/g) 1,408.1 1,514.6 230.0 
AUClast (h*ng/g) 116,611.6 132,954.2 8,437.0 
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Table 2.10 PK parameters of PTX for plasma and organs in tumor bearing mice. 
Formulations Parameters 
POx/PTX=50/20 POx/PTX=50/40 Taxol 
150mg/kg 150mg/kg 20mg/kg 
Plasma 
t1/2, α (h) 3.1 3.5 2.5 
Cmax (ng/g) 82,627.8 111,647.5 62,367.5 
AUClast 
(h*ng/g) 
416,296.3 275,087.8 63,151.2 
Clobs (ml/h/kg) 348.5 457.3 302.9 
Vdobs (ml/kg) 46,320.8 87,879.4 49,118.4 
Spleen 
Cmax (ng/g) 161,748.5 162,418.0 15,073.1 
AUClast 
(h*ng/g) 
725,490.3 542,404.2 64,077.4 
Liver 
Cmax (ng/g) 591,636.5 415,542.3 55,531.1 
AUClast 
(h*ng/g) 
2,566,200.3 1,797,720.6 332,588.0 
Kidney 
Cmax (ng/g) 303,429.2 294,134.4 20,341.8 
AUClast 
(h*ng/g) 
1,289,454.2 722,532.2 64,369.1 
Lung 
Cmax (ng/g) 89,356.1 86,601.7 16,165.1 
AUClast 
(h*ng/g) 
395,808.9 277,682.5 49,156.0 
Heart Cmax (ng/g) 228,724.0 185,828.7 13,752.2 
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AUClast 
(h*ng/g) 
1,322,810.7 638,352.3 49,146.4 
Brain 
Cmax (ng/g) 1,510.1 1,549.2 181.4 
AUClast 
(h*ng/g) 
215,549.6 194,804.3 12,237.3 
Tumor 
Tmax (h) 0.5 1.0 1.0 
Cmax (ng/g) 32,856.0 49,872.5 7,679.0 
AUClast 
(h*ng/g) 
657,938.7 605,549.3 101,683.6 
 
 t1/2, α = half-life at the biodistribution phase; Cmax = maximum plasma concentration; AUClast = area under 
the curve from time 0 to 168 h; Clobs = observed total body clearance; Vdobs = total volume of distribution 
observed; Tmax = time of maximum concentration. 
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Figure 2.1 Standard operating procedure (SOP) for small scale (1-5 mg) micelle production. 
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Figure 2.2 Construction and physicochemical properties of PTX nanoformulations.  
(A) Schematic and chemical structures of poly(2-oxazoline) triblock copolymer and PTX. (B) The 
nanoformulation is easily prepared employing the thin-film approach. (C) Transmission electron 
microscopy (TEM) shows the spherical morphology of the nanoformulation. (Scale bar = 100 nm) 
(D) Small size and narrow size distribution is corroborated by dynamic light scattering (DLS) 
(blue: POx/PTX 50/40 g/L, red: POx/PTX 50/20 g/L). 
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Figure 2.3 Characterization of POx/PTX formulation.  
(A), Small size, narrow size distribution and size stability is corroborated by dynamic light 
scattering (DLS). (B), Nanoformulation release PTX in phosphate-buffered saline at 37 ºC without 
burst if drug loading is ≤ 45%wt. Data are means ± s.e.m., n = 3. (C), The POx/PTX 50/40 
formulation was lyophilized and reconstituted without adding any cryo-protectants. Each vial 
contains 10mg PTX and 12.5mg POx. (D), Stability of POx/PTX 50/40 and 50/20 formulations in 
pure water over 13 days by measuring size and PDI in DLS. 
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Figure 2.4 In vitro toxicity evaluation.  
(A) Complement activation, (B) hemolysis, (C) platelet aggregation, (D) prothrombin time (PT), 
(E) thrombin time and (F) Activated partial thromboplastin time (APTT) of POx polymer or 
POx/PTX micelles (concentration range from 0.006-1.52 mg/mL, 1.52 mg/mL corresponds to 
approx. 2-fold the value we would expect to observe in humans) as compared to Taxol. Negative 
control (NC) was PBS (complement activation, hemolysis) and normal plasma standard (PT, 
thrombin and APTT) were used, respectively. As positive control, cobra venom factor (CVF, 
complement activation), Triton X-100 (hemolysis), collagen (platelet aggregation) and abnormal 
plasma standard (PT, thrombin and APTT) were used, respectively. Data are shown as means ± 
SD (n=3 or n=2 for C). 
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Figure 2.5 MTD in tumor bearing nude mice and toxicology profiles.  
(A) Mice body weight (% of initial) after repeated administration of various PTX formulations. 
(B) Maximum tolerated dose of the POx/PTX 50/40 formulation (150 mg/kg) is considerably 
higher as compared to two clinically approved formulations Taxol (20 mg/kg) and Abraxane (90 
mg/kg) in a q4d x 4 regimen. (C) Histological examination of liver, kidney, spleen, and lung tissues 
by hemotoxylin & eosin (H&E) staining from animals treated with Abraxane (90 mg PTX/kg), 
Taxol (20 mg PTX/kg), POx/PTX (50/40, 150 mg/kg), POx (150 mg/kg) or saline. Tissues were 
harvested two weeks after the last dose of q4d x 4 regimen. Scale bar 200 µm, 100 µm for kidney.    
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Figure 2.6 Tissue biodistribution and PET/CT images of tumor bearing (A2780 xenograft) 
nude mice obtained after i.v. injection of formulations containing 0.2 mCi 64Cu-POx.  
Mouse injected with (A) 64Cu-POx polymer alone below cmc concentration, (B) 64Cu-POx/PTX 
50/40 micelle formulation at dose of 150 mg/kg, (C) 64Cu-POx/PTX 50/20 micelle formulation at 
dose of 150 mg/kg, and (D) 64Cu-POx 50 micelles without drug loading at equivalent dose. 
PET/CT images were taken dynamically for the first hour and then at 4 h and 24 h post i.v. 
injection. Biodistribution data were obtained from quantification of PET images. Strong 64Cu 
signals were mainly observed in the kidney. Representative PET/CT images were taken at 4 h post 
injection (n = 1 for each group). Abbreviations: suv-standardized uptake value; T/M-tumor/muscle 
ratio. Tumor region is circled. 
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Figure 2.7 Quenching of BSA fluorescence by micellar PTX.  
Spectra were recorded 30 min after addition of (A) the polymer alone, (B) POx/PTX 50/20, (C) 
and POx/PTX 50/40. Arrows show the BSA alone spectra and point towards the direction of 
development of fluorescence intensity with increasing concentration. The concentrations in the 
plot (µM) correspond to the final concentration of the polymer. The POx : PTX molar ratios in 
drug formulations are approx. 1:5 and 1:10 in POx/PTX 50/20 and POx/PTX 50/40 respectively. 
The BSA samples were prepared at 2.5 µM, PBS, pH 7.4. Therefore, the molar ratio of PTX/BSA 
is 400/1 (POx/PTX=50/40) and 200/1 (POx/PTX=50/40), respectively.  
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Figure 2.8 Pharmacokinetics, biodistribution and tumor inhibition in A2780 human ovarian 
tumor bearing mice.  
(A,B) Plots of PTX concentration in plasma (A) and tumor (B) over 168 h following single 
intravenous (i.v.) injection of POx/PTX 50/40 or 50/20 and Taxol formulations at MTD dose. 
(C,D) Biodistribution after single i.v. injection of PTX administered as POx/PTX 50/40, POx/PTX 
50/20 and Taxol formulation at 1 h p.i. (C) and 24 h p.i. (D). Tumor growth inhibition (E) and 
Kaplan-Meier survival plots (F) of tumor bearing mice after single i.v. injection of POx/PTX 
50/40, POx/PTX 50/20 and Taxol formulation at MTD. For A-D, data are expressed as means ± 
SD, n = 3 for all groups. For E, data for Taxol and saline control are expressed as means ± s.e.m., 
n = 7, while for POx/PTX 50/40, POx/PTX 50/20 nanoformulations, the data of individual animals 
are presented. 
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Figure 2.9 PK and biodistribution in tumor free nude mice.  
(A) Plasma, (B) Spleen, (C) Liver, (D) Kidney, (E) Lung, and (F) brain concentration of PTX over 
168 h following single intravenous (i.v.) injection of POx/PTX 50/40 (blue) or 50/20 (red) and 
Taxol formulations (black) at MTD dose (mean ± SEM, n=4).  
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Figure 2.10 Pharmacokinetics in A2780 human ovarian tumor bearing mice.  
(A,B) Plots of PTX concentration in plasma (A) and tumor (B) over 168 h following single 
intravenous (i.v.) injection of POx/PTX 50/40 or 50/20 and Taxol formulations at MTD dose 
(mean ± SD, n = 3). 
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Figure 2.11 Biodistribution of POx and PTX in A2780 xenograft mice.  
Biodistribution of POx and PTX in A2780 xenograft mice for 1min, 5min, 10min, 30min, 1hr, 2hr, 
4hr and 24hr after receiving single i.v. injection of POx/PTX (50/40) micelle formulation (150 mg 
PTX/kg) in (A) plasma, (B) tumor, (C) brain, (D) spleen, (E) liver, (F) kidney, (G) lung and (H) 
heart. 
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Figure 2.12 Antitumor efficacy of PTX formulations in A2780 tumors of small size.  
(A,B) Comparison of tumor growth inhibition of (A) POx/PTX 50/40 formulation (@MTD = 150 
mg/kg) and Taxol (@MTD = 20 mg/kg), and (B) POx/PTX 50/40 formulation (@MTD and 
½MTD dose = 150 and 75 mg/kg, respectively) and Abraxane (@MTD and ½MTD = 90 and 45 
mg/kg, respectively). Each formulation was injected on days 0, 4, 8, 12. Data is expressed as mean 
± s.e.m., n=7. ***p<0.001. (C) A representative image of mice (day 6) treated with saline (left), 
Taxol (middle) and POx/PTX 50/40 (right), respectively. (D) Kaplan-Meier survival plot for all 
groups in (A) and (B) ****p<0.0001. (E) Changes of body weight of animals in each group (mean 
± s.e.m., n = 7). 
 
 
 
  70 
Figure 2.13 Antitumor efficacy of various PTX formulations in different tumors.  
(A,B) Comparison of tumor growth inhibition of (A) POx/PTX 50/40 formulation (@MTD dose 
= 150 mg/kg) and Taxol (@MTD dose = 20 mg/kg), and (B) POx/PTX 50/40 formulation (@MTD 
and ½MTD dose = 150 and 75 mg/kg, respectively) compared to Abraxane (@MTD and ½MTD 
dose = 90 and 45 mg/kg). Growth inhibition in triple negative breast cancer (C) and survival (D) 
of mice bearing LCC6-MDR tumors. Treatment was performed at respective MTDs or dose of 
polymer corresponding to MTD (POx control). (E,F) Tumor growth inhibition (E) and survival 
(F) of mice bearing T11 tumors. Treatment was performed at respective MTD and ½MTD dose or 
dose of polymer corresponding to MTD (POx control). The formulation was injected on days (A-
D) 0, 4, 8, and 12, or (E,F) 2, 6, 10, 14, and 18, respectively. Data is expressed as mean ± s.e.m., 
n=7. *p<0.05, **p<0.01, ***p<0.001. 
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CHAPTER 3 : CO-DELIVERY OF PACLITAXEL AND CISPLATIN IN HIGH 
CAPACITY POLY(2-OXAZOLINE) POLYMERIC MICELLES IMPROVES 
TREATMENT OF OVARIAN AND BREAST CANCER 1 
3.1  Summary 
Concurrent delivery of multiple drugs using nanoformulations can improve outcomes of 
cancer treatments. Here we demonstrate that this approach can be used to improve the paclitaxel 
(PTX) and alkylated cisplatin prodrug (CP) combination therapy of ovarian and breast cancer. 
The drugs are co-loaded in the polymeric micelle system based on amphiphilic block copolymer 
poly(2-methyl-2-oxazoline-block-2-butyl-2-oxazoline-block-2-methyl-2-oxazoline) (P(MeOx-b-
BuOx-b-MeOx). A broad range of drug mixing ratios and exceptionally high two-drug loading of 
over 50 % wt. drug in dispersed phase is demonstrated. The drugs co-loading in the micelles 
result in a slowed-down release, improved pharmacokinetics and increased tumor distribution of 
both drugs. A superior anti-tumor activity of co-loaded PTX/CP drug micelles compared to 
single drug micelles or their combination was demonstrated in cisplatin-resistant human ovarian 
carcinoma xenograft A2780/CisR tumor and multidrug resistant breast cancer LCC-6-MDR 
orthotopic tumor models. A hypothesis has been formulated that the sustained release of the 
micelle-incorporated hydrophobic drug to intermediate drug carriers, such as serum proteins in 
the body, is pivotal for successful delivery of this drug to the tumors. Overall, the results provide 
support for the use of PTX and cisplatin micelles as a strategy for improved chemotherapy of 
ovarian and breast cancer. 
1 This chapter previously appeared as a manuscript soon to be submitted. Y.M. performed the synthesis of prodrugs.   
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3.2  Introduction 
The combination chemotherapy using sequential administration of paclitaxel (PTX) 
followed by a platinum-based regimen is currently the first-line therapy for ovarian cancer as 
well as common treatment for breast cancer [199, 200]. PTX is a member of Taxanes family, which 
arrest cells in the G2/M phase by binding to the β-tubulin subunits, inhibiting depolymerization 
of microtubules, and leading to apoptosis through cell-signaling cascades [201]. However, taxane 
compounds, including PTX, are very poorly soluble and thereby require the use of toxic 
excipients in clinical formulations, such as Chremophor EL in Taxol, which can cause severe 
hypersensitivity reactions in patients. Platinum anticancer drugs, such as cisplatin, the most 
potent member of the platinum drug family, penetrate into the nucleus of cancer cells and form 
adducts with DNA leading to apoptosis [202]. Clinical use of cisplatin is complicated by the dose-
limiting side effects as well as rapid development of drug resistance [203]. Moreover, cisplatin 
also has formulation issues such as relatively low solubility in both aqueous and organic solvents 
[204]. 
Co-delivery of drug combinations in the same vehicle may improve the chemotherapy of 
tumors by synchronizing their exposure to the drugs and achieving synergistic pharmacological 
action in the tumor cells [205]. Hence, the delivery of multiple chemotherapeutic agents in a single 
nanoparticle carrier has attracted attention as a strategy for improving treatment responses, 
reducing side effects, and overcoming drug resistance [206]. One major success of this strategy is 
exemplified by a recent approval by the US Food and Drug Administration of Vyxeos (CPX-
351), a liposomal combination of daunorubicin and cytarabine, for newly diagnosed therapy-
related acute myeloid leukemia (t-AML) in adult patients and AML with myelodysplasia-related 
changes (AML-MRC) [205]. Moreover, several preclinical formulations of multiple drugs co-
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loaded into various nanoparticle carriers have also been evaluated and shown some promise for 
the treatment of cancers [192, 207]. 
A principal bottleneck in the development of co-loaded drug nanoformulations is that 1) 
many drugs have poor miscibility with each other, and 2) many nanoparticle carriers have a 
fairly low loading threshold for such drugs. One novel drug carrier system that stands apart from 
the others in that regard is polymeric micelles (PM), based on the block copolymers of poly(2-
methyl-2-oxazoline) (PMeOx) and poly(2-butyl-2-oxazoline) (PBuOx) [208]. Interestingly, despite 
the mild hydrophobicity of the core-forming PBuOx block, we have found that triblock 
copolymer PMeOx-PBuOx-PMeOx exhibits an unprecedentedly high capacity for solubilization 
of extremely hydrophobic drugs, including taxanes, and several drug combinations [160, 209]. For 
many drugs, the aqueous POx micelle solutions can be readily prepared that contain 10 to 50 g/L 
of extremely poorly soluble drug and are stable for days and weeks. The solubility of these drugs 
in POx micelles system is increased by a factor of 1,000 to 100,000 times. The amount of POx 
micelles excipient needed to prepare such solutions is dozens to hundreds of times less than the 
amounts of excipients used in current formulations of water-insoluble drugs.  Specifically, PTX 
POx micelles have ca. 4 to 100 times higher drug loading and ca. 10 to 20 times higher drug 
concentration than the current PTX clinical formulations Taxol, Genexol-PM, and Abraxane. 
This alone have been shown to be highly beneficial for cancer treatment in animal tumor models 
by decreasing the excipient-related toxicity, widening the therapeutic index and allowing high 
dose PTX therapy [160, 209]. Here we take our work one step further by evaluating possibilities of 
POx micelle platform for co-delivery of PTX and hydrophobic cisplatin prodrugs (CP) for 
improved treatment of ovarian and breast Cancer in animal tumor models. 
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3.3  Materials and Methods 
3.3.1 Materials 
Amphiphilic triblock copolymers P(MeOx37-b-BuOx21-b-MeOx36), Mn=10.0 kg/mol, Đ 
(Mw/Mn) = 1.14 were synthesized as previously described [210]. PTX was purchased from LC 
Laboratories (Woburn, MA). Hydrophobic derivatives of cisplatin, with aliphatic chains of 
different length (n = 4, 6, 8 and 10 carbon atoms) at the axial positions, C6CP, C8CP, and C10CP, 
were synthesized [186]. (Fig. 3.1 and Fig. 3.2-3.3) for the details of the synthesis and 
characterization). All other materials were from Fisher Scientific Inc. (Fairlawn, NJ), all reagents 
were HPLC grade and used as received. The A2780 cells and A2780/CisR (cisplatin resistant) 
cells were originally obtained from Sigma-Aldrich. MDA435/LCC-6-mdr1 (LCC-6-MDR) cells 
were originally obtained from Dr. R. Clarke, Georgetown University Medical School, 
Washington, DC. LCC-6-MDR cells, which express high levels of P-glycoprotein (P-gp), were 
derived from LCC-6-WT (wildtype) cells stably transfected with a retrovirus engineered to 
constitutively express the mdr1 gene. [171] The parent LCC-6-WT cells were derived from 
estrogen receptor (ER)-negative, aggressive and metastatic MDA-MB-435 cells. A2780 and 
A2780/CisR cells were cultured in RPMI1640 medium (Gibco 11875-093), and LCC-6-MDR 
cells were cultured in DMEM medium (Gibco 11965-092) supplemented with 10% FBS and 1% 
penicillin-streptomycin.  Nude mice were purchased from UNC DLAM animal facility.  
3.3.2 Synthesis of 64Cu-DOTA-POx 
Tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), 1-ethyl-3-[3-
(dimethylamino)propyl] carbodiimide (EDC), and N-hydroxysulfonosuccinimide (SNHS) at a 
molar ratio of DOTA:EDC:SNHS  = 10:9:8 were mixed and kept at r.t. for 30 min (pH = 5.5, 
0.1M NaOH). The sulfosuccinimidyl ester of DOTA (DOTA-OSSu) used without purification 
was then reacted with POx in a theoretic stoichiometry of 40:1 and allowed to stand at 4℃ 
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overnight (pH = 8.5, borate buffer).  The DOTA-POx conjugate was sequentially purified on PD-
10 column using PBS as the mobile phase, followed by LH-20 column using MeOH as the 
mobile phase. The solvent was evaporated and the DOTA-POx conjugate was reconstituted in 
PBS. The yield was 80%. 64Cu was produced on a CS-15 biomedical cyclotron at Washington 
University School of Medicine. The DOTA-POx conjugate was labeled with 64Cu by addition of 
37 MBq (1 mCi) 64Cu (1.5 µg DOTA-POx conjugate per MBq 64Cu) in 0.1M ammonium acetate 
buffer (pH = 5.5) followed by 50 min incubation at 40℃. The reaction was terminated by adding 
5 µL of 10 mmol/L ethylenediaminetetraacetic acid solution. 64Cu-DOTA-POx was purified on a 
PD-10 column using PBS as the mobile phase. The yield was 1.24 mCi in 100 µg POx.  
3.3.3 Synthesis and characterization of hydrophobic platinum (IV) prodrugs (CPs) 
Ten milliliters of c,c,t-[Pt(NH3)2Cl2(OH)2] (0.69 g, 2.05 mmol) solution in DMSO were 
mixed with 10 mL of the solution in dimethylformamide of a respective aliphatic anhydride: 
C4CP, butyric anhydride (0.40 g, 3.9 mmol),  C6CP, hexanoic anhydride (0.90 g, 4.2 mmol), 
C8CP, octanoic anhydride (2.18 g, 8.2 mmol) or C10CP, decanoic anhydride (2.53 g, 7.8 mmol), 
and the reaction mixture was stirred at room temperature (r.t.) for 48 h. Water (approx. 20 mL) 
was added to the mixture to precipitate light yellow solids followed by filtration and isolation. 
The yellow solids were washed several times with diethyl ether and dried. The yields of C4CP, 
C6CP, C8CP and C10CP were all approximately 40 wt. %. The synthesized prodrugs were soluble 
in ethanol (5 g/L, 5 g/L, 2 g/L and 2 g/L respectfully). 
3.3.4 Preparation and characterization of POx PM 
PTX/CP PM were prepared by a thin film method as previously described. [210] Briefly, 
pre-determined volumes of POx, PTX and CP stock solutions (5 g/L in ethanol) were mixed, 
followed by complete evaporation of ethanol. Appropriate amounts of normal saline were used to 
rehydrate the dried thin-film (under heating at 50-600C for PTX PM and CP/PTX PM and room 
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temperature for CP PM) for up to 15 min in order to obtain drug loaded PM. The excess of non-
incorporated drug was removed by centrifugation. The resulting micelle formulation was stored 
as aqueous solution in refrigerator for up to 2 weeks or as lyophilized powder for long-term 
storage. 
The drug concentrations in PM were determined by reversed-phase high-performance 
liquid chromatography (HPLC) method using an Eclipse XDB-C18-5µm column (150 mm × 4.6 
mm) and Agilent 1200 HPLC. Each sample was diluted 20 times in mobile phase 
(acetonitrile/water; 50/50, v/v) and 20 µL of the diluted sample was injected into the HPLC. The 
drugs were detected by a gradient method consisting of solvent A (water) and B (acetonitrile), 
where the gradient started at 50% B and kept for 3 min; changed to 20% B in 4 min and kept for 
3 min; and changed back to 50% B in 2 min and kept for 3 min. The retention times of C4CP, 
C6CP, C8CP, C10CP and PTX were approximately 2.9 min, 6.9 min, 9.7 min, 12.6 min, and 4.7 
min, and the detection wavelength was 245 nm and 227 nm (PTX) while the flow rate was 1.0 
mL/min and column temperature was 30oC. A standard curve range from 5 µg/mL to 1000 
µg/mL was used to calibrate the quantity of each drug. 
3.3.5 In vitro drug release  
The drug release PTX/CP PM was studied by membrane dialysis under the “perfect sink 
conditions”. Briefly, drug loaded PM were diluted to 0.1 g/L total drug in phosphate buffered 
saline (PBS), pH 7.4 containing 40 g/L bovine serum albumin (BSA). The micelle solutions (100 
µL) were placed in floatable Slide-A-Lyzer MINI dialysis devices (100 µL, 20 kDa MWCO; 
Thermo Scientific) and dialyzed against 20 mL PBS containing 40 g/L BSA. Three devices were 
used for every time point. At each time point the samples were withdrawn from dialysis device 
and remaining drug amounts were determined quantified by HPLC and inductively coupled 
plasma mass spectrometry (ICP-MS). Drug release profiles were constructed by plotting the 
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amount of drug(s) released over time. 
3.3.6 In vitro cytotoxicity assays 
In vitro cytotoxicity of free and micelle incorporated drugs was determined using [3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] (MTT) assay in A2780 and A2780/CisR 
ovarian cancer cell lines as well as LCC-6-MDR breast cancer cell line. Briefly, cells were 
seeded in 96-well plates at a density of 3000 cells/well 24h prior to drug treatment and then 
treated with drugs serially diluted in full medium. After 72 h the medium was removed and MTT 
(100 µg/well) in 100 µL of fresh medium was added for additional 4h at 37°C. Then the medium 
was discarded, the formed formazan salt dissolved in 100 µL of dimethyl sulfoxide and 
absorbance at 562 nm recorded using a plate reader (SpectraMax M5, Molecular Devices). Cell 
survival rates were calculated in comparison to control untreated wells. Data represent average of 
six wells in means ± standard deviation (SD). The mean drug concentration required for 50% 
growth inhibition (IC50) was determined using Graphpad Prism 5 software. The combination 
Index (CI) analysis based on the Chou and Talalay method [72] was done using CompuSyn 
software.  
3.3.7 Pharmacokinetics (PK) and tumor accumulation 
 Female athymic nude mice (6-8 weeks) with well-developed 100 mm3 A2780/CisR 
xenograft tumors were administered intravenously (i.v.) via tail vein with a single dose of the 
following formulations: 1) C6CP/PTX PM (20 mg/kg C6CP and 20 mg/kg PTX mouse body 
weight), 2) C8CP/PTX PM (20 mg/kg C8CP and 20 mg/kg PTX mouse body weight), 3) C6CP 
PM (20 mg/kg C6CP), 4) C8CP PM (20 mg/kg C8CP), and 5) PTX PM (20 mg/kg PTX). All 
injections contained 64Cu-labelled POx (4 µCi/mouse) and PTX injections contained 3H-PTX (5 
µCi/mouse). 64Cu-labelled POx was synthesized as described in Supplementary methods. At 
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various time points 0.083, 0.5, 1, 2, 6, and 15 h post injection three animals from every treatment 
group were euthanized, the blood was collected by cardiac puncture, the organs (spleen, liver, 
kidney) and the tumor was removed, washed in ice-cold saline, weighted and homogenized in a 
glass tissue homogenizer (TearorTM, BioSpec Products, Inc.). Polymer and drug concentrations 
in plasma, organs and tumors were measured by radioactivity counts using a g-counter 
(PerkinElmer) for 64Cu-labelled POx, and liquid scintillation counter, Tricarb 4000 for 3H-PTX 
or by determining platinum content by ICP-MS for C6CP or C8CP. PK parameters were 
determined with Phoenix WinNonlin (version 6.0) software using non-compartmental analysis.  
3.3.8 Efficacy and tumor accumulation studies 
The maximal tolerated dose (MTD) was estimated prior to the in vivo efficacy studies. 
Healthy 6-8 week old female nude mice, which received escalating doses of the combination 
drugs: 1) 10/10, 20/20 or 30/30 mg/kg of PTX/C6CP PM (2/2/10) or PTX/C8CP PM (2/2/10), or 
2) 40/3, 60/4.5 and 80/6 mg/kg of PTX/C6CP PM (40/3/50), using a q4d x 4 regimen (total 4 
times repeated dosing). Mice well-being and body weight changes were monitored daily over 
two weeks in all groups. The highest dose that did not cause animal death or noticeable toxicity 
(as defined by a median body weight loss of 15% of the control or abnormal behavior including 
hunched posture and rough coat) was used as MTD for efficacy experiments. 
3.3.8.1 A2780/CisR ovarian cancer xenograft model 
Female athymic nude mice (6-week-old) were subcutaneously (s.c.) inoculated in the 
right flank with 8 x 106 human A2780/CisR ovarian cancer cell resuspended in 50% growth 
medium and 50% Matrigel. Animals were randomized into groups of five or six mice, each 
group having approximately same mean tumor volumes of ~ 300 mm3, and then administered via 
tail vein using q4d x 4 regimen (days 0. 4. 8. 12) with the test articles. In one study the injection 
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solutions were: 1) PTX/C6CP PM (2/2/10) (20 mg/kg PTX and 20 mg/kg C6CP); 2) PTX/C8CP 
PM (2/2/10) (20 mg/kg PTX and 20 mg/kg C8CP); 3) PTX PM (2/10) and C6CP PM (2/10) 
mixture (20 mg/kg PTX and 20 mg/kg C6CP); 4) PTX PM (2/10) and C8CP PM (2/10) mixture 
(20 mg/kg PTX and 20 mg/kg C8CP); 5) PTX PM (2/10) (20 mg/kg PTX); 6) C6CP PM (2/10) 
(20 mg/kg C6CP); 7) C8CP (2/10) PM (20 mg/kg C8CP); 8) cisplatin (3 mg/kg), and 9) saline. In 
another study, the injected solutions were: 1) PTX/C6CP PM (40/3/50) (60 mg/kg PTX and 4.5 
mg/kg C6CP); 2) PTX PM (40/50) and C6CP PM (3/50) mixture (60 mg/kg PTX and 4.5mg/kg 
C6CP); 3) PTX PM (40/50) (60 mg/kg PTX); 4) C6CP PM (3/50) (4.5 mg/kg C6CP); 5) 3 mg/kg 
cisplatin and 6) saline. Tumor volume and survival were monitored twice weekly and end-points 
defined by tumor volume (> 2000 mm3), animal weight loss (> 15%), or animals becoming 
moribund. Tumor length (L), width (W) were measured and tumor volume (TV) was calculated 
as TV =1/2 ´ L ´ W2. Mice well-being and body weight changes were monitored daily. 
3.3.8.2 Orthotopic model of LCC-6-MDR human triple-negative breast cancer model 
Briefly, 100 µl of dispersion containing 5x106 LCC-6-MDR cells and 50% Matrigel were 
implanted into mammary fat pad of 6-week-old female nude mice using a 25 gauge needle. 
When tumor volumes reached about 200 mm3, animals were randomized into the groups of five 
and injected with the test articles using q4d x 4 regimen. The injected solutions were: 1) 
PTX/C6CP PM (40/3/50) (60 mg/kg PTX and 4.5 mg/kg C6CP); 2) PTX PM (40/50) and C6CP 
PM (3/50) mixture (60 mg/kg PTX and 4.5mg/kg C6CP); 3) PTX PM (40/50) (60 mg/kg PTX); 
4) C6CP PM (3/50) (4.5 mg/kg C6CP); 5) 3 mg/kg cisplatin and 6) saline. Tumor volume and 
survival were monitored every other day. Mice were sacrificed when tumor reached volume of 
2,000 mm3 or developed ascites metastasis. 
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3.3.9 Statistical Analysis  
Quantitative results were expressed as mean ± SD. Statistical comparisons for drug 
release, PK, tumor accumulation, and tumor inhibition data were done using one-way analysis of 
variance (ANOVA) with Holm-Sidak post-hoc test for multiple comparisons. Statistical analysis 
was performed using Prism 7.03 software. Statistical comparison of animal survival was done by 
Log-rank test. Differences were considered to be statistically significant if the p value was less 
than 0.05.  
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3.4  Results 
3.4.1 Synthesis of CPs 
Cisplatin as a hydrophilic water-soluble drug would not preferentially incorporate in a 
hydrophobic core of PM. To enable cisplatin formulation and delivery within POx micelles we 
used the prodrug strategy. [186] As the synthetic approach, cisplatin derivatives with aliphatic 
chains of different length (n = 4, 6, 8 and 10 carbon atoms) at the axial positions have been 
synthesized as previously reported. [187, 188] The derivatives are designated as C4CP, C6CP, C8CP, 
C10CP according to the length of the aliphatic chain. Their chemical structures were confirmed 
by 1H-NMR spectroscopy and mass spectrometry (Fig. 3.2, Fig. 3.3). 
3.4.2 Preparation and characterization of PTX and CP loaded POx PM 
The drug-containing PM were prepared using the thin film method as described in the 
experimental section. To prepare two drugs co-loaded PM we set the polymer concentration to a 
fixed value (10 g/L or 50 g/L) and examined different PTX and CP feed concentrations. Two 
ranges of the drug concentrations were evaluated (Table 3.1). In the first range the PTX and CP 
concentrations were kept relatively close to each other, PTX/CP/POx wt. ratios 1/3/10, 2/2/10 
and 3/1/10. As a result, the PTX/CP molar ratios varied from ~0.2 to ~1.9 PTX/C6CP or ~0.25 to 
~2.25 for PTX/C10CP, and were close to PTX: cisplatin dose ratios used in the clinical 
chemotherapy regimens [211]. The overall LC values in these PM formulations were high ~28 %, 
but not maximal for this PM system. In the second range, used for PTX/C6CP combination only, 
we kept the PTX concentration maximal and added smaller amounts of C6CP, so that the 
PTX/C6CP molar ratios varied from ~1.4 to ~15.8. As a result, the overall LC and the total drug 
concentration in these formulations were maximized reaching as much as ~46 % and ~43 g/L, 
respectively. In this case, we followed our recently published study on the high dose – high 
concentration PTX PM formulation that have shown extremely high anti-tumor activity in animal 
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models [210]. In the context of the present work we were interested to determine whether addition 
of the cisplatin derivative to such high capacity formulation could further improve its anticancer 
efficacy. 
The actual amount of the poorly soluble drug that incorporates into PM formulations is 
defined by the LE. As seen in Table 3.1 with almost all feed concentrations the LE for PTX was 
close to 100%, except for the very highly loaded micelle formulations, for which the PTX LE 
varied between ~80 % to ~90 %. As far as the incorporation CP is concerned it was nearly 
complete except for the 20/5/50 PTX/C6CP/POx PM, for which the LC decreased to ~33.5 %. 
Also, there appeared to be a consistent trend for different CP in the PM composition: as the 
length of the aliphatic tail in the cisplatin derivative increased, the LE for this derivative also 
decreased (Table 3.1).  
The particle sizes and PDI values varied, although in this case there was also a clear 
tendency for the particle size increase upon incorporation of increasing amount of CP (Table 3.1, 
Fig. 3.4a-f). Moreover, at the same weight fraction of the CP the particle size appeared to 
become larger as the length of the alkyl chain increased (Table 3.1, Fig. 3.4d). All prepared PM 
formulations remained quite stable in dispersion displaying little if any changes of the particle 
sizes and no drug precipitation for at least as long as 12 days (Fig. 3.4b-f). No significant 
differences in the particle morphology was found between various PM as their shapes were 
nearly spherical by TEM (Fig. 3.4g-j).  
3.4.3 Drug co-loading in the PM slows down drug release compared to single-drug PM 
The drug release profiles from PM were examined under sink conditions (Fig. 3.5). For 
the CP containing micelles there was a clear trend observed - as the length of the aliphatic tail in 
the cisplatin derivative increased the rate of the release decreased. As a result while for C6CP 
was released faster than PTX form both single and combination drug micelle (Fig. 3.5a,b) for the 
  83 
C8CP these rates were close to each other (Fig. 3.5c), while for C10CP the situation was inverse 
and with this hydrophobic cisplatin derivative being released slower than PTX (Fig. 3.5d). 
Strikingly, there was a clear evidence of drug-drug interactions in the micelle core as the release 
of both drugs from combination micelles was slower that their release from the single drug PM. 
This effect was the most pronounced for PTX in all combination formulations, was quite 
noticeable for high loaded PTX/C6CP PM as well as combination drug micelles containing two 
more hydrophobic cisplatin prodrugs (Fig. 3.5).  
3.4.4 Drug combination micelles exhibit synergy in ovarian cancer cells 
The cytotoxicities of the single and combination drug micelles was examined in two 
ovarian cancer cell lines one of which, A2780/CisR, was cisplatin-resistant and another, A2780, 
cisplatin-sensitive (Fig. 3.7). In the sensitive A2780 cell line, the IC50 values of single CP loaded 
PM were 0.309 µg/ml, 0.058 µg/ml and 0.045 µg/ml for C6CP, C8CP and C10CP PM, 
respectively, compared to cisplatin of 1.141 µg/ml (Fig. 3.8). Therefore, the prodrug with the 
longer alkyl chain (C10CP) was ~30 times more toxic compared to cisplatin, while the prodrug 
with the shorter alkyl chain (C6CP) was only ~4 times more toxic. Same trend was observed in 
A2780/CisR cell line (Fig. 3.6a). In this case the IC50 values were 0.546 µg/ml, 0.219 µg/ml, and 
0.149 µg/ml for C6CP, C8CP and C10CP PM, respectively, compared to cisplatin of 10.88 µg/ml. 
There was practically no difference in the cytotoxicity of the single PTX PM in these two cell 
lines with the IC50 values measuring 38.66 µg/ml and 47.36 µg/ml in the A2780 and A2780/CisR 
cells, respectively (Fig. 3.6a). 
In both cancer cell models the combination drug PM were substantially more active than 
either of the single drugs (Fig. 3.6a,f, Fig. 3.8). Moreover, increases in the content of the CP in 
the combination micelles in all cases were accompanied by apparent increases in the 
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cytotoxicity. However, a consideration of the drug pharmacological synergy by the analysis CI 
using the isobologram equation of Chou–Talalay [71], suggested that the synergy strongly 
depends on the drug ratio. It is critical that the optimized doses and ratios of combined drugs are 
examined to promote synergistic rather than antagonistic effects [181]. In these cases, the CI 
values less than 1, indicating drug synergy, were observed for PM with relatively higher content 
of PTX and lower content of the cisplatin prodrug (Fig. 3.6b-e, Fig. 3.8). In contrast, the 
compositions with relatively higher content of CP displayed CI values exceeding 1, suggesting 
antagonism of the two drugs. This trend was observed for each cisplatin derivative but was 
perhaps the most pronounced for the PTX/C6CP PM (Fig. 3.6b,c). In this case we also compared 
five PM compositions with high and super-high drug loadings. The micelles with feed ratios 
1/3/10 and 2/2/10 displayed no or minimal synergy, while the higher PTX content micelles 
3/1/10 and high-loaded micelles 20/3/50 and 40/3/50 were showing pronounced and clear 
synergistic effect with CI value < 1 over a wider range Fa values from 0.1 to 1.0.  (Fig. 3.6b,c). 
3.4.5 PK and tumor accumulation in A2780/CisR ovarian tumor bearing mice 
The drug PK and distribution profiles for PTX/C6CP PM (2/2/10) and PTX/C8CP PM 
(2/2/10) at MTD were compared to those of the single drug micelles in A2780/CisR tumor 
bearing mice (Fig. 3.9). The drug PK parameters calculated using a non-compartment model are 
presented in Tables 3.2 and Table 3.3. The PK parameters of the POx polymers for the same 
drug PM formulations are presented in the Supplementary Table 3.4. In the case of PTX/C6CP 
PM (2/2/10) it is apparent that the co-loading of C6CP and PTX in the PM increased the plasma 
half-life of each drug when compared to the respective single drug micelles (t1/2, α 7.67 h vs. 6.20 
h for C6CP and 5.12 h vs. 3.67 h for PTX) (Table 3.2). Still the half-life of both drugs is less 
than that of the POx polymer alone (t1/2, α 9.6 h). The Cmax in the plasma was also increased ~2.0 
fold for C6CP and ~1.4 fold for PTX. Moreover, there was ~1.9 fold increase in the plasma AUC 
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of PTX (~1.46 fold decrease in CL) as well as ~1.3 fold increase Vdobs of this drug. At the same 
time there was practically no changes in the plasma AUC and CL of C6CP. In addition to the 
overall improved plasma PK the PTX/C6CP PM formulation also displayed considerable 
improvements in the tumor Cmax and AUC of both drugs when compared with the single drug 
micelles. Specifically, the Cmax increased by ~2.0 fold for C6CP and ~1.4 fold for PTX (Table 
3.2). The peak concentrations of both drugs in the tumors were observed at ~1 h post injection 
for all investigated formulations. The tumor AUC were increased ~2.9 fold for C6CP and ~1.3 
fold for PTX. 
In the case of PTX/C8CP PM the effects of co-loading were less dramatic and seen 
mainly for PTX but not for C8CP (Table 3.3) In fact, for the co-loaded drug formulation the 
plasma half-life of C8CP was even slightly decreased when compared to the single drug micelles 
(t1/2, α 6.54 h vs. 7.40 h), although the half-life of PTX was still increased (t1/2, α 5.68 h vs. 3.67 h). 
Likewise, although there was a slight (~1.1 fold) decrease in the Cmax of C8CP in the plasma, the 
Cmax of PTX increased ~2.0 fold. The improvement in the PK of PTX in the PTX/C8CP PM 
formulation was further evidenced by ~2.2 fold increase in the plasma AUC of this drug (~1.7 
fold decrease in CL) and slight (~1.1 fold) increase in the Vdobs. Again, the plasma AUC of 
C8CP in the co-loaded micelles was slightly decreased, although, surprisingly, these was almost 
~2.1 fold increase in Vdobs. Consistent with the plasma PK, the Cmax of PTX in PTX/C8CP PM 
was increased ~2.0 fold while the Cmax of C8CP remained unchanged when compared to single 
drug micelles. Interestingly, the tumor AUCs for both C8CP and PTX in the PTX/C8CP PM 
(2/2/10) increased by only ~1.1 fold.  
Further analysis suggests that the tumor to plasma AUC ratios for C6CP in the co-loaded 
drug micelles, PTX/C6CP PM (2/2/10), exceeded the same ratio for C6CP in the single drug 
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micelles, C6CP PM (2/10), by only ~1.1 times (Table 3.5). The similar tumor to plasma AUC 
ratio for PTX in co-loaded drug micelles exceeded the ratio for PTX in the single drug micelles 
by ~1.5 times. The tumor to plasma AUC ratios for C8CP in the co-loaded drug micelles, 
PTX/C8CP PM (2/2/10), exceeded the ratio for C8CP in the single drug micelles, C8CP PM 
(2/10), by ~1.4 times; and ~1.1 times exceeded for PTX. In other words, there is slight or 
considerable increase of the tumor delivery for each of the drugs in the co-loaded drug micelles.  
Overall the co-loaded drug micelles displayed a considerably improved PK and 
biodistribution in the blood and tumor of either one or both drugs as compared to the single drug 
micelles. Analysis of the tumor PK parameters also suggests that the PTX/C6CP or PTX/C8CP 
ratios actually recorded in the tumor did not differ substantially from the drug ratios in the initial 
co-loaded drug micelle formulations. Thus, the tumor Cmax ratios were ~1.2 for both 
formulations, and the tumor AUC ratios were 1.0 and 0.9 for PTX/C6CP and PTX/C8CP, 
respectively. Therefore, one could expect that the delivered drugs would exhibit a synergistic 
anticancer effect on the tumor. 
3.4.6 In vivo efficacy 
The in vivo anti-tumor activity of the PM formulations was evaluated in the cisplatin-
resistant human ovarian carcinoma xenograft A2780/CisR tumor model and multidrug resistant 
breast cancer LCC-6-MDR orthotopic tumor model. The animals were treated with the 
combination drug micelles, PTX/C6CP PM or PTX/C8CP PM, the single drug micelles or their 
mixture. In all experiments, the treatment groups also included free cisplatin. Since PTX PM 
have been previously consistently superior to marketed PTX forms Taxol and Abraxane [210] the 
latters were not included in treatment comparisons. All micellar drugs were administered at the 
MTD of either high or super-high loaded drug combination PM. The MTD values were 
determined in healthy 6-8 week old female nude mice using a q4d x 4 regimen. These MTD were 
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1) 20 mg PTX/kg and 20 mg CP/kg for PTX/CP PM (2/2/10), and 2) 60 mg/kg PTX and 4.5 
mg/kg C6CP for PTX/C6CP PM (40/3/50). The MTD of the free cisplatin was 3 mg/kg.  
First, we compared the anti-tumor effects of PTX/C6CP (2/2/10) PM and PTX/C8CP 
(2/2/10) PM with the same doses of single drug micelles, PTX PM, C6CP PM and C8CP PM, or 
their mixtures in the A2780/CisR tumor model. This tumor is very aggressive and rapidly grows 
within the first week of the study, with the animals median lifespan of 10.5 days (Fig. 3.10a,b). 
Free cisplatin had small but significant effect by delaying the tumor growth and extending the 
median lifespan to 14.5 days. The treatments with the single micelle drugs including PTX PM 
and both cisplatin prodrug forms, C6CP PM and C8CP PM resulted in greater delay of the tumor 
growth and the significant increase in the median lifespan to ~18-20 days (Tables 3.6, Table 
3.7). However, there was no statistical difference between any of the single drug micelle groups. 
A major improvement in the anti-tumor treatment was observed with both combination drug 
micelles, PTX/C6CP (2/2/10) PM and PTX/C8CP (2/2/10) PM, which resulted in pronounced 
tumor growth inhibition and increase in the median lifespan to ~46.5-55.4 days. In these cases, 
there were 2/6 and 3/6 long-term survivors (beyond day 50), for PTX/C6CP (2/2/10) PM and 
PTX/C8CP (2/2/10) PM, respectively. However, the differences between these two combination 
drug micelle treatment groups in the tumor growth inhibition and animal lifespan were not 
significant. Interestingly, the co-loaded drug micelles, appeared to be more efficient than the 
mixtures of the single drug micelles PTX PM and C6CP PM (or C8CP PM). No long-term 
survivors were observed for any of the studied single drug micelles mixture (Fig. 3.10b). While 
the differences in the tumor inhibition between these groups were not significant the co-loaded 
PTX/C8CP PM group had a statistically higher lifespan than the respective PTX PM and C8CP 
PM single drug mixture (Tables 3.6 and Table 3.7).  
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Next, we examined the treatments effects of the super-high loaded drug combination 
micelles, PTX/C6CP PM (40/3/50). In this case along with the free cisplatin and single drug 
micelles we also incorporated a mixture of the single micelles, PTX PM (40/50) and C6CP PM 
(3/50) administered simultaneously at the same drug doses as the combination micelles.  
Interestingly, C6CP PM (3/50), had similar effect on the tumor growth and animal lifespan as 
C6CP PM (2/10) administered in the above study at ~4.4-times higher dose of the cisplatin 
prodrug (Fig. 3.10c,d). However, in this case the difference between the free drug and C6CP PM 
(3/50) in tumor growth curves was not significant (Table 3.6). The treatment with PTX PM 
(40/50) had the greatest effect of the single drug micelles both in the tumor growth inhibition and 
the increased lifespan. Surprisingly, however, the two single drug micelles mixture PTX PM 
(40/50) and C6CP PM (3/50) did not exhibit statistically significant improvement compared to 
PTX PM (40/50) alone (Fig. 3.10c,d). In contrast, the same dose of the two drugs co-formulated 
together PTX/C6CP PM (40/3/50) had a profound therapeutic effect superior to any of the other 
treatment or control groups. Like in the previous case of combination drug micelles these effects 
were not only statistically significant but also resulted in 2/5 long-term survivors (beyond day 
60). 
Finally, to validate the observed phenomena we evaluated same treatment regimens in the 
MDR LCC-6-MDR orthotopic tumor model. Historically, Taxol at MTD has not been 
therapeutically active in this model [160]. Surprisingly, however, cisplatin alone (3mg/kg) 
produced considerable antitumor effect, which was superior in this case to the single drug 
micelles carrying the cisplatin prodrug, C6CP PM (3/50) (Fig. 3.10e,f). Like in the previous case 
PTX PM (40/50) had somewhat greater effect by decreasing the tumor growth rate compared to 
any other single drug group but this effect was not significant and neither were the difference in 
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the lifespan compared to these treatment groups. Like in the previous case, the effects of the two 
single drug micelles mixture PTX PM (40/50) and C6CP PM (3/50) on the tumor growth were 
practically indistinguishable from that of the PM (40/50). The combination drug micelles 
PTX/C6CP PM (40/3/50) had the greatest effect surpassing any of the treatment groups in both 
the inhibition of the tumor growth and in the prolongation of the lifespan to a median of (Fig. 
3.10e,f, Tables 3.6, and Table 3.7). In this treatment group, there was 1/5 long-term survivor 
(beyond day 100). 
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3.5  Discussion 
In this study, we co-loaded PTX and CP in POx micelles resulting in the micellar 
formulations with LC from ~28 % to ~46 % of the total drug in the dispersed phase, and the total 
drug concentration in the solution from about 3 g/L to over 40 g/L. We also varied the PTX and 
CP ratios (wt.) in a broad range from excess of CP vs. PTX (3:1) to a considerable excess of 
PTX vs. CP (45:1). In most cases, except for the very highly drug (PTX) loaded systems, both 
drugs incorporated in the PM nearly completely (LE ~100%). The nanoparticles in the obtained 
formulations were small, mostly uniform (PDI 0.11 to 0.2), and stable upon storage for over 12 
days. Unexpectedly, we discovered that co-loading of the drugs in the micelles slowed down the 
release of these drugs, especially PTX, to the external media containing serum albumin when 
compared to the release rates observed with the single-drug PM.  
Due to facile miscibility of both drugs in the POx PM systems we were able to analyze 
the pharmacological synergy of the drugs at different ratios as assessed by the CI values in the 
cisplatin-resistant and cisplatin-sensitive breast cancer cells. There was a trend for the synergy 
increase upon increase of the relative content of PTX vs. CP. The most pronounced drug synergy 
was observed in the very high PTX-loaded micelles, PTX/C6CP PM (40/3/50). This was one 
formulation selected for the animal efficacy studies. The two other formulations evaluated in the 
animal models were PTX/C6CP PM (2/2/10), and PTX/C8CP PM (2/2/10), containing two 
different cisplatin derivatives. Since the drug synergy displayed by these formulations in the cell 
culture was moderate to high (depending on the cell model), a possible shift in the concentrations 
of the drugs that would actually reach tumors could be of potential concern for treatment. 
Therefore, we characterized the PK and tumor distribution of the both drugs in these 
formulations in the animal model of drug-resistant ovarian cancer. 
The PK results were quite insightful suggesting an overall improvement of the PK and 
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distribution of both drugs as a result of their co-loading in the POx micelles, when compared 
with the single drug micelles. Specifically, there were increases in the plasma half-life, Cmax, 
AUCs, and decreases in the clearance of both drugs observed for the co-loaded micelles 
PTX/C6CP PM (2/2/10), containing a relatively less hydrophobic cisplatin derivative, C6CP. 
There was also a considerable improvement in Cmax and AUC of both drugs in the tumor. In the 
case of the co-loaded micelles PTX/C8CP PM (2/2/10), containing a relatively more hydrophobic 
cisplatin derivative C8CP, improved plasma PK was observed for PTX only, but not for C8CP. 
Likewise, the improvement in drug delivery to the tumor using co-loaded micelles PTX/C8CP 
PM (2/2/10) was less pronounced when compared with PTX/C6CP PM (2/2/10). However, a 
detailed analysis of the PK data suggests that the apparent differences in the effect of the co-
loading for the drug pairs are a result of the difference in the PK behavior of the single drug 
micelles, C6CP PM (2/10) and C8CP PM (2/10), rather than that of the co-loaded micelles. 
Indeed, C8CP PM (2/10) appears to have considerably higher Cmax and AUC both in plasma and 
in tumor when compared with C6CP PM (2/10), while the PK parameters of the respective drugs 
in PTX/C8CP PM (2/2/10) and PTX/C6CP PM (2/2/10) are similar.  
Interestingly, the rates of release of relatively more hydrophobic C8CP from both single 
drug and co-loaded drug micelles are nearly twice lower than those of the less hydrophobic 
C6CP. Thus, it is tempting to suggest that the differences in the PK appear to correlate with the 
drug release results. Specifically, a decrease in the release rate of C6CP observed as a result of 
co-loading of this drug with PTX may be responsible for a relatively better retention of C6CP in 
the co-loaded micelles in plasma and improvement in the plasma and tumor PK as result of co-
loading. In contrast, the retention of C8CP in either co-loaded or single drug micelles is relatively 
good, and therefore the differences in the PK for this drug in the co-loaded and single drug 
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micelles are attenuated. 
Since micelles are dynamic structures they are expected to exchange their components 
with the environment. Specifically, the block copolymer chains are partitioned between the 
micelles and external solution (single block copolymer chains called “unimers”), while the 
hydrophobic drugs, such as PTX and CP, are partitioned between the micelles and serum 
proteins present in the blood. As a result, complex equilibriums should establish in a steady state 
condition, although an existence of any such equilibrium in the body should not be assumed 
automatically, because the redistribution of the solutes between the PM and environment could 
be quite slow. As the concentration of the components of the PM in the circulation decreases due 
to their clearance, the equilibriums are expected to shift. Thereby the PK of each component that 
is redistributed between various circuiting formats (micelles, unimers for POx chains, serum-
bound drugs) should be an integral result of the PK properties of an individual format as well as 
their redistribution kinetics. Despite of the obvious complexity of the resulting picture, it is 
possible to dissect some individual formats behavior from the PK data. For example, our 
previous study of the plasma PK and biodistribution of Pluronic P85 was carried out at the 
critical micelle concentration (CMC), when only unimers were present, and well above this 
concentration, when both unimers and micelles were present. It was discovered, that clearance 
was independent on the concentration, which was indicative of the renal clearance of the unimers 
but not the micelles (that were above the renal clearance limit). 
With this consideration in mind, comparing the PK results for the drugs and POx block 
copolymers can provide further insight into the behavior of the drug-containing micelles in vivo. 
As already mentioned the drugs plasma half-life even in the co-loaded micelles (when the drug 
half-life was increased compared to the single drug micelles) was less than that of the POx 
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copolymer. That means that the drugs were cleared faster than the micelles and suggests at least 
partial release of the drugs from the micelles to serum proteins. Moreover, Vdobs of the drugs was 
from about 7.5- to about 27-fold higher than the Vdobs of the POx copolymer. A drastic, 5- to 20-
fold difference in the Tumor AUC/Plasma AUC and Tumor Cmax/Plasma Cmax ratios between the 
drugs and POx copolymer also suggests that the drugs are partitioned to the tumor more 
efficiently than the copolymer. One possible explanation is that the drug molecules are 
transferred to the serum proteins and then accumulate in the tumors separately from the micelles, 
perhaps, in a serum-bound state, or that both the micelles and serum bound drugs carry the drug 
to the tumor.  
This hypothesis on a surface is counterintuitive.  On the one hand, based on our data, the 
stronger the drug is retained in the micelles, the greater the plasma exposure is, and the greater 
the tumor accumulation of this drug is. One other hands the drug appears to be delivered to the 
tumor, at least in part and, perhaps, in a greatest part, separately from the micelles.  However, 
one needs to appreciate that sustained circulation of the drug in the form of the micelles, with 
continuous transfer of the drug molecules to the serum proteins, also enhances the sustained 
circulation of the serum-bound drug format and overall increased exposure of the tumor to either 
serum-bound or micelle-bound formats. Therefore, we postulate here, as a hypothesis, a pivotal 
role of the sustained release of the micelle-incorporated hydrophobic drug to intermediate drug 
carriers, such as serum proteins in the body, for successful delivery of this drug to the tumors. 
There is no doubt that the serum bound drug is active upon tumors as the release of the drug, in 
particular PTX, to the serum is a putative mechanism of the anti-tumor activity of Taxol [212], and 
another blockbuster PTX-based drug, Abraxane, represents the complex of PTX with serum 
albumin [213]. 
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Coming back to the initial question about the ratio of PTX and CP in the tumor observed 
with the PTX/C6CP PM (2/2/10), and PTX/C8CP PM (2/2/10) formulations, the PK data give a 
clear answer. Indeed, the resulting PTX/C6CP or PTX/C8CP ratios in the tumor did not differ 
substantially from the drug ratios in the initial co-loaded drug micelle formulations. Consistent 
with this the efficacy studies suggested that these co-loaded micelles are superior to any of the 
single drug micelle formulation and even the mixture of the single drug micelles administered at 
the same dose. Even more striking effect of the co-loading of the drugs on the anti-tumor activity 
of the PM formulation was observed for the highly loaded PTX/C6CP PM (40/3/50). In this case 
both drugs displayed highly potent, synergistic effect in vitro in cell culture. The co-loaded drug 
micelles displayed greatly improved anti-tumor effect in animal tumor models, which was 
superior not only to the either drugs-loaded micelles but also to the mixture of the single micelles 
at the same doses. Overall, the data provide support of the beneficial effect of co-loading drugs 
into the micelles as a strategy for improved chemotherapy. 
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Table 3.1 Characteristics of C6CP/ETO PMa.  
 
Feeding ratio 
(g/L) 
LE (%) LC (%) Drug concentration in solution (g/L) Deff (nm) PDI 
PTX CP PTX CP PTX+CP PTX CP PTX+CP 
PTX/C6CP/POx           
1/3/10 100 99.7 7.2 21.4 28.6 1.0 3.0 4.0 86.4 ± 0.6 0.12 ± 0.05 
2/2/10 100 100 14.3 14.3 28.6 2.0 2.0 4.0 79.7 ± 0.3 0.11 ± 0.07 
3/1/10 100 100 21.4 7.14 28.4 3.0 1.0 3.0 54.2 ± 0.5 0.12 ± 0.01 
20/3/50 99.3 92.7 27.3 3.8 31.1 19.9 2.8 22.7 34.2 ± 0.2 0.16 ± 0.01 
20/5/50 92.9 33.5 26.4 2.4 28.8 18.6 1.7 20.3 35.7 ± 0.4 0.14 ± 0.01 
45/1/50 81.1 100 41.7 1.2 42.2 36.5 1.0 37.5 74.2 ± 0.8 0.20 ± 0.01 
45/2/50 85.8 100 42.6 2.2 44.8 38.6 2.0 40.6 69.7 ± 0.7 0.19 ± 0.01 
45/3/50 89.6 100 43.2 3.2 46.4 40.3 3.0 43.3 66.4 ± 0.6 0.18 ± 0.01 
PTX/C8CP/POx           
1/3/10 100 96.3 7.20 20.8 28.0 1.00 2.89 3.89 110.4 ± 0.8 0.11 ± 0.01 
2/2/10 100 98.5 14.3 14.1 28.4 2.00 1.97 3.97 97.8 ± 0.9 0.12 ± 0.01 
3/1/10 100 100 21.4 7.14 28.54 3.00 1.00 4.00 68.7 ± 0.6 0.11 ± 0.02 
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PTX/C10CP/POx           
1/3/10 100 92.3 7.26 20.1 27.36 1.00 2.77 3.77 141.4 ± 0.6 0.14 ± 0.03 
2/2/10 100 94.5 14.4 13.6 28.0 2.00 1.89 3.89 121.8 ± 0.4 0.17 ± 0.02 
3/1/10 100 97.0 21.5 6.94 28.44 3.00 0.97 3.97 99.2 ± 0.7 0.15 ± 0.02 
 
a Size (Deff) and PDI of POx polymeric micelles as measured by DLS. Drug concentration in solution as measured by HPLC. LE and LC calculated 
using equations (1)-(2) in the methods section. Drug solubilization studies were done at 10 g/L or 50 g/L POx. All DLS measurements were carried 
out at 1 g/L POx. All data mean ± SD, n=3. 
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Table 3.2 PK parameters of C6CP and PTX in plasma and tumor after administering PM in A2780/CisR tumor bearing mice. 
 
a t1/2, α, half-life at the biodistribution phase; Cmax, maximum plasma concentration; AUClast, area under the curve from time 0 to 15 h; Clobs, observed 
total body clearance; Vdobs, total volume of distribution observed; Tmax, time of maximum concentration. 
  
 Parametersa 
PTX, 20 mg/kg C6CP, 20 mg/kg 
C6CP/PTX 
PM PTX PM 
Parameter ratio 
(C6CP/PTX PM: PTX 
PM) 
C6CP/PTX 
PM PTX PM 
Parameter ratio 
(C6CP/PTX PM: C6CP 
PM) 
Plasma 
t1/2, α (h) 5.12 3.67 1.40 7.67 6.20 1.24 
Cmax 
(µg/mL) 6.51 4.62 1.41 9.40 4.73 1.99 
AUClast 
(h*µg/mL) 18.41 9.78 1.88 34.80 30.00 1.16 
Clobs 
(mL/h/kg) 984.06 1434.66 0.69 527.40 541.00 0.97 
Vdobs 
(mL/kg) 10112.89 7689.6 1.32 5077.11 7963.56 0.64 
Tumor 
AUClast 
(h*µg/g) 111.14 87.28 1.27 110.92 38.68 2.87 
Cmax 
(µg/g) 8.34 5.38 1.55 9.86 4.34 2.27 
Tmax (h) 1 1  1 1  
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Table 3.3 PK parameters of C8CP and PTX in plasma and tumor after administering PM in A2780/CisR tumor bearing mice. 
 
a t1/2, α, half-life at the biodistribution phase; Cmax, maximum plasma concentration; AUClast, area under the curve from time 0 to 15 h; Clobs, observed 
total body clearance; Vdobs, total volume of distribution observed; Tmax, time of maximum concentration. 
 Parametersa 
PTX, 20 mg/kg C8CP , 20 mg/kg 
C8CP/PTX 
PM PTX PM 
Parameter ratio 
(C8CP/PTX PM: PTX 
PM) 
C8CP/PTX 
PM C8CP PM 
Parameter ratio 
(C8CP/PTX PM: C8CP 
PM) 
Plasma 
t1/2, α (h) 5.68 3.67 1.55 6.54 7.40 0.88 
Cmax 
(µg/mL) 9.39 4.62 2.03 9.50 10.92 0.87 
AUClast 
(h*µg/mL) 21.69 9.78 2.22 37.23 45.89 0.81 
Clobs 
(mL/h/kg) 850.12 1434.66 0.59 416.82 421.87 0.99 
Vdobs 
(mL/kg) 8197.41 7689.6 1.07 6417.86 3066.92 2.09 
Tumor 
AUClast 
(h*µg/g) 95.18 87.28 1.09 86.85 76.77 1.13 
Cmax 
(µg/g) 7.74 5.38 1.44 9.38 9.34 1.00 
Tmax (h) 1 1  1 1  
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Table 3.4 PK parameters of POx polymer in plasma and tumor in A2780/CisR tumor bearing mice. 
 
a t1/2, α, half-life at the biodistribution phase; Cmax, maximum plasma concentration; AUClast, area under the curve from time 0 to 15 h; Clobs, observed 
total body clearance; Vdobs, total volume of distribution observed; Tmax, time of maximum concentration. 
 
  
 Parametersa 
POx, 100 mg/kg POx, 100 mg/kg 
PTX/C6CP PM C6CP PM PTX/C8CP PM C8CP PM  
Plasma 
t1/2, α (h) 12.60 13.59 12.30 13.66  
Cmax (µg/mL) 364.79 502.58 455.75 534.15  
AUClast (h*µg/mL) 2713.51 2971.27 3016.13 3072.73  
Clobs (mL/h/kg) 30.38 24.40 20.63 19.05  
Vdobs (mL/kg) 420.94 408.54 367.28 336.16  
Tumor 
AUClast (h*µg/g) 880.25 747.60 934.16 904.66  
Cmax (µg/g) 81.77 55.91 82.81 58.33  
Tmax (h) 1 1 1 1  
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Table 3.5 Comparison of PK parameters of drugs in PM in plasma and tumor in A2780/CisR tumor bearing mice. 
 
Comparative analysis of PK data 
PTX/C6CP PM PTX/C8CP PM PTX PM C6CP PM C8CP PM 
PTX C6CP POx PTX C8CP POx PTX C6CP POx C8CP POx 
Tumor AUC/Plasma AUC 6.04 3.19 0.32 4.39 2.33 0.31 4.02 2.96 0.25 1.67 0.29 
Tumor Cmax/Plasma Cmax 1.28 1.05 0.22 0.82 0.99 0.11 1.16 0.92 0.18 0.76 0.11 
(Tumor AUC/Plasma AUC for PTX/CP PM) 
divided by (Tumor AUC/Plasma AUC for 
single drug PM) 
1.50 1.08 1.28 1.09 1.39 1.07    
(Tumor Cmax/Plasma Cmax for PTX/CP PM) 
divided by (Tumor Cmax/Plasma Cmax for 
single drug PM) 
1.10 1.14 1.22 0.71 1.29 1.00    
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Table 3.6 Statistical comparisons of tumor growth between groups. (by one-way ANOVA with Holm-Sidak post-hoc test for 
multiple comparisons at a significance levels of p < 0.05 (*, p < 0.05, **, p < 0.01, ***, p < 0.001)  
 
A2780/CisR model (Figure 3.10a) 
Groups Cisplatin PTX PM C6CP PM C8CP PM PTX PM+C6CP PM PTX PM+C8CP PM PTX/C6CP PM PTX/C8CP PM 
Saline * *** *** **** **** **** **** **** 
Cisplatin  ** ** ** **** **** **** **** 
PTX PM   ns ns * * * ** 
C6CP PM    ns ** ** ** *** 
C8CP PM     * * * ** 
PTX PM+C6CP PM      ns ns * 
PTX PM+C8CP PM       ns ns 
PTX/C6CP PM        ns 
 
a Analyzed by comparing areas under the curve for 8 days observation when compared with saline, 12 days for cisplatin, 16 days for C6CP PM and 
C8CP PM, 20 days for PTX PM and 22 days for the remaining groups as presented in Figure 3.10a.  
 
A2780/CisR model (Figure 3.10c) 
Groups Cisplatin PTX PM C6CP PM PTX PM + C6CP PM PTX/C6CP PM 
Saline ns ** * ** ** 
Cisplatin  * ns * ** 
PTX PM   ** ns * 
C6CP PM    ** ** 
PTX PM + C6CP PM     * 
 
a Analyzed by comparing areas under the curve for 8 days observation when compared with saline, 12 days for Cisplatin, 16 days for C6CP PM, 20 
days for PTX PM, and 22 days for the remaining groups as presented in Figure 3.10c.  
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LCC-6-MDR model (Figure 3.10e) 
Groups Cisplatin PTX PM C6CP PM PTX PM + C6CP PM PTX/C6CP PM 
Saline ** *** ns *** **** 
Cisplatin  ns ns ns ** 
PTX PM   * ns * 
C6CP PM    * **** 
PTX PM + C6CP PM     * 
 
a Analyzed by comparing areas under the curve for 16 days observation when compared with saline, 32 days for cisplatin, 26 days for C6CP PM, 
and 40 days for the remaining groups as presented in Figure 3.10e.  
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Table 3.7 Statistical comparisons of animal survival by Log-rank (Mantel-Cox) test. 
 
A2780/CisR model (Figure 3.10a) 
Groups Cisplatin PTX 
PM 
C6CP 
PM 
C8CP 
PM 
PTX 
PM+C6CP 
PM 
PTX 
PM+C8CP 
PM 
PTX/C6CP 
PM 
PTX/C8CP 
PM 
Saline ** *** *** *** *** *** *** *** 
Cisplatin  ** * ** *** *** *** *** 
PTX PM   ns ns *** *** *** *** 
C6CP PM    ns *** *** *** *** 
C8CP PM     ** ** *** *** 
PTX 
PM+C6CP 
PM 
     ns ns * 
PTX 
PM+C8CP 
PM 
      ns * 
PTX/C6CP 
PM 
       ns 
 
A2780/CisR model (Figure 3.10c) 
Groups Cisplatin PTX PM C6CP PM PTX PM + C6CP PM PTX/C6CP PM 
Saline ** ** ** ** ** 
Cisplatin  ** * ** ** 
PTX PM   ** ns ** 
C6CP PM    ** ** 
PTX PM + C6CP 
PM     * 
 
LCC-6-MDR model (Figure 3.10e) 
Groups Cisplatin PTX PM C6CP PM PTX PM + C6CP PM PTX/C6CP PM 
Saline ** ** ** ** ** 
Cisplatin  ns ns ns * 
PTX PM   ns ns * 
C6CP PM    ns * 
PTX PM + C6CP 
PM     * 
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Figure 3.1 Structure of CP and their reduction to free cisplatin. 
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Figure 3.2 1H-NMR of cisplatin prodrugs (CPs).  
(A) C4CP; (B) C6CP; (C) C8CP; (D) C10CP. 1H-NMR spectra were collected in DMSO-d6.  
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C4CP. cis,cis,trans-[Pt(NH3)2Cl2(OOC(CH2)2CH3)2]: Off-white solid, 201 mg (71%), mp. (dec) 270 – 274 °C. 1H NMR (500 MHz, 
DMSO-d6) δ = 0.87 (t, 6H, 7.5 Hz), 1.47 (sext, 4H, 7.3 Hz), 2.19 (t, 4H, 7.25 Hz), 6.53 (s, 6H).  
C6CP. cis,cis,trans-[Pt(NH3)2Cl2(OOC(CH2)4CH3)2]: Off-white solid, 240 mg (75%), mp. (dec) 194 – 196 °C. 1H NMR (500 MHz, 
DMSO-d6) δ = 0.85 (t, 6H, 6.8 Hz), 1.25 (m, 8H), 1.45 (quin, 4H, 7.4 Hz), 2.20 (t, 4H, 7.5 Hz), 6.52 (s, 6H). 
C8CP. cis,cis,trans-[Pt(NH3)2Cl2(OOC(CH2)6CH3)2]: Off-white solid, 226 mg (64%), mp. (dec) 186 – 191 °C. 1H NMR (500 MHz, 
DMSO-d6) δ = 0.85 (t, 6H, 6.9 Hz), 1.24 (m, 16H), 1.44 (quin, 4H, 7.2 Hz), 2.20 (t, 4H, 7.5 Hz), 6.52 (s, 6H).  
C10CP. cis,cis,trans-[Pt(NH3)2Cl2(OOC(CH2)8CH3)2]: White solid, 264 mg (69%), mp. (dec) 185 – 190 °C. 1H NMR (500 MHz, DMSO-
d6) δ = 0.85 (t, 6H, 6.7 Hz), 1.24 (m, 24H), 1.44 (quin, 4H, 7.0 Hz), 2.19 (t, 4H, 7.5 Hz), 6.52 (s, 6H).  
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Figure 3.3 Electrospray Ionization Mass Spectra (ESI-MS) analysis of CPs.  
(A) C4CP, m/z: 496.03 ([M+Na]+, calcd. 496.03); (B) C6CP, m/z: 552.09 ([M+Na]+, calcd. 552.09); (C) C8CP, m/z: 608.16 ([M+Na]+, 
calcd. 608.15); (D) C10CP, m/z: 664.22 ([M+Na]+, calcd. 664.22).   
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Figure 3.4 Physicochemical characterization of PTX/CP PM.  
Size (Deff) distribution (a, d) and time dependence of size (b, e) and PDI (c, f) of PTX/CP PM 
measured by DLS. (a-c) PTX/C6CP (red), PTX/C8CP (blue), and PTX/C10CP (green) PM, all 
2/2/10; (d-f) 20/3/50 (green) and 40/3/50 (blue) PTX/C6CP PM. The DLS measurements were 
done at 1 g/L POx. (g-j) TEM micrographs of PTX/C6CP (g, j), PTX/C8CP PM (h), and 
PTX/C10CP (i) PM. The TEM measurements were done at 10 g/L POx or 50 g/L POx. Scale bar = 
100 nm.  
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Figure 3.5 Drug release profiles of PTX and CP from single and combination drug PM 
containing PTX and (a, b) C6CP, (c) C8CP and (d) C10CP.  
The drug/polymer feed ratios were 2/2/10 (a, c, d) or 40/3/50 (b) for combination PM and 2/10 (a, 
c, d) or 40/50 and 3/50 (b) for single drug PM. The studies were performed at sink conditions at 
37°C in PBS, pH 7.4 in the presence of 40 g/L BSA. Data are mean ± SD, (n=3)    
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Figure 3.6  In vitro cytotoxicity of PTX/CP PM in A2780/CisR human ovarian cancer cell 
lines.  
(a, f) IC50 and (b-e) CI values of PTX/C6CP, PTX/C8CP and PTX/C10CP. (a, e) For the 
combination drug micelles the IC50 values correspond to the total amount of both drugs.  
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Figure 3.7  In vitro cytotoxicity of single and combination drug PM in (a, b) A2780/CisR and 
(c) A2780 cell lines.  
Drug formulations were (a, c) saline, free cisplatin, PTX PM (2/10), C6CP PM (2/10), C8CP PM 
(2/10), C10CP PM (2/10), and various ratio combination PTX/C6CP PM (1/3/10, 2/2/10 and 
3/1/10), PTX/C8CP PM (1/3/10, 2/2/10 and 3/1/10) and PTX/C10CP PM (1/3/10, 2/2/10 and 
3/1/10) and (b) PTX PM (40/50), C6CP PM (3/50), PTX/C6CP PM (20/3/50) and PTX/C6CP PM 
(40/3/50. Data are means ± SD, n = 6. 
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Figure 3.8  In vitro cytotoxicity of PTX/CP PM in A2780 human ovarian cancer cell line.  
(a) IC50 and (b-d) CI values of PTX/C6CP, PTX/C8CP and PTX/C10CP. (a) For the combination 
drug micelles the IC50 values correspond to the total amount of both drugs. 
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Figure 3.9  Pharmacokinetics and biodistribution in A2780/CisR human ovarian tumor 
bearing mice.  
Plots of PTX, platinum (Pt) and POx concentrations in (a, c, e, g) plasma and (b, d, f, h) tumor 
over 15 h after single i.v. injection of co-loaded (a, b) PTX/C6CP PM (2/2/10), and (e, f) 
PTX/C8CP PM (2/2/10) as well as single drug loaded (c, d) C6CP PM (2/10) and (g, h) C8CP PM 
(2/10). Data are expressed as mean ± SD, n = 3 for all groups. 
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Figure 3.10  Anti-tumor effects of the single and combination drug polymeric micelles.   
Anti-tumor effects of the single and combination drug polymeric micelles in the (a-d) cisplatin-
resistant human ovarian carcinoma xenograft A2780/CisR tumor and (e, f) multidrug resistant 
breast cancer LCC-6-MDR orthotopic tumor models. (a, c, e) Tumor volume changes and (b, d, 
f) Kaplan-Meier survival plots. The treatments regimen was q4d x 4. Drug injection doses were: 
(a, b) 20 mg PTX/kg and/or 20 mg CP/kg for PTX/C6CP PM (2/2/10), PTX/C8CP PM (2/2/10), 
PTX PM (2/10) and C6CP PM (2/10) mixture, PTX PM (2/10) and C8CP PM (2/10) mixture, PTX 
PM (2/10), C6CP PM (2/10) and C8CP (2/10) PM; (c-f) 60 PTX mg/kg and/or 4.5 C6CP mg/kg for 
PTX/C6CP PM (40/3/50), PTX PM (40/50) and C6CP PM (3/50) mixture, PTX PM (40/50), C6CP 
PM (3/50); (a-f) and 3 mg/kg cisplatin. (a, c, e) Data are mean ± SD, n = 5. (a-f) * p<0.05. *** 
p<0.001, (n = 6 (a, b) or 5 (c-f)). For detailed statistical comparisons see Tables 3.6 and Table 
3.7. 
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CHAPTER 4 : DRUG COMBINATION SYNERGY IN WORM-LIKE POLYMERIC 
MICELLES IMPROVES TREATMENT OUTCOME FOR SMALL CELL AND NON-
SMALL CELL LUNG CANCER 1 
4.1  Summary 
Nanoparticle systems for concurrent delivery of multiple drugs can improve outcomes of 
cancer treatments, but face challenges because of differential solubility and fairly low threshold 
for incorporation of many drugs. Here we demonstrate that this approach can be used to greatly 
improve the treatment outcomes of etoposide (ETO) and platinum drug combination (“EP/PE”) 
therapy that is the backbone for treatment of prevalent and deadly small cell lung cancer (SCLC). 
A polymeric micelle system based on amphiphilic block copolymer poly(2-oxazoline)s (POx) 
poly(2-methyl-2-oxazoline-block-2-butyl-2-oxazoline-block-2-methyl-2-oxazoline) (P(MeOx-b-
BuOx-b-MeOx) is used along with an alkylated cisplatin prodrug to enable co-formulation of 
EP/PE in a single high-capacity vehicle. A broad range of drug mixing ratios and exceptionally 
high two-drug loading of over 50 % wt. drug in dispersed phase is demonstrated. The highly 
loaded POx micelles have worm-like morphology, unprecedented for polymeric micelles, which 
usually form spheres upon drug loading. The two drugs co-loading in the micelles result in a 
slowed-down release, improved pharmacokinetics and increased tumor distribution of both 
drugs. A superior anti-tumor activity of co-loaded EP/PE drug micelles compared to single drug 
micelles was demonstrated using several animal models of SCLC non-small cell lung cancer. 
 
1 This chapter previously appeared as a manuscript has been submitted. Dr. Yuanzeng Min performed the synthesis 
and characterization of cisplatin prodrug. Y.M. and X.W. performed in vivo 344SQ orthotopic lung cancer model.   
  116 
4.2  Introduction 
Drug combination therapy is a common way to treat cancer. [81] The therapeutic outcomes 
can possibly be improved by using nanoparticle-based formulations that could provide a single 
vehicle for the concurrent delivery of multiple drugs to tumor cells to maximize therapeutic 
efficacy, overcome treatment resistance, and decrease adverse side effects of these drugs. [181]  
One notable success in this area is CPX-351 (Vyxeos), a fixed-combination of daunorubicin and 
cytarabine in liposomes, recently approved by the US Food and Drug Administration for adult 
patients with newly diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with 
myelodysplasia-related changes (AML-MRC), based on an improvement in overall survival in a 
phase III study. Here we explore possibility of extending the nanoformulation approach to 
improve combination therapy to one of the most challenging malignancies, lung cancer. 
Lung cancer is the most common malignancy and the leading cause of death from cancer 
in the world for several decades, with an estimated 1.6 million new cases and 1.38 million deaths 
per year. [182] Of all lung cancers about 80 to 85% are non-small cell lung cancer (NSCLC) while 
10% to 15% are small-cell lung cancer (SCLC). [183] Depending of the stages these cancers differ 
in the prognosis and the therapy. [183] Although several new treatments were introduced for 
NSCLC the advances in chemotherapy of SCLC have been poor. [182] Currently etoposide (ETO) 
and platinum remain (“EP/PE”) as the backbone of therapy of SCLC and since introduction of 
this drug combination chemotherapy there were no significant advances in first line therapy of 
SCLC for over 30 years. [183] We posit that the EP/PE combination therapy outcomes can be 
improved by using nanoformulation approach. 
The co-delivery of drugs in a single nanofomulation remains a principal challenge since 
poor solubility and differential pharmacokinetics (PK) severely restricts the selection of drugs 
that can be translated into successful combination treatments. Critical to success is optimizing 
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the relative doses of the drugs to obtain synergistic effects on tumors. [4] Most nanoparticles have 
a fairly low threshold for incorporation of such drugs. Previously, we have reported a nanosized 
polymeric micelles (PM) formulation based on highly defined amphiphilic triblock copolymers 
of poly(2-oxazoline)s (POx), poly(2-methyl-2-oxazoline-block-2-butyl-2-oxazoline-block-2-
methyl-2-oxazoline) (P(MeOx-b-BuOx-b-MeOx)), that have greatly enhanced the solubility of 
single and multiple drug combinations. [1, 2] In particular, the POx-based PM of paclitaxel (PTX) 
with unprecedentedly high drug loading of nearly 45 % wt. and controllable ~30 to 40 nm size 
displayed reduced toxicity and superior efficacy in early and late stage breast cancer models 
compared to clinically approved Taxol and Abraxane. [3] Here, we propose that co-loading of 
ETO and platinate at synergistic drugs ratios in the POx-based drug delivery platform can safely 
and efficiently treat both SCLC and NSCLC lung cancer. 
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4.3  Materials and Methods 
4.3.1 Materials 
Amphiphilic triblock copolymers P(MeOx37-b-BuOx21-b-MeOx36), Mn = 10.0 kg/mol, 
Ð (Mw/Mn) = 1.14 was synthesized as described in the previous studies by means of living 
cationic ring-opening polymerization and characterized by 1H-NMR spectroscopy and gel 
permeation chromatography. [2, 3] ETO was purchased from LC Laboratories (Woburn, MA). 
Cisplatin was purchased from Sigma, and VePesid® was purchased from UNC Hospital 
Pharmacy. All other materials were from Fisher Scientific Inc. (Fairlawn, NJ) and all reagents 
were HPLC grade. The A549 NSCLC cell line and H69AR SCLC cell line were originally 
obtained from Sigma-Aldrich (City, State). Cells were cultured in Dulbecco's Modified Eagle's 
medium (DMEM) (Gibco 11965-092) supplemented with 10% fetal bovine serum (FBS) and 1% 
pen-strep. The 344SQ/Luc. NSCLC cell line (expressing luciferase) was originally provided by 
Dr. John Kurie (MD Anderson Cancer Center, Houston, TX). The 344SQ/Luc. cells were 
cultured in DMEM medium with 10% FBS and 5 µg/mL puromycin.  
4.3.2 Synthesis and characterization of hydrophobic platinum (IV) prodrugs (CPs) 
Ten milliliters of c,c,t-[Pt(NH3)2Cl2(OH)2] (0.69 g, 2.05 mmol) solution in DMSO were 
mixed with 10 mL of the solution in dimethylformamide of a respective aliphatic anhydride: 
C4CP, butyric anhydride (0.40 g, 3.9 mmol),  C6CP, hexanoic anhydride (0.90 g, 4.2 mmol), 
C8CP, octanoic anhydride (2.18 g, 8.2 mmol) or C10CP, decanoic anhydride (2.53 g, 7.8 mmol), 
and the reaction mixture was stirred at room temperature (r.t.) for 48 h. Water (approx. 20 mL) 
was added to the mixture to precipitate light yellow solids followed by filtration and isolation. 
The yellow solids were washed several times with diethyl ether and dried. The yields of C4CP, 
C6CP, C8CP and C10CP were all approximately 40 wt. %. The synthesized prodrugs were soluble 
in ethanol (5 g/L, 5 g/L, 2 g/L and 2 g/L respectfully). 
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4.3.3 Preparation and characterization of drug loaded POx PM  
Drug loaded PM were prepared by the thin film method as previously described. [2, 3, 160] 
Briefly, pre-determined amounts of POx, ETO and CPs were dissolved in ethanol (5-10 g/L) and 
mixed, followed by complete removal of ethanol. Appropriate amounts of normal saline were 
used to rehydrate the dried thin-film under mild heating at 50-60 ºC (or r.t. for CPs PM) for up to 
15 min in order to obtain drug loaded PM. The excess of non-incorporated drug was removed by 
centrifugation from the otherwise stable micellar solution. The resulting micelle formulation was 
stored as aqueous solution in refrigerator for up to 2 weeks or as lyophilized powder for long-
term storage. 
A Nano-ZS (Malvern Instruments Inc., UK) Dynamic Light Scattering (DLS) equipment 
was used to measure size distribution of POx micelles. Briefly, each sample was diluted 10 times 
with deionized water (DI H2O) to yield 1 g/L final polymer concentration before the 
measurement. The intensity-mean z-averaged particle size (effective diameter) and the 
polydispersity index (PDI) of PM were determined by cumulate analysis. Results are the average 
of three independent micelle samples measurements.  
The morphology of PM was studied using a LEO EM910 TEM operating at 80 kV (Carl 
Zeiss SMT Inc., Peabody, MA). Digital images were obtained using a Gatan Orius SC1000 CCD 
Digital Camera in combination with Digital Micrograph 3.11.0 software (Gatan Inc., Pleasanton, 
CA). One drop of each PM solution (diluted 200 times using DI H2O) was deposited on a copper 
grid/carbon film for 5 min and excess solution was wicked off using fine filter paper. Then one 
drop of staining solution (1% uranyl acetate) was added and allowed to dry for 10 s prior to the 
TEM imaging.  
Atomic force microscopy (AFM) was used to visualize the drug loading effect on micelle 
shape and size. Solutions of empty and drug-loaded micelles (20 µg/mL POx in H2O) were 
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deposited onto freshly cleaved mica substrates by spin casting. The imaging was performed in 
PeakForce QNM mode using a multimode AFM (Brüker) with a NanoScope V controller and 
silicon probes (resonance frequency of 70 Hz and spring constant of 0.4 N/m). Both Nanoscope 
Analysis (Brüker) and ImageJ (NIH) software were used to characterize micelle dimensions. 
4.3.4 In vitro drug release  
The drug release studies were performed by membrane dialysis method against phosphate 
buffered saline (PBS), pH 7.4 at 37 0C. Briefly, drug loaded PM were diluted in PBS containing 
40 g/L BSA to achieve ~ 0.1 g/L of total drug concentration. The 100 µL of the diluted micelle 
solutions were added into floatable Slide-A-Lyzer MINI dialysis devices (100 µL capacity, 20 
kDa MWCO; Thermo Scientific) and suspended in 20 mL PBS supplemented with 40 g/L BSA 
to ensure the sink conditions. Three devices were used for every time point. At each time point 
the samples were withdrawn from dialysis device and quantified by HPLC to obtain remaining 
drug amount of sample. Drug release profiles were constructed by plotting the amount of drug(s) 
released over time. 
4.3.5 Serum binding studies 
Reverse-phase Thermo Scientific™ SOLA™ HRP solid phase extraction (SPE) 
cartridges were used for separation and determination of micellar and protein bound forms of 
ETO and C6CP in serum. The micellar drugs did not retain on the stationary phase (Fractions A3 
and A4), while the protein bound drug was retained and eluted only with acidified methanol 
(fraction A6). The sample preparation was performed as follows. The formulations (100 µL of 
C6CP/ETO PM (4/8/10), mixture of C6CP PM (4/10) and ETO PM (8/10), C6CP PM (4/10), and 
ETO PM (8/10) comprising 3H-labeled ETO (3H-ETO, 2.5 µCi/mg ETO) were added to 2 mL of 
100% FBS, incubated at 37 °C, and 200 µL samples were collected from the mixture solution at 
1hr and 4hr. Each 200 µL serum sample was mixed with 200 µL of PM solution (2 mg/mL) in 
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PBS, pH 7.4. The following fractionation procedure was used: (A1) Column conditioning: Add 
0.5 mL methanol (discard to waste); (A2) Equilibrate: Add 0.5 mL water (discard to waste); (A3) 
Application: load pre-treated sample (encapsulated drug, collect); (A4) Wash 1: 2 × 0.25 mL 
POx in phosphate buffered saline (2 mg/mL), pH 7.4 added sequentially (encapsulated drug, 
collect); (A5) Wash 2: 2 × 1 mL water / methanol (90:10 v/v) added sequentially (discard to 
waste); (A6) Elution: 0.5 mL methanol and 0.1% formic acid (albumin bound drug, collect).  
4.3.6 In vitro cytotoxicity and combination index (CI) analysis 
In vitro cytotoxicity of drug loaded PM was evaluated in A549, H69AR and 344SQ/Luc 
lung cancer cell lines using [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] 
(MTT) assay. Briefly, cells were seeded in 96-well plates at a density of 3,000 cells/well 24 h 
prior to drug treatment. Subsequently, cells were treated with drug loaded PM in full medium. 
Following 72 h the incubation medium was removed and 100 µL of fresh medium with MTT 
(100 µg/well) was added and incubated for 4h at 37°C. The medium was discarded, the formed 
formazan salt was dissolved in 100 µL of DMSO and absorbance was read at 562 nm using a 
plate reader (SpectraMax M5, Molecular Devices). Cell survival rates were calculated as 
normalized to control untreated wells. Data represents average of hexaplicate in means ± 
standard error means (SEM). The mean drug concentration required for 50% growth inhibition 
(IC50) was determined using Graphpad Prism 5 software. The CI analysis based on the Chou and 
Talalay method was performed using CompuSyn software. [184] Briefly, for each level of growth 
inhibition Fa the CI values for binary drug combinations are calculated according to the 
following equation: CI = (D)1/(Dx)1 + (D)2/(Dx)2, where (D)1 and (D)2 are the concentrations of 
each drug in the combination resulting in Fa x 100% growth inhibition, and (Dx)1 and (Dx)2 are 
the concentrations of the drugs alone resulting in Fa x 100% growth inhibition. CI values for drug 
combinations are plotted as a function of Fa. Generally, the CI values between Fa = 0.2 and Fa = 
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0.8 are considered valid. The best-fit CI value at IC50 is used to show and compare the 
synergistic effects of drug combinations with different drug ratios or for different cell lines. CI 
values less than 1 or more than 1 demonstrate synergism or antagonism of drug combinations, 
respectively. 
4.3.7 In vitro cell uptake 
344SQ/Luc. cells (5 × 103/well) were seeded in 24-well plates. After 24 h the medium was 
replaced (200 µL) and exposed to 1) C6CP PM, 2) ETO PM, 3) C6CP/ETO PM, or 4) a mixture of 
C6CP PM and ETO PM in the fresh medium for 30 min, 1 h, 4 h, 8 h, 24 h and 48 h. Each single 
drug concentration during exposure was same as that of IC50 of C6CP/ETO PM. All ETO test articles 
contained 3H-ETO (2.5 µCi/mg ETO). After that cells were washed thrice with PBS, harvested with 
200 µL trypsin containing ethylenediaminetetraacetic acid (EDTA) and lysed with 100 mM Tris buffer 
containing 5 mM EDTA, 200 mM NaCl, 0.2% sodium dodecyl sulfate, pH8.0 for 1 h at 370C. The 
homogenates were divided into two vials, one of which was analyzed for 3H-ETO using a Tricarb 
4000 (Packard, Meriden). To the other vial ca. 100 µL of concentrated HNO3 was added and the 
samples were incubated at 60oC overnight, followed by dissolving in DI water (5 mL). Platinum 
concentration was measured by Inductively Coupled Plasma Mass Spectrometry (ICP-MS). All 
experiments were repeated three times, and the average C6CP and ETO contents (ng/5 × 103 cells) 
were calculated. [185] 
4.3.8 Maximum Tolerable Dose (MTD) determination 
MTD evaluation for C6CP/ETO PM was performed in dose escalation study in healthy 6-
8 week old female nude mice. Animals (three mice per group) received i.v. injections (tail vein) 
of 10/20, 12.5/25, 15/30 and 20/40 C6CP/ETO mg/kg of C6CP/ETO PM using a q4d x 4 regimen 
(total 4 times repeated dosing, every 4th day with saline as a control). Mice survival and changes 
in the body weight were observed daily over two weeks in all groups following the last injection. 
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The highest dose that did not cause animal death or noticeable toxicity (as defined by a median 
body weight loss of 15% of the control or abnormal behavior including hunched posture and 
rough coat) was used as MTD for efficacy experiments. 
4.3.9 Toxicology studies 
Female athymic nude mice (6-8 weeks) with H69AR xenograft tumors were administered 
with saline, or respective MTDs of free cisplatin and ETO mixture, C6CPs PM (4/10) and ETO 
PM (8/10) mixture, or C6CP/ETO PM (4/8/10) (at MTD) using a q4d x 4 regimen. Two days 
after the last injection mice were sacrificed, blood was collected and centrifuged at 7,500 rpm for 
5 min to obtain the serum. Blood urea nitrogen (BUN), creatinine and alanine aminotransferase 
(ALT) levels were assayed as indicators of renal and hepatic function. Whole blood was used 
albumin level test. To evaluate the organ-specific toxicity, major organs (brain, spleen, liver, 
lung, kidney, heart and tumor) were harvested, fixed in formalin, and subjected to pathological 
analysis by hemotoxylin & eosin (H&E) staining.  
4.3.10 PK and tumor accumulation 
  Female athymic nude mice (6-8 weeks) with well-developed 100 mm3 H69AR xenograft 
tumors were administered a single dose of following formulations via tail vein: 1) C6CP/ETO 
PM (15 mg/kg C6CP and 30 mg/kg ETO mouse body weight, the MTD for this formulation), 2) 
C6CP PM and ETO PM mixture (15 mg/kg C6CP and 30 mg/kg ETO), 3) C6CP PM (15 mg/kg 
C6CP), and 4) ETO PM (30 mg/kg ETO). All ETO injections contained 3H-ETO (5 µCi/mouse). 
At several time points 0.083, 0.5, 1, 2, 6, 24, and 48 h post injection three animals from every 
treatment group were euthanized, the blood was collected by cardiac puncture, the organs 
(spleen, liver, kidney) and the tumor was removed, washed in ice-cold saline, weighted and 
homogenized in a glass tissue homogenizer (TearorTM, BioSpec Products, Inc.). Drug 
concentrations in plasma, organs and tumors were measured by radioactivity counts using a 
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Tricarb 4000 for 3H-ETO or by platinum content using ICP-MS for or C6CP. PK parameters 
were determined with Phoenix WinNonlin (version 6.0) software using non-compartmental 
analysis.  
4.3.11 In vivo tumor growth inhibition 
4.3.11.1 A549 and H69AR xenograft models. 
Female athymic nude mice (6-8 weeks) were subcutaneously inoculated in the right flank 
with 1 x 106 human A549 cells or 3 x 106 human H69AR cells, each re-suspended in 50% 
growth medium and 50% Matrigel. For each tumor model, the animal treatments started when 
tumor sizes reached ca. 100 mm3. Animals were randomized into 7 groups of six mice each with 
similar mean tumor volumes between groups and then treated with the following formulations: 
1) C6CP/ETO PM (15 mg/kg C6CP and 30 mg/kg ETO mouse body weight), 2) C6CP PM and 
ETO PM mixture (15 mg/kg C6CP and 30 mg/kg ETO), 3) C6CP PM (15 mg/kg C6CP), 4) ETO 
PM (30 mg/kg ETO), 5) Free drug mixture (2 mg/kg cisplatin and 4 mg/kg ETO as VePesid), 6) 
PM alone (at the POx dose equivalent to that in the C6CP/ETO PM group), 7) Saline alone. The 
formulations were administered via tail vein using q4d x 4 regimen (on the days 0, 4, 8, 12). 
Survival and body weight were monitored daily. Tumor length (L), width (W) were measured 
and tumor volume (TV) was calculated as TV =1/2 ´ L ´ W2. Tumor growth was monitored 
twice weekly for 13 weeks or earlier end-points defined by tumor volume (> 2000 mm3), animal 
weight loss (> 15 %), or animals becoming moribund. Tumors were removed at the end of the 
observation and subjected to histopathological examination. 
4.3.11.2 344SQ orthotopic model.  
The orthotopic model was created by directly transplanting 344SQ/Luc. cells into female 
mice lung by an intrapulmonary technique (5 ´ 103 cells/mouse in 40 µl 3:1 mixture of Hanks' 
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balanced salt solution, and BD Matrigel (BD Biosciences)). Mice are anesthetized using 3% 
isoflurane in O2 and then kept under 1.5-2% isoflurane in O2. A ~1cm incision was made in the 
left chest wall. Chest muscles were separated by sharp dissection and costal and intercostal 
muscles were exposed. A 27-gauge needle was inserted through the intercostal space between the 
3rd and 4th ribs. Cells were slowly injected into the left lung over 30 seconds. The skin was 
closed using tissue adhesive and surgical suture in an interrupted pattern. The animals were 
randomized and treated via tail vein following q4d x 4 regimen the next day after cells injection. 
IVIS imaging were taken every two days to monitor tumor growth. 1) C6CP/ETO PM (15 mg/kg 
C6CP and 30 mg/kg ETO mouse body weight), 2) C6CP PM and ETO PM mixture (15 mg/kg 
C6CP and 30 mg/kg ETO), 3) C6CP PM (15 mg/kg C6CP), 4) ETO PM (30 mg/kg ETO), 5) free 
cisplatin (2 mg/kg), 6) free ETO as VePesid (4 mg/kg), 7) free drug mixture (2 mg/kg cisplatin 
and 4 mg/kg ETO), 8) PM alone (at the POx dose equivalent to that in the C6CP/ETO PM 
group), 9) Saline alone (n = 5). For in vivo imaging, mice were placed onto the warmed stage 
inside the camera box and received continuous exposure to 2.5% isoflurane to sustain sedation 
during imaging. Every group of mice was imaged for 30 s. The light emitted from the mice were 
detected by the IVIS-100 camera system, integrated, digitized, and displayed. 
4.3.12 Tumor sections histology  
4.3.12.1 Pt-DNA adducts staining of tumor sections. 
The Pt-DNA adducts were detected using anti-cisplatin modified DNA antibody 
[CP9/19] (Abcam, Cambridge, MA). The tumor sections were collected during efficacy 
experiments (the second day after the last treatment), deparaffinized, antigen recovered, blocked 
with 1% BSA in PBS for 1h at r.t., incubated with a 1:250 dilution of [CP9/19] antibody at 4 °C 
overnight, and then incubated with Alexa 555-labeled goat anti-rat IgG antibody (1:200, Santa 
Cruz, CA). The sections were also counter-stained with VECTASHIELD mounting media with 
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DAPI (Vector laboratories, Burlingame, CA). The tumor sections were analyzed and the staining 
was quantified using a Zeiss LSM 700 Confocal Laser Scanning Microscope (Zeiss, USA). 
4.3.12.2 Caspase-3 levels staining of tumor sections.  
The apoptosis was detected using Caspase-3 (Cleaved) polyclonal antibody [CP229 A] 
(Biocare Medical). The tumor sections were collected and processed as described above but 
incubated with a 1:200 dilution of [CP229 A] antibody at 4°C overnight, and then incubated with 
Alexa 555-labeled goat anti-rabbit IgG antibody (1:250, Santa Cruz, CA). The sections were also 
counter-stained and analyzed as described above. 
4.3.13 Statistical Analysis  
Quantitative results were expressed as mean ± SD. Statistical comparisons for drug 
release, cellular uptake, PK, tumor accumulation, histology quantitation images and tumor 
inhibition data were done using one-way analysis of variance (ANOVA) with Holm-Sidak post-
hoc test for multiple comparisons. Statistical analysis was performed using Prism 7.03 software. 
Statistical comparison of animal survival was done by Log-rank test. Differences were 
considered to be statistically significant if the p value was less than 0.05.  
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4.4  Results 
4.4.1 Synthesis of CPs 
Cisplatin as a hydrophilic water-soluble drug would not preferentially incorporate in a 
hydrophobic core of PM. To enable cisplatin formulation and delivery within POx micelles we 
used the prodrug strategy. [186] As the synthetic approach, cisplatin derivatives with aliphatic 
chains of different length (n = 4, 6, 8 and 10 carbon atoms) at the axial positions have been 
synthesized as previously reported. [187, 188] The derivatives are designated as C4CP, C6CP, C8CP, 
C10CP according to the length of the aliphatic chain (Fig. 4.2). Their chemical structures were 
confirmed by 1H-NMR spectroscopy and mass spectrometry (Fig. 3.2, Fig. 3.3). 
4.4.2 Preparation and characterization of drug-loaded micelles 
4.4.2.1 High capacity ETO PM 
Previously, we have reported on ETO loaded POx-based PM but did not examine 
different feed concentrations of this drug and the morphology of the particles formed. [2] In this 
study, we set the polymer concentration to a fixed value (10 g/L) and increased the ETO feeding 
concentration (here and below we designate the feeding ratios for single drug micelles as wt. 
ratios of targeted amounts “drug/polymer”). Surprisingly, even at the highest ETO concentration 
(feeding ratio 10/10), nearly all drug was incorporated into the PM (Fig. 4.4). Under these 
conditions the LE and LC were ~98 % and ~50 %, respectively and the micellar solution 
contained ~9.7 g/L ETO, which is at least ~300-fold higher than ETO maximal solubility in pure 
water. [189] For the entire range of ETO concentrations the drug-loaded PM solutions were 
transparent or slightly opaque. The DLS analysis revealed the presence of small particles with 
the hydrodynamic diameters ranging from ~25 nm to ~36 nm depending on the drug feeding 
ratio (Table 4.1). Interestingly, the ETO PM displayed a relatively broad size distribution (PDI > 
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0.5). Such size distribution can possibly be caused by the non-spherical worm-like morphology 
of these micelles observed by TEM (Fig. 4.3). 
4.4.2.2 High capacity CPs PM  
Like in the previous case the polymer concentration in the final formulation was set at 10 
g/L and the CPs concentration was varied from 2 g/L to 10 g/L. For each of the four CPs the 
maximal compound concentration in the micellar solution was achieved at drug/polymer feeding 
ratio 10/10 (Fig. 4.5). However, there were marked differences in the solubility of these 
compounds that was as high as ~8.4 g/L for C4CP and C6CP and relatively lower ~2.6 to 3.1 g/L 
for C8CP and C10CP. These differences are also reflected in the corresponding LE and LC values 
(LE ~82-85 % and LC ~45-46 %, for C4CP and C6CP, and LE ~32-50 % and LC ~23-32 % for 
C8CP and C10CP) (Table 4.2-4.5) The CPs PM solutions were transparent and remained stable 
with no signs of drug precipitation while stored for at least two weeks at 40C. The DLS 
hydrodynamic diameters of the micelles increased as the length of the aliphatic chain of the CPs 
increased from under 30 nm for C4CP to over 140 nm for C10CP. At high drug loading, the 
particle size distribution varied from being very narrow for C6CP PM (PDI < 0.1), to moderately 
narrow for C8CP PM and C10CP PM (PDI < 0.2), to relatively broad for C4CP PM (PDI ~ 0.3-
0.4) (Table 4.2-4.5). Based on the solubilization, particle size, stability, and cytotoxicity analysis 
(described below) we selected C6CP PM for further testing.  
4.4.2.3 Combination C6CP/ETO PM have increased drug loading and worm-like shape  
The preparation of PM containing two drugs is as straightforward and simple as the 
procedure to solubilize a single drug loaded POx micelle. The drug(s) and the polymer are 
solubilized in a common solvent (ethanol), the solution mixed with a desired drug(s) polymer 
ratio, the solvent removed to obtain a thin solid film and the film is finally hydrated with buffer 
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or water to give a micellar solution (Fig. 4.2b,c). To prepare C6CP/ETO PM, we selected three 
different C6CP/ETO wt. ratios of 8/4, 6/6 and 4/8 (g/g) and, like in the cases of single drugs, kept 
the POx concentration constant (10 g/L) to examine the drug loading. (Consequently, for the co-
loaded drug micelles the feeding ratios were defined as wt. ratios “drug1/drug2/polymer”) In this 
case, however, each drug contents in the micellar solution were measured separately, to give two 
sets of values for LE and LC. With any of the chosen ETO/C6CP ratios, the LE of C6CP was 
above 85%, and the LE of ETO was nearly quantitative (Fig. 4.3a, Table 4.6). The LC values for 
each drug varied with the drug feed but the net LC for both drugs always exceeded 50 %. 
Remarkably, the total concentration of two drugs in the micellar solution was nearly 11 g/L (Fig. 
4.3b,c) with only 10 g/L polymer used. Thus, the total drug solubilization is higher for the co-
loading of both drugs compared to the solubilization of the respective single drugs. 
The particle size and polydispersity was strongly affected by the drug ratio (Fig. 4.3d-f, 
Table 4.6). At the similar overall drug loading the micelles with the highest ETO content had the 
smallest size ~75 nm while the micelles with highest C6CP content were considerably larger 
~103 nm. Interestingly, the PDI changed in the opposite direction. The co-loaded PM with the 
highest C6CP content were close to uniform (PDI 0.08) while the co-loaded PM with the highest 
ETO content were more heterogeneous (PDI 0.22). Nevertheless, the co-loading of the drugs 
greatly decreased the polydispersity of C6CP/ETO PM as compared to ETO single loaded 
micelles (PDI > 0.5), indicating that upon co-loading both drugs strongly interact with each other 
and/or the block copolymer. The co-loaded micelles remained stable in solution and no change in 
size or PDI was detectable for at least two weeks of storage (Fig. 4.3e,f). Notably, although their 
PDI decreased and the size increased, the co-loaded micelles still retained the elongated worm-
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like shape characteristic of single ETO PM, in contrast to CP PM loaded with only one drug or 
empty micelles as observed by TEM (Fig. 4.3g).  
The changes in the morphology of the PM upon co-loading of the drugs were further 
examined by the AFM. Based on this study, the majority of empty micelles adopted a spherical 
shape, however, there were few exceptions where elongated particles formed, attributable to 
micelle aggregation (Fig. 4.6a). A size histogram of dry empty micelles is presented in Fig. 4.6c 
with analysis provided in Fig. 4.7. Micelle height is uniform (4 nm) and shows insignificant 
signs of spreading upon deposition (“Mexican hat”). Assuming a spherical shape, we estimate 
the radius of a dry micelle to be R = 9 nm. Drug loading had a major impact on the resulting 
micelle shape. In particular, dry C6CP/ETO PM displayed two distinct populations of spherical 
and elongated, worm-like particles (Fig. 4.6b). These populations were separated based on the 
particle circularity and their dimensions were measured independently as shown in histograms 
(Fig. 4.6d and Fig. 4.8). In addition, the spherical and worm-like particles differed in their 
average aspect ratios, which in the case of elongated particles (circularity from 0.5 to 0.9) varied 
from ~1.3 to ~3.5 (for details see Fig. 4.9-4.11). 
4.4.3 Drug release and serum binding are decreased in co-loaded C6CP/ETO PM   
The rate of drug release from a nanoparticle carrier can significantly affect the 
therapeutic outcomes. This makes a time controlled drug release a key consideration in the 
micelle design. As PM are dynamic structures that can exchange both the macromolecules and 
the drugs with the environment, we determined the release of C6CP and ETO from the single and 
co-loaded drug micelles in the presence of serum protein using two distinct techniques. First, the 
drug release was studied by the dialysis method under sink conditions using PBS with 40% w/w 
BSA as the release media. The C6CP was released faster than ETO from as well as single drug as 
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well as co-loaded micelles. Surprisingly, the release rates of both, C6CP and ETO, from the co-
loaded micelles were lower as compared to the corresponding single drug micelles (Fig. 4.12). 
Specifically, the time of 50% drug release from C6CP/ETO PM was prolonged from ~2 to ~3 h 
for C6CP, and from ~4 h to ~6 h for ETO. 
Second, the binding of micellar drugs with serum proteins was examined. In this 
experiment, the PM containing single and co-loaded drugs as well as the mixture of PM each 
containing different single drugs were incubated for either 1h or 4h with 2 mL of FBS to mimic 
the dilution of the formulations in the blood. The distribution of the drug between the micelles 
and serum was determined using a solid phase extraction (SPE) column (SOLA™ HRP), which 
selectively retains free and protein-bound drugs, but not the drug incorporated in the micelles. 
The results suggest that the co-loaded drug micelles retained higher amount of both drugs as 
compared to single drug loaded micelles of their mixture (Table 4.7). For example, after 1h 
incubation time, ~79% of ETO remained encapsulated in the C6CP/ETO PM compared to ~71% 
for the mixture of C6CP PM and ETO PM and ~70% for the single drug loaded ETO PM. 
Likewise, ~78% of C6CP remained encapsulated in the C6CP/ETO PM but only ~70% for the 
mixture of C6CP PM and ETO PM and ~63% for the single drug loaded C6CP PM. The 
differences between the single drug micelles and C6CP/ETO PM somewhat diminished after 4h 
incubation time, especially for the mixture group but remained considerable in comparison with 
either C6CP PM or ETO PM groups. Probably, a slow inter-micellar drug exchange occurs in the 
mixture of single loaded micelles upon incubation produces some co-loaded micelles. In 
conclusion, co-formulation of the two drugs in the same PM increased the retention of these 
drugs in the micelles by slowing down the drug release and exchange with the serum proteins. 
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4.4.4 Combination C6CP/ETO PM display high activity drug synergy in cancer cells 
We evaluated the in vitro drug cytotoxicity of each of the CPs PM in H69AR human 
SCLC cells and 344SQ/Luc. murine NSCLC cells using the MTT assay (Fig. 4.14 and Table 
4.9). In H69AR cell line, the cytotoxicity profiles of the CPs PM strongly depended on the length 
of CPs aliphatic chain. For these micelle-incorporated prodrugs the cytotoxicity increased almost 
50-fold as the length of the aliphatic chain increased (IC50 2.86 µg/mL for C4CP, 0.31 µg/mL for 
C6CP, 0.06 µg/mL for C8CP and 0.06 µg/mL for C10CP). However, each prodrug in PM was 
substantially more active in this cell line as compared to free cisplatin (IC50 21.50 µg/mL). The 
cytotoxicity differences between various CPs PM were less pronounced in the 344SQ/Luc. cells 
(IC50 4.01 for C4CP and 0.65, 0.47 and 0.38 µg/mL for C6CP, C8CP and C10CP respectively). In 
this case, the prodrug with the shortest aliphatic chain was less toxic and the three other prodrugs 
were more toxic than cisplatin (IC50 2.01 µg/mL).  
By poisoning the DNA topoisomerase II, ETO suppresses the repair of cisplatin-induced 
DNA lesions, which results in the synergy of these drugs. [190, 191] Based on the cytotoxicity 
results for the C6CP prodrug as well as the data on the co-formulation loading and stability, we 
further examined the cytotoxicity of the co-loaded C6CP/ETO PM for different drug ratios. In 
both cell lines the cytotoxicity of the co-loaded drug micelles increases as the fraction of ETO in 
the drug mixture increases (Fig. 4.13a,c, and Table 4.8). The lowest IC50 value of the three drug 
ratios was observed for C6CP/ETO PM (4/8/10). Interestingly, the mixture of C6CP PM (4/10) 
and ETO PM (8/10) with the same drug ratio as C6CP/ETO PM (4/8/10) was less active in both 
cell lines. To assess drugs synergy, the CI was calculated using the isobologram equation of 
Chou–Talalay [72]. The most pronounced and strong drug synergy in H69AR was observed for 
C6CP/ETO PM (4/8/10) (CI < 0.2), while lower synergy was observed for C6CP/ETO PM 
(4/8/10) (CI < 0.5) (Fig. 4.13b). Similarly, in 344SQ/Luc. cells, the C6CP/ETO PM (4/8/10) 
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formulation displayed a clear synergistic effect between the drugs (CI < 0.5) (Fig. 4.13d). 
However, the two other formulations with lower ETO content displayed drug antagonism (CI > 
1.0). Based on the in vitro cell studies, we selected the C6CP/ETO PM (4/8/10) system was 
selected for further animal studies.  
4.4.5 Combination C6CP/ETO PM increase drug accumulation in cancer cells 
The intracellular accumulation of ETO and C6CP in PM was examined in 344SQ/Luc. 
cells. In this study, the cells were incubated for up to 50 h with either co-loaded C6CP/ETO PM 
(4/8/10) or single drug PM or the mixture of respective single drug-loaded PM. As can be seen in 
Fig. 4.13e,f, the uptake of both drugs is enhanced when the drugs are coformulated C6CP/ETO 
PM (4/8/10) compared to the mixture of C6CP PM (4/10) and ETO PM (8/10) with the same 
drugs ratio. Although the difference with the single drug micelles, C6CP PM (4/10) and ETO PM 
(8/10) was not so dramatic, the co-loaded drug micelles appear to be superior to these 
formulations as well.  
4.4.6 Toxicology studies MTD and toxicology profiles of co-loaded C6CP/ETO PM 
The MTD for the co-loaded drug micelles, C6CP/ETO PM (4/8/10) was determined in 
healthy 6-8 week old female nude mice using a q4d x 4 regimen. The MTD was determined as 
15 mg/kg for C6CP and 30 mg/kg for ETO. Therefore, we further used this dose for animal 
treatments with C6CP/ETO PM (4/8/10) was well as all other micellar formulations in this study. 
The MTD of the free cisplatin was 2.5 mg/kg and the MTD of the mixture of free drugs was 2 kg 
cisplatin and 4 mg/kg ETO mg/kg body weight. 
In vivo safety of drugs was also evaluated in the H69AR tumor bearing nude mice by 
examining clinical chemistry parameters for kidney and liver function after administering MTDs 
of free or micelle incorporated drugs. There were no significant changes in ALT, BUN and 
Albumin levels that were in the normal range (Table 4.10). Albeit the levels of Creatinine 
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seemed to be below the normal range, they were similar to the levels measured in mice treated 
with saline (Table 4.10).  
Mild renal toxicity was observed in animals treated with the combination of free cisplatin 
and ETO (Fig. 4.15). The samples from these animals revealed mild to moderately atrophied 
tubules having thinner and outstretched cell lining. Rare individual sloughed (dead) cells were 
also seen in the lumen of the tubules. Few scattered tubules have proteinaceous fluid or casts 
(Fig. 4.15 arrow in kidney samples). The renal toxicity appeared to be less in mice treated with 
the C6CP/ETO PM (4/8/10) and the mixture of C6CP PM (4/10) and ETO PM (8/10), where 
considerably lower scattered tubular damage was observed. 
4.4.7 Combination C6CP/ETO PM have improved PK in tumor-bearing mice 
 The drug PK and distribution profiles for C6CP/ETO PM (4/8/10) at MTD were 
compared to those for the mixture, C6CP PM (4/10) and ETO PM (8/10) as well as the single 
drug micelles in H69AR tumor bearing mice (Fig. 4.16a,b and Fig. 4.17). The PK parameters 
calculated using a non-compartment model are presented in Table 4.11. It is apparent that the 
co-loaded drug micelles considerably increased the plasma half-life of each drug as compared to 
the single drug micelles and their mixture (t1/2, α 15.15 h vs. 8.79 h and 11.91 h for C6CP and 
18.37 h vs. 14.82 h and 13.29 h for ETO). Moreover, there was a ~2.6 fold increase in the plasma 
AUC (~2.7 fold decrease in CL) and ~1.5 fold decrease Vdobs for C6CP in the co-loaded drug 
micelles compared to single drug micelles. There were little if any changes in the corresponding 
parameters for ETO. The Cmax in the plasma did not seem to change much for any of the drugs in 
different formulations. However, the tumor Cmax were considerably increased for both drugs in 
the co-loaded drug micelles when compared to the single micelles or their mixtures (Cmax 4.87 
µg/g vs. 3.51 µg/g and 3.25 µg/g for C6CP and 16.12 µg/g vs. 10.36 µg/g and 13.93 µg/g for 
ETO). The peak concentrations of both drugs in the tumors were reached at ~1 h post injection 
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for all investigated formulations, however, for at least as long as 6 h and 24 h the tumor 
concentrations of both C6CP and ETO for the co-loaded drug micelles were significantly higher 
that these concentrations for the single drug micelles and their mixture (Fig. 4.16c,d). Notably, 
the tumor AUC were increased by ~1.6 to 1.8- fold for C6CP and ~2.0 to 2.6-fold for ETO when 
these drugs were administered in the C6CP/ETO PM (4/8/10) format compared to either single 
micelles or their mixture. Further, analysis suggests that the tumor to plasma AUC ratios for 
C6CP in the co-loaded drug micelles, C6CP/ETO PM (4/8/10), exceeded these ratios for C6CP in 
the single drug micelles, C6CP PM (4/10), or mixture of the micelles, C6CP PM (4/10) and ETO 
PM (8/10), by ~1.4 and ~1.7 times respectively (Fig. 4.17). The similar AUC ratio for ETO in 
co-loaded drug micelles exceeded these ratios for ETO in the single drug micelles and the 
mixture of micelles by ~1.3 and ~2 times, respectively. Overall the co-loaded drug micelles 
displayed a considerably improved PK and biodistribution in the blood and tumor as compared to 
the single drug micelles or their mixture. 
4.4.8 Combination C6CP/ETO PM have superior anti-tumor activity in vivo  
The in vivo anti-tumor activity of the PM formulations was evaluated in three models of 
lung cancer: 1) A549 NSCLC, 2) H69AR SCLC, and 3) 344SQ NSCLC. The animals were 
treated with the co-loaded drug micelles, C6CP/ETO PM (4/8/10), the single drug micelles or 
their mixture. For some experiments, the treatment groups also included free cisplatin, free ETO 
or the mixture (4/8) of the free drugs. All drugs formulated in PM were administered at the MTD 
of C6CP/ETO PM. The free drugs were administered at the MTD of cisplatin and ETO mixture 
(2 mg/kg cisplatin and 4 mg/kg ETO). 
4.4.8.1 A549 xenograft model of NSCLC 
The tumor growth curves after various treatments are presented in Fig. 4.18a. The control 
groups treated with saline or PM alone displayed similar growth rates with the tumor volume 
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increasing from ca. 100 to 1,500 mm3 during 40 days. The groups treated with single drug 
micelles, ETO PM or C6CP PM, displayed slight, albeit significant decrease in the tumor 
volumes compared to the saline controls. Considerable tumor inhibition was observed for 
animals treated with the mixture of the single drug micelles, C6CP PM and ETO PM, where the 
final tumor volume was ca. 600 mm3. The co-loaded drug micelles, C6CP/ETO PM exhibited the 
most pronounced anti-tumor effect and decreased the final tumor volume to only ca. 350 mm3 
(Fig. 4.18a). The mixture of C6CP PM and ETO PM and the co-loaded C6CP/ETO PM extended 
the animals median survival from 45 days (saline control), to 67 and 69 days, respectively (Fig. 
4.20). Notably, while all animals in the C6CP PM and ETO PM mixture group died by day 80, 
2/6 of mice treated with the co-loaded drug micelles survived beyond day 90.     
4.4.8.2 H69AR xenograft model of SCLC 
Similar promising efficacies of PM formulations were observed in a more aggressive 
H69AR SCLC xenograft model that rapidly grew from ca. 100 to 2,400 mm3 during 31 days 
(Fig. 4.18b). In this case, however, single drug micelles, C6CP PM, caused modest tumor 
inhibition while ETO PM had slight but statistically significant effect on the tumor volume. The 
mixture of the single drug micelles, C6CP PM and ETO PM, inhibited tumor growth 
considerably and extended the mean survival time from 32 to 55 days, albeit all mice died before 
day 60 (Fig. 4.20b). Like in the previous model case, the co-loaded drug micelles, C6CP/ETO 
PM, produced the strongest tumor growth inhibition, with 2/6 long-term survivors recorded 
beyond day 60.  
4.4.8.3 344SQ orthotopic model of NSCLC   
We further evaluated various formulations in the orthotopic 344SQ NSCLC model. The 
344SQ/Luc. cancer cells used in this experiment were transfected with luciferase, allowing a 
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continuous monitoring of the tumor growth by IVIS imaging (Fig. 4.19) as well as direct 
observation of the animals’ lifespan (Fig. 4.20). The free drugs as well as their combination had 
little if any anti-tumor effect in this model with no animals surviving by day 29. In contrast, both 
single drug micelles produced some extension of the lifespan. Specifically, 2/5 and 3/5 mice 
survived at day 29 in the groups treated with C6CP PM and ETO PM, respectively. The mixture 
of the single drug micelles, C6CP PM and ETO PM, significantly extended the lifespan as 
compared to the controls, with 4/5 mice surviving on day 29. But still, the longest lifespan was 
observed with the co-loaded drug micelles, C6CP/ETO PM with all (5/5) mice surviving on day 
29. The IVIS images clearly show that the tumor burden in this group was much less as 
compared to the group treated with the mixture of the single drug micelles as well as in all other 
groups (Fig. 4.19). 
4.4.9 Combination C6CP/ETO PM increase DNA damage and apoptosis in tumors 
 The inhibition of DNA repair by topoisomerase II upon treatment with ETO slows down 
the removal of Pt-DNA adducts formed during treatment with cisplatin and results in the 
synergistic effects of these drugs. [190, 191] In this work, we evaluated these effects in the H69AR 
tumor model, by staining the tumor sections with the Alexa-555-labeled anti Pt-DNA adduct 
antibody on day 2 after the last drug treatment (Fig. 4.18c). As seen from quantifications in Fig. 
4.18e a significant increase in the amount of Pt-DNA adducts was observed groups treated with 
the co-loaded drug micelles, C6CP/ETO PM, compared to both the single drug C6CP PM and 
mixture of C6CP PM and ETO PM treatment groups. Further to elucidate the level of apoptosis 
following various treatments, the apoptosis marker Caspase-3 [181] was quantified in the tumor 
sections on day 2 days after the last treatment (Fig. 4.18d). Consistent with the data on the Pt-
DNA adducts formation Caspase-3 was significantly elevated in the C6CP/ETO PM treatment 
groups compared to all other groups (Fig. 4.18f).  
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4.5  Discussion 
Development of novel nanoparticle drug carriers that can simultaneously encapsulate 
several drugs that differ in physicochemical and pharmacological properties is extremely 
important for combination chemotherapy of malignant diseases. [181] Critical to the success of 
such strategy are efficient drug loading and ability to precisely control the ratio of the drugs to be 
administered. For the first time, we report on PM based on POx block copolymers that can 
simultaneously incorporate two important chemotherapeutic drugs, ETO and cisplatin, in a form 
of a pro-drug, in a single, stable and injectable solution, and with minimal amount of the polymer 
excipient. This study demonstrates that these two drugs can be combined in a broad range of 
drug ratios, with unparalleled high net drug loadings over 50 wt. % as stable micellar 
formulations. The herein reported drug loadings are, to the best of our knowledge, unprecedented 
for other PM containing two different drugs. [192] 
The ETO and cisplatin combination chemotherapy is a well-known chemotherapy 
treatment used to treat several cancers. [193] ETO induces DNA strand breaks by forming a 
tertiary complex with DNA and DNA topoisomerase II. When used together with cisplatin ETO 
suppresses the DNA repair, leading to more efficient DNA damage. [194] Due to the 
pharmacological synergy between these two drugs, ETO and cisplatin combination has shown 
cumulative effects against many forms of cancer, but in particular against NSCLC and SCLC. 
Based on the clinical successes of this combination therapy, we posited that co-encapsulation 
within POx PM could even further improve the therapeutic index. As expected, the co-loaded 
drug micelles displayed greatly improved in vitro cytotoxicity compared to the single drug 
micelles. A profound synergistic effect has been observed in CI studies in the lung cancer cells 
for the co-loaded drug micelles. However, in addition to the pharmacological synergy of the 
drugs, the co-loaded drug micelles displayed several unexpected and highly beneficial properties.  
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These properties are beneficial for the therapy as have been evident by the increase of the 
loading capacity, as well as the reduced release rates and improved retention of drugs in the co-
loaded micelles. This phenomenon probably reflects an increased miscibility of the specific drug 
pair, ETO and C6CP within the BuOx core of the micelles. Surprisingly, the uptake of each of the 
drugs in the co-loaded drug micelles was also improved as compared to the mixture of the single 
drug micelles. We posit that the co-loaded drug micelles are more efficiently delivered into the 
cells due to a smaller number of particles, in which both drugs are residing and which are taken 
up into the cells by endocytosis.  
Perhaps, most notably we observed the elongated, worm-like morphology of the co-
loaded drug micelles. It has been reported that non-spherical particles, such as gold rods or 
polymer brushes, have altered cellular uptake and PK as compared to respective spheres. [195, 196] 
Of relevance to our work, Discher et al. has suggested potential benefits of worm-like vs. 
spherical micelles in terms of PK for drug delivery. [197] Yet their study neither used drug-loaded 
micelles nor characterized drug delivery to tumors. To the best of our knowledge, herein we 
describe for the first time highly loaded PM compositions with elongated morphology (short 
worms) that is highly unusual and very rare for drug-loaded micelles. In previous reports 
addition of the drug disrupted worm-like morphology. For example, empty PM, represented a 
heterogeneous mixture of spheres and filaments/worms in the absence of the drug, but became 
spherical and uniform upon addition of PTX. [153] The complete transition from worms to spheres 
occurred at the drug loadings less than 3% for P(MeOx-b-(2-nonyl-2-oxazoline)-b-MeOx) and 
less than 10% for the high capacity P(MeOx-b-BuOx-b-MeOx) triblock. [153] The recently 
reported poly(ethylene glycol-b-e-caprolactone) and poly(ethylene glycol-b-a-benzyl 
carboxylate e-caprolactone) filomicelles containing PTX have very low drug loadings of only 
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~2.5 to ~3.2 %. [198] Such low drug loadings are very unfavorable for drug delivery of 
chemotherapeutic agents to treat cancer. [3] In the present study, however, the highly loaded 
ETO-containing POx micelles displayed elongated morphology, which was sustained for the 
ETO/C6CP PM even though the single drug micelles of C6CP were spherical. It is amazing that 
the elongated morphology was observed at drug loadings as high as ~ 43 % for single drug ETO 
PM and ~ 52 % for co-loaded C6CP/ETO PM. When compared with the literature [153] for the 
same POx polymer we observed the worm-like micelles with least 10 times higher ETO loading 
as compared to PTX. This suggests that the filament morphology is governed by specific drug-
polymer interactions and is characteristic for a given drug structure, in our case ETO. Moreover, 
drug-drug interactions in the micelle core can result in the morphology switch, specifically, 
transition from spheres for single C6CP micelles to worms upon addition of ETO in the co-
loaded drug micelles.  
The PK and biodistribution data of the co-loaded drug micelles for both delivered drugs 
is highly encouraging. In particular, co-loaded drug micelles considerably increased the plasma 
half-life of each drug compared to the single drug micelles and their mixture. Moreover, the 
tumor Cmax and the tumor AUCs of each drug in the co-loaded drug micelles was also greatly 
increased, with the overall result being a drastic improvement of the PK and tumor distribution 
of the co-loaded formulation compared to the single drug micelles or their mixture. The superior 
PK and tumor distribution of the drugs in the co-loaded drug micelles may be due to several 
factors including 1) improved circulation of the drugs in the blood due to shape differences, 2) 
decreased drug release rates and better retention of the drugs in the micelles in the presence of 
serum and 3) perhaps, improved drug internalization in the cells as observed in the drug uptake 
studies.  
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The major and most impressive manifestation of the drug co-loading effect is a 
considerably increased anti-tumor activity of co-loaded drug micelles, not only compared with 
the individual single drug micelles but also with the mixture of the two single drug micelles 
administered at the same dose. This has been shown using three different tumor models of the 
NSCLC and SCLC along with the observed great improvement of the co-loaded drug micelle 
therapy compared to the free drug combinations. Overall, the highly loaded, worm-like micelles 
carrying ETO and C6CP have shown high promise in treatment of lung cancer. The ability of 
controlling the nanoparticle morphology, drug retention, PK and therapeutic efficacy by blending 
multiple drugs in a single particle is novel and of both basic and practical significance. 
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Table 4.1 Characteristics of ETO loaded PM.a 
 
ETO/POx 
feeding ratio Deff (nm) PDI LE (%) LC (%) 
Drug 
concentration 
in solution 
(g/L) 
2/10 26.37 ± 0.64 0.52 ± 0.02 82.0 ± 2.0 14.1 ± 0.1 1.64 ± 0.04 
4/10 25.85 ± 1.12 0.50 ± 0.02 100.0 ± 0.0 28.6 ± 0.0 4.00 ± 0.03 
6/10 24.98 ± 0.21 0.45 ± 0.01 100.0 ± 0.0 37.5 ± 0.0 6.00 ± 0.04 
8/10 29.17 ± 0.82 0.48 ± 0.06 95.2 ± 2.3 43.2 ± 2.0 7.61 ± 0.18 
10/10 36.69 ± 1.22 0.70 ± 0.00 97.3 ± 1.7 49.3 ± 1.0 9.73 ± 0.17 
 
a Size (effective diameter, Deff) and polydispersity index (PDI) of ETO POx PM as measured by DLS. Drug 
concentration in solution as measured by HPLC. LE and LC calculated using equations (1)-(2) in the 
methods section. All data mean ± SD, n=3. Here and below feeding ratios are presented as weight (g) ratios.  
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Table 4.2-4.5 Characteristics of CPs (C4CP, C6CP, C8CP and C10CP) loaded PM.a 
Table 4.2 Characteristics of C4CP loaded PM. 
C4CP/POx 
feeding ratio Deff (nm) PDI LE (%) LC (%) 
Drug 
concentration 
in solution 
(g/L) 
2/10 22.11 ± 0.17 0.30 ± 0.01 72.5 ± 1.7 12.7 ± 0.3 1.45 ± 0.04 
4/10 25.17 ± 1.01 0.36 ± 0.02 76.0 ± 1.0 23.3 ± 0.7 3.04 ± 0.10 
6/10 23.34 ± 1.31 0.33 ± 0.01 70.0 ± 0.8 29.6 ± 1.6 4.20 ± 0.48 
8/10 28.59 ± 0.97 0.37 ± 0.01 83.5 ± 3.5 40.0 ± 1.0 6.68 ± 0.28 
10/10 28.87 ± 0.92 0.28 ± 0.02 83.5 ± 1.5 46.1 ± 0.1 8.35 ± 0.15 
 
Table 4.3 Characteristics of C6CP loaded PM. 
C6CP/POx 
feeding ratio Deff (nm) PDI LE (%) LC (%) 
Drug 
concentration 
in solution 
(g/L) 
2/10 77.28 ± 0.69 0.27 ± 0.01 69.5 ± 0.5 12.2 ± 1.2 1.39 ± 0.01 
4/10 102.3 ± 2.20 0.08 ± 0.01 97.3 ± 2.7 28.0 ± 1.0 3.89 ± 0.11 
6/10 99.56 ± 1.3 0.09 ± 0.00 95.0 ± 3.0 36.3 ± 0.3 5.70 ± 0.18 
8/10 108.03 ± 2.17 0.08 ± 0.01 84.8 ± 3.2 40.4 ± 0.4 6.78 ± 0.26 
10/10 110.86 ± 0.56 0.08 ± 0.01 84.0 ± 4.0 45.7 ± 0.7 8.40 ± 0.40 
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Table 4.4 Characteristics of C8CP loaded PM. 
C8CP/POx 
feeding ratio Deff (nm) PDI LE (%) LC (%) 
Drug 
concentration 
in solution 
(g/L) 
2/10 101.03 ± 0.38 0.10 ± 0.01 75.5 ± 2.5 13.1 ± 0.1 1.51 ± 0.05 
4/10 122.21 ± 0.79 0.13 ± 0.01 47.5 ± 2.5 16.0 ± 2.0 1.90 ± 0.10 
6/10 132.72 ± 0.58 0.14 ± 0.02 40.0 ± 5.0 19.4± 1.4 2.40 ± 0.30 
8/10 141.21 ± 0.72 0.09 ± 0.02 32.5 ± 2.5 20.6 ± 0.6 2.60 ± 0.20 
10/10 139.41 ± 0.82 0.17 ± 0.08 26.4 ± 1.4 20.9 ± 0.9 2.64 ± 0.14 
 
Table 4.5 Characteristics of C10CP loaded PM. 
 
C10CP/POx 
feeding ratio Deff (nm) PDI LE (%) LC (%) 
Drug 
concentration 
in solution 
(g/L) 
2/10 108.5 ± 0.28 0.07 ± 0.02 70.5 ± 0.5 12.4 ± 1.4 1.41 ± 0.01 
4/10 125.0 ± 0.86 0.08 ± 0.02 45.3 ± 1.3 15.3 ± 1.3 1.81 ± 0.05 
6/10 144.9 ± 1.96 0.19 ± 0.01 50.3 ± 0.3 23.2 ± 1.2 3.01 ± 0.18 
8/10 142.34 ± 0.93 0.19 ± 0.01 37.5 ± 2.5 21.9 ± 1.3 3.00 ± 0.20 
10/10 145.76 ± 0.83 0.18 ± 0.02 31.2 ± 1.2 21.5 ± 1.9 3.12 ± 0.12 
 
a Size (Deff) and PDI of CPs PM as measured by DLS. Drug concentration in solution as measured by HPLC. 
LE and LC calculated using equations (1)-(2) in the methods section. All data mean ± SD, n=3. 
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Table 4.6 Characteristics of C6CP/ETO PM.a  
 
C6CP/ETO/POx  
feeding ratio 
Deff (nm) PDI 
LE (%) LC (%) Drug concentration in solution (g/L) 
C6CP ETO C6CP ETO C6CP and ETO C6CP ETO C6CP and ETO 
8/4/10 103.26 ± 0.70 0.08 ± 0.01 85.1 ± 0.06 100.0 ± 0.01 32.7 ± 0.02 19.2 ± 0.00 51.9 ± 0.02 6.82 ± 0.40 4.01 ± 0.03 10.83 ± 0.43 
6/6/10 84.63 ± 0.64 0.12 ± 0.00 89.2 ± 0.01 100.0 ± 0.01 25.0 ± 0.03 28.1 ± 0.00 53.2 ± 0.03 5.35 ± 0.02 6.00 ± 0.07 11.35 ± 0.72 
4/8/10 74.89 ± 1.17 0.22 ± 0.01 85.3 ± 0.02 95.3 ± 0.02 16.2 ± 0.00 36.2 ± 0.01 52.4 ± 0.01 3.41 ± 0.07 7.62 ± 0.13 11.03 ± 0.20 
 
a Size (Deff) and PDI of POx polymeric micelles as measured by DLS. Drug concentration in solution as measured by HPLC. LE and LC calculated 
using equations (1)-(2) in the methods section. All data mean ± SD, n=3. 
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Table 4.7 Serum binding of drugs in PM.  
SPE column separation of co-loaded drug C6CP/ETO PM (4/8/10), mixture of single drug C6CP PM (4/10) and ETO PM (8/10), single 
drug ETO PM (8/10) and single drug C6CP PM (4/10) after incubation with 100% FBS for 1h and 4h. All micellar solutions were at the 
POx concentration of 0.468 g/L. 
 
Formulation 
Drug concentration 
(g/L) 
C6CP elution (%)a ETO elution (%)a 
1h incubation 4h incubation 1h incubation 4h incubation 
C6CP ETO 
micelle  
fractionb 
protein 
fractionc 
micelle  
fractionb 
protein 
fractionc 
micelle  
fractionb 
protein 
fractionc 
micelle  
fractionb 
protein 
fractionc 
C6CP/ETO PM 0.188 0.375 77.8 ± 2.9 18.2 ± 1.4 59.7 ± 3.1 33.4 ± 2.8 79.4 ± 1.7 18.9 ± 0.4 64.8 ± 2.5 31.7 ± 3.5 
C6CP PM and ETO PM 
mixture 0.188 0.375 69.9 ± 2.9 27.5 ± 2.7 58.4 ± 1.8 34.3 ± 3.0 71.4 ± 1.6 26.0 ± 2.7 59.3 ± 2.8 35.8 ± 3.3 
ETO PM N/A 0.375 N/A N/A N/A N/A 70.1 ± 2.1 27.5 ± 3.2 57.9 ± 3.2 37.2 ± 2.7 
C6CP PM 0.188 N/A 63.4 ± 3.5 32.6 ± 2.7 50.8 ± 3.4 44.4 ± 2.9 N/A N/A N/A N/A 
 
a data represent means ± SD (n = 3) 
b fractions A3 and A4 as described in the experimental section. 
c fractions A6 as described in the experimental section. 
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Table 4.8 Cytotoxicity of the single drug and co-loaded drug PM in SCLC H69AR and NSCLC 344SQ/Luc. cell lines. 
 
Cell lines 
IC50 (µg/mL) 
ETO  cisplatin  
ETO 
PM 
(8/10) 
C6CP 
PM 
(4/10) 
C6CP/ETO PM  Mixture C6CP 
PM (4/10) and 
ETO PM 
(8/10) 
(8/4/10) (6/6/10) (4/8/10) 
H69AR 19.21 21.50 12.18 0.35 0.53 0.35 0.26 0.68 
344SQ/Luc 3.01 2.01 2.18 0.64 0.61 0.46 0.37 0.76 
 
a The cytotoxicity data are expressed as IC50 values, µg/mL (counting per single drug or both drugs for co-loaded drug PM and mixture of single 
drug PM). Based on data in Figure 4.13a, c.  
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Table 4.9 IC50 values of single CP PM and free drug in SCLC H69AR and NSCLC 344SQ/Luc. cell lines.  
 
Cell lines 
IC50 (µg/mL)a 
Cisplatin C4CP PM 
C6CP 
PM 
C8CP 
PM 
C10CP 
PM 
H69AR 21.50 2.86 0.31 0.06 0.06 
344SQ/Luc. 2.01 4.01 0.65 0.47 0.38 
 
a Based on data in Figure 4.14. 
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Table 4.10 Clinical chemistry parameters of H69AR tumor bearing female Nu/Nu mice.  
Clinical chemistry parameters of H69AR tumor bearing female Nu/Nu mice receiving saline, cisplatin and ETO mixture, C6CPs PM 
(4/10) and ETO PM (8/10) mixture, or C6CP/ETO PM (4/8/10). Blood samples were collected 2 days after the last injection. Drugs were 
administered using q4d x 4 regimen at respective MTDs: free drugs - 2 mg/kg cisplatin and 4 mg/kg ETO, micellar drugs - 15 mg/kg 
C6CP and 30 mg/kg ETO. (In dose escalation study the first signs of toxicity of C6CP/ETO PM (4/8/10) were observed after the second 
dosing at 20 mg/kg C6CP and 40 mg/kg ETO when the animals lost over 15% of their body weight.) 
 
 
a ALT, alanine amino transferase; BUN, blood urea nitrogen. Units: ALT (U/L); creatinine and BUN (mg/dL); albumin (g/dL). 
 
  
Parametersa Normal range 
 Formulations   
Saline Cisplatin and ETO mixture 
C6CPs PM and ETO PM 
mixture C6CP/ETO PM 
ALT 17 – 77 44 45 55 62 
Creatinine 0.2 – 0.9 <0.2 <0.2 <0.2 <0.2 
BUN 9 - 33 26 24 18 23 
Albumin 2.5 – 4.6 2.8 3.0 2.7 2.6 
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Table 4.11 PK parameters of ETO and C6CP in plasma and tumor in H69AR tumor bearing mice. (n=3) 
 
 
a t1/2, α = half-life at the biodistribution phase; Cmax = maximum plasma concentration; AUClast = area under the curve from time 0 to 168 h; Clobs = 
observed total body clearance; Vdobs = total volume of distribution observed; Tmax = time of maximum concentration 
  
 Parametersa 
C6CP, 15 mg/kg ETO, 30 mg/kg 
C6CP/ETO 
PM 
C6CP PM and 
ETO PM 
mixture 
C6CP PM C6CP/ETO PM 
C6CP PM 
and ETO PM 
mixture 
ETO PM 
Plasma 
t1/2, α (h) 6.78 5.10 5.38 7.18 5.30 4.04 
Cmax (µg/mL) 6.48 6.16 5.86 12.11 9.76 10.69 
AUClast (h*µg/mL) 27.96 21.31 19.25 58.84 45.68 52.98 
Clobs (mL/h/kg) 508.22 687.59 761.70 477.99 637.52 559.18 
Vdobs (mL/kg) 4973.11 5063.76 5920.62 4956.52 4876.56 3261.75 
Tumor 
AUClast (h*µg/g) 67.25 30.44 32.72 196.25 73.15 118.01 
Cmax (µg/g) 3.88 2.60 1.91 12.90 8.72 8.29 
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Comparative analysis of PK data  
C6CP/ETO PM C6CP PM and ETO PM mixture 
ETO 
PM 
C6CP 
PM 
ETO C6CP ETO C6CP ETO C6CP 
Tumor AUC/Plasma AUC 3.34 2.41 1.60 1.43 2.58 1.70 
Tumor Cmax/Plasma Cmax 1.07 0.60 0.89 0.42 0.78 0.33 
(Tumor AUC/Plasma AUC for C6CP/ETO PM) 
divided by (Tumor AUC/Plasma AUC for C6CP PM 
and ETO PM mixture) 
2.08 1.68         
(Tumor AUC/Plasma AUC for C6CP/ETO PM) 
divided by (Tumor AUC/Plasma AUC for single drug 
PM) 
1.29 1.42         
(Tumor Cmax/Plasma Cmax for C6CP/ETO PM) 
divided by (Tumor Cmax/Plasma Cmax for C6CP PM 
and ETO PM mixture) 
1.19 1.42         
(Tumor Cmax/Plasma Cmax for C6CP/ETO PM) 
divided by (Tumor Cmax/Plasma Cmax for single drug 
PM) 
1.37 1.84         
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Table 4.12 Statistical comparisons of tumor growth between groups.  
(by one-way ANOVA with Holm-Sidak post-hoc test for multiple comparisons at a significance 
levels of p < 0.05 (*, p < 0.05, **, p < 0.01, ***, p < 0.001) (Graphpad Prism, version 7.03) 
 
A549 modela 
Test Significant? Summary Adjusted p Value 
C6CP/ETO PM vs. POx Yes *** 0.0005 
C6CP/ETO PM vs. Saline Yes *** 0.001 
C6CP/ETO PM vs. C6CP PM Yes ** 0.004 
C6CP/ETO PM vs. C6CP PM and ETO 
PM mixture 
Yes * 0.0109 
C6CP/ETO PM vs. ETO PM Yes ** 0.0017 
C6CP/ETO PM vs. Cisplatin and ETO 
mixture 
Yes *** 0.0005 
Saline vs. POx No n.s. 0.1693 
Saline vs. C6CP PM Yes *** 0.0002 
Saline vs. C6CP/ETO PM Yes *** 0.001 
Saline vs. C6CP PM and ETO PM mixture Yes *** 0.0002 
Saline vs. ETO PM Yes *** 0.001 
Saline vs. cisplatin and ETO mixture Yes * 0.0293 
 
a Analyzed by comparing areas under the curve for 40 days observation as presented in Figure 4.18a. 
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H69AR model 
Test Significant? Summary Adjusted p Value 
C6CP/ETO PM vs. Saline Yes **** 0.0001 
C6CP/ETO PM vs. C6CP PM Yes *** 0.0007 
C6CP/ETO PM vs. C6CP PM and ETO 
PM mixture Yes ** 0.004 
C6CP/ETO PM vs. ETO PM Yes *** 0.0005 
C6CP/ETO PM vs. cisplatin and ETO 
mixture Yes *** 0.0011 
Saline vs. C6CP PM Yes *** 0.0002 
Saline vs. C6CP/ETO PM Yes **** 0.0001 
Saline vs. C6CP PM and ETO PM 
mixture Yes *** 0.0004 
Saline vs. ETO PM Yes ** 0.003 
Saline vs. Cisplatin and ETO mixture Yes * 0.0344 
 
a Analyzed by comparing areas under the curve for 28 days observation when compared with saline, 
cisplatin and ETO and ETO PM for 31 day for the remaining groups as presented in Figure 4.18b. 
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Table 4.13 Statistical comparisons of animal survival by Log-rank (Mantel-Cox) test. 
A549 model 
Groups POx Cisplatin and ETO mixture C6CP PM ETO PM 
C6CP PM 
and ETO 
PM mixture 
C6CP/ETO PM 
Saline ns * 0.0249 ns 0.0514 ns 0.0514 ** 0.0010 ** 0.0010 
POx  * 0.0382 ns 0.0567 ns 0.0943 ** 0.0014 *** 0.0006 
Cisplatin and ETO mixture   ns ns 0.4089 * 0.0161 ** 0.0036 
C6CP PM    ns 0.4597 * 0.0155 ** 0.0037 
ETO PM     ** 0.0072 ** 0.0022 
C6CP PM and ETO PM 
mixture      * 0.0247 
H69AR model 
Groups POx Cisplatin and ETO mixture 
C6CP 
PM ETO PM 
C6CP PM and ETO 
PM mixture C6CP/ETO PM 
Saline ns 
0.7071 
* 0.0489 ** 0.0023 ns 0.1048 *** 0.0007 *** 0.0007 
POx  ns 0.1198 ** 0.0046 ns 0.2084 *** 0.0005 *** 0.0005 
Cisplatin and ETO 
mixture 
  ns 0.1078 ns 0.4825 ** 0.0060 ** 0.0019 
C6CP PM    * 0.0367 ns 0.08 ** 0.0045 
ETO PM   
 
  ** 0.0012 *** 0.0005 
C6CP PM and ETO PM 
mixture      * 0.0367 
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344SQ-Luc. model 
Groups POx Cisplatin ETO 
Cisplatin 
and ETO 
mixture 
C6CP PM ETO PM 
C6CP PM and 
ETO PM 
mixture 
C6CP/ETO 
PM 
Saline ns * 0.0145 ** 0.0035 ** 0.0035 ** 0.0035 ** 0.0035 ** 0.0035 ** 0.0035 
POx PM         
Cisplatin    * 0.0411 * 0.0145 * 0.0145 ** 0.0035 ** 0.0035 
ETO    ns 0.5485 ns 0.08528 ns 0.0993 ** 0.0080 ** 0.0023 
Cisplatin and ETO 
mixture     ns 0.0847 ns 0.1729 * 0.0116 ** 0.0031 
C6CP PM      ns 0.5454 * 0.1025 ** 0.0027 
ETO PM       * 0.0473 ** 0.0018 
C6CP PM and ETO 
PM mixture        * 0.0188 
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Figure 4.1 Scheme of co-delivery of Etoposide and cisplatin prodrug via poly (2-oxazoline) co-polymeric micelle.  
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Figure 4.2 Preparation of binary PM containing ETO and CPs.  
(a) Chemical structure of the hydrophobic CPs and the scheme of release of cisplatin in the cells; 
(b) Schematic and chemical structures of POx triblock copolymer, ETO and C6CP; (c) Schematic 
representation of the POx micelles preparation by the thin-film technique. 
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Figure 4.3 Characterizations of C6CP/ETO PM formulations.  
(a) LE, (b) LC and (c) drug concentration at various drug feeding ratios C6CP/ETO/POx: 8/4/10, 
6/6/10 and 4/8/10. (d) DLS size (Deff) distribution analysis at ~1 h after preparation and (e, f) 
stability of the C6CP/ETO PM (4/8/10) at r.t. as determined by the particle size and PDI 
measurements over time. The DLS analysis was performed at POx final concentration of 1 g/L in 
DI water. The Deff of the micelles at ~1 h after preparation is ~75 nm and the PDI is ~0.220. (g) 
TEM images of ETO PM (ETO/POx 8/10), C6CP PM (C6CP/POx 4/10) and co-loaded POx micelle 
(C6CP/ETO/POx 4/8/10). Scale bar = 100 nm. 
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Figure 4.4 Solubilization of ETO loaded POx PM.  
The LE (Aa), LC (Bb) and the total drug concentration in solution (Cc) are shown. All data mean 
± SD, n=3. The corresponding values are presented in Table 4.1. 
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Figure 4.5 Characterization of single CPs loaded micelle.  
The LE (a), LC (b) and the total drug concentration in solution (c) are shown. All data mean ± SD, 
n=3. The corresponding values are presented in Tables 4.2-4.5. 
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Figure 4.6 Typical AFM images and particle area histograms for empty POx PM and drug 
loaded micelles, C6CP/ETO PM (4/8/10). 
(a, b) Typical AFM images and (c, d) particle area histograms for (a, c) empty POx PM and (b, d) 
drug loaded micelles, C6CP/ETO PM (4/8/10). (a, b) Red circles indicate elongated, worm-like 
particles. The area histograms present (c) the entire population of particles for empty POx PM and 
(d) separately, elongated (red, circularity 0.5-0.9) and spherical (blue, circularity > 0.9) for 
C6CP/ETO PM (4/8/10). 
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Figure 4.7 AFM size measurement for empty POx PM. 
(a) Typical AFM image; (b) cross-sectional profiles; (c) population size (area) distribution. Table 
presents mean parameters for the entire population. 
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Figure 4.8 AFM size measurement for drug co-loaded C6CP/ETO PM (4/8/10). 
(a, b) Typical AFM images and size measurements for (a) worms and (b) spheres, and (c, d) cross-
sectional profiles for (c) worms and (d) spheres. Worm-like particles are relatively uniform (~3 
nm high). Spherical particles display size variation. Table presents mean parameters for each 
sphere and worm-like particle population as separated by circularity of the particles, see Figures 
4.6 and 4.7. 
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Figure 4.9 AFM population analysis for drug co-loaded C6CP/ETO PM (4/8/10).  
(a) Left panel displays a correlation between circularity and size: typically, larger particles are less 
circular and presumably more elongated. (b) Right panel presents correlation between circularity 
and aspect ratio: as expected, less circular (elongates) particles have a larger aspect ratio. 
Circularity is computed using equation !"#$" = &'×$)*+)$#,)-)$.. 
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Figure 4.10 Population separation by circularity of particles in AFM images for drug co-
loaded C6CP/ETO PM (4/8/10).  
Circularity is chosen to separate the two populations due to superior ability to distinguish between 
shapes. 
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Figure 4.11 Population separation by circularity of particles in AFM images for drug co-
loaded C6CP/ETO PM (4/8/10).  
(a, b) particle area and (c, d) aspect ratio histograms for (a, c) raw populations and (b, d) separated 
populations. 
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Figure 4.12 Drug release profiles for single and co-loaded drug PM.  
Micelles were prepared at following feeding ratios: C6CP/ETO PM (4/8/10), C6CP PM (4/10) and 
ETO PM (8/10). The drug release study was performed at drug concentration 0.1 mg/mL in PBS, 
pH7.4 at 37oC under sink conditions (against 200 x volume of 40 g/L BSA in PBS). The data are 
mean ± SD, n=3 *, p<0.05. 
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Figure 4.13 Cytotoxicity, synergy and drug uptake for single and co-loaded drug PM in (a, 
b) SCLC H69AR and (c-f) NSCLC 344SQ/Luc. cell lines.  
(a, c) Cell inhibition curves, (b, d); CI as function of cell inhibition Fa (CI < 1 indicates synergistic 
effect); (e, f) Kinetics of intracellular accumulation of C6CP and ETO in cells exposed to various 
drug formulations. Drug formulations were (a-d) free cisplatin, free ETO, C6CP/ETO PM (6/6/10), 
C6CP/ETO PM (8/4/10), and (a-f) C6CP PM (4/10), ETO PM (8/10), C6CP/ETO PM (4/8/10), and 
mixture C6CP PM (4/10) and ETO PM (8/10). Drug concentrations were varied (a-d) or IC50 of 
C6CP/ETO PM (4/8/10) (e, f) in each experiment. (a, c, e, f) Data points are means ± SD, n = 6 (a, 
c) or n = 3 (e, f) (*, p<0.05, **, p<0.01). 
 
 
  
  169 
Figure 4.14 In vitro cytotoxicity of single CPs loaded micelles.  
In vitro cytotoxicity of various CP loaded micelle formulations vs. cisplatin in (a) H69AR cells 
and (b) 344SQ/Luc. cells. Data are mean ± SD, n = 6. The weight ratio of CPs to POx was fixed 
as 2:10 in all groups.  
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Figure 4.15 Histological examination kidney and tumor tissues by hemotoxylin & eosin 
(H&E) staining. 
Histological examination kidney and tumor tissues by hemotoxylin & eosin (H&E) staining in 
H69AR tumor bearing mice treated with saline, cisplatin and ETO mixture, C6CPs PM (4/10) and 
ETO PM (8/10) mixture, or C6CP/ETO PM (4/8/10). Tissues were harvested 2 days after the last 
injection. Drugs were administered using q4d x 4 regimen at respective MTDs: free drugs - 2 
mg/kg cisplatin and 4 mg/kg ETO, micellar drugs - 15 mg/kg C6CP and 30 mg/kg ETO. Scale bar 
200 µm, 100 µm for kidney.  
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Figure 4.16 PK and tumor accumulation of C6CP and ETO in H69AR SCLC bearing mice.  
(a, b) Plasma (a) and tumor (b) biodistribution of both C6CP (black) and ETO (red) after single 
injection of various POx micelle formulations: C6CP/ETO PM (4/8/10), C6CP PM (4/10) and ETO 
PM (8/10) mixture, ETO PM (8/10), and C6CP PM (4/10). (c) C6CP and (d) ETO levels in 
accumulated in tumor 6 h, 24 h and 48 h post injection. Data are mean ± SD, * p<0.05 (n = 3).  
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Figure 4.17 Biodistribution after single i.v. injection of various POx micelle formulations at 
1hr p.i. (n=3)  
 
 
 
  
  173 
Figure 4.18 Anti-tumor effects of the single and co-loaded drug PM in NCSLC and SCLC 
animal models.  
(a) A549 and (b-f) H69AR. (a, b) Tumor volume changes; (c, d) Histology and (e, f) quantitation 
of % Pt-DNA adduct (red) and Caspase-3 (red) in H69AR tumor sections two days after the last 
treatment (DAPI staining (blue) indicates nucleus, the scale bar is 20 µm). The treatments regimen 
was q4d x 4. Drug injection doses were: 30 mg ETO/kg and 15 mg C6CP/kg for C6CP/ETO PM 
(4/8/10) and mixture of C6CP PM (4/10) and ETO PM (8/10); 30 mg ETO/kg for ETO PM (8/10), 
15 C6CPs mg/kg for C6CP PM (4/10); 2 mg/kg cisplatin and 4 mg/kg ETO for free drugs mixture. 
Empty PM were injected at the polymer dose equivalent to that in the co-loaded micelle 
formulation. (a, b) Data are mean ± SD, n = 6, * p<0.05 (vs. C6CP PM and ETO PM mixture group 
(a) or vs. C6CP PM group (b)), * p<0.05 (vs. C6CP PM and ETO PM mixture group (b)). For 
detailed statistical comparisons see Table 4.12-4.13. (e, f) Five randomly selected microscopic 
fields were analyzed on Image J. * p<0.05; ** p<0.01. 
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Figure 4.19 Efficacy of various drug formulations in 344SQ-Luc lung cancer model.  
(a) Schedule of treatments, and (b) IVIS images of 344SQ/Luc. tumor bearing animals at various 
time points after day 0. The treatments regimen was q4d x 4. Drug injection doses were: 30 mg 
ETO/kg and 15 mg C6CP/kg for C6CP/ETO PM (4/8/10) and mixture of C6CP PM (4/10) and ETO 
PM (8/10); 30 mg ETO/kg for ETO PM (8/10), 15 C6CPs mg/kg for C6CP PM (4/10); 2 mg/kg 
cisplatin or 4 mg/kg ETO for free drugs; 2 mg/kg cisplatin and 4 mg/kg ETO for free drugs 
mixture. Empty PM were injected at the polymer dose equivalent to that in the co-loaded micelle 
formulation. 
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Figure 4.20 Kaplan-Meier survival plot showing anti-tumor effects of the single and co-
loaded drug PM in 344SQ/Luc. NCSLC animal model.  
The treatments regimen was q4d x 4. Drug injection doses were: 30 mg ETO/kg and 15 mg 
C6CP/kg for C6CP/ETO PM (4/8/10) and mixture of C6CP PM (4/10) and ETO PM (8/10); 30 mg 
ETO/kg for ETO PM (8/10), 15 C6CPs mg/kg for C6CP PM (4/10); 2 mg/kg cisplatin or 4 mg/kg 
ETO for free drugs; 2 mg/kg cisplatin and 4 mg/kg ETO for free drugs mixture. Empty PM were 
injected at the polymer dose equivalent to that in the co-loaded micelle formulation. * p <0.05 (vs. 
C6CP PM and ETO PM mixture group), ** p<0.01 (vs. C6CP PM group). For detailed statistical 
comparisons see Table 4.13. 
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Figure 4.21 Kaplan-Meier survival plot in various treatment groups. 
Kaplan-Meier survival plot in various treatment groups in (a) A549 NSCLC model; (b) H69AR 
SCLC model. * p<0.05 (vs. C6CP PM and ETO PM mixture group). For detailed statistical 
comparisons of animal survival see Table 4.13. 
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CHAPTER 5  SUMMARY AND FUTURE DIRECTIONS 
In this dissertation, I reviewed the history of polymeric micelles and introduced its 
applications in the field of clinical cancer therapy, the combination therapy and the importance 
of morphology of polymeric micelles. Limitations with this formulation to be used as an in vivo 
cancer therapy agent are summarized, and different approaches to overcome these limitations are 
discussed.  
High ratio of excipient in current chemotherapeutic agent formulation and the high 
toxicity as a consequence is one of the biggest obstacles for their development and application. 
The formulation of poly (2-oxazoline) tri-black co-polymer based polymeric micelles addresses 
this problem by extreme high anti-cancer drug loading, dramatically reducing the toxicity caused 
by the excipient.  
Stability of polymeric micelles in vivo is another biggest obstacle for the development 
and application.  POx micelles exhibit good stability in serum as almost 80% of drug remain in 
formulated nanoparticle after 4 h. PTX single loaded PMs dramatically improve in vivo MTD, 
with very limited toxicity. The PMs administered to various tumor models, including xenograft 
and orthotopic models, significantly improve the antitumor efficacy.   
The combination of various anti-cancer drugs in the same micelle particle represent 
another direction of our research by exploring the rational design of agents with various 
anticancer mechanism. The co-formulation of the two drugs in the same POx PM increased the 
retention of these drugs in the micelles by slowing down the drug release and exchange with the 
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serum proteins. An improved PK profile with longer circulation and higher exposure in tumor 
site, and as the consequence, better antitumor efficacies have been observed in both PTX/C6CP 
and C6CP/ETO combination PMs, in ovarian cancer tumor and lung cancer tumor, respectively. 
The demonstrated superior efficacies of the PTX and cisplatin or cisplatin and ETO co-loaded 
micelles suggest that co-loading of drugs in one strategy for improved chemotherapy of cancer. 
Moreover, the results interestingly present a morphology – efficacy relationship.  In peer 
studies, similar observations have been found as well. However, more studies should be done in 
the future to fully understand the exact impact of the shape of nanoparticles on the therapeutic 
outcomes.  
  
  179 
REFERENCES 
1. Luxenhofer, R., et al., Doubly amphiphilic poly(2-oxazoline)s as high-capacity delivery 
systems for hydrophobic drugs. Biomaterials, 2010. 31(18): p. 4972-9. 
2. Han, Y., et al., Synergistic combinations of multiple chemotherapeutic agents in high 
capacity poly(2-oxazoline) micelles. Mol Pharm, 2012. 9(8): p. 2302-13. 
3. He, Z., et al., A high capacity polymeric micelle of paclitaxel: Implication of high dose 
drug therapy to safety and in vivo anti-cancer activity. Biomaterials, 2016. 101: p. 296-
309. 
4. Tardi, P.G., et al., Drug ratio-dependent antitumor activity of irinotecan and cisplatin 
combinations in vitro and in vivo. Mol Cancer Ther, 2009. 8(8): p. 2266-75. 
5. Liu, J., H. Lee, and C. Allen, Formulation of drugs in block copolymer micelles: drug 
loading and release. Curr Pharm Des, 2006. 12(36): p. 4685-701. 
6. Lu, Y. and K. Park, Polymeric micelles and alternative nanonized delivery vehicles for 
poorly soluble drugs. Int J Pharm, 2013. 453(1): p. 198-214. 
7. Cabral, H. and K. Kataoka, Progress of drug-loaded polymeric micelles into clinical 
studies. J Control Release, 2014. 190: p. 465-76. 
8. Kim, T.Y., et al., Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, 
polymeric micelle-formulated paclitaxel, in patients with advanced malignancies. Clin 
Cancer Res, 2004. 10(11): p. 3708-16. 
9. Kim, S.C., et al., In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity 
and efficacy. J Control Release, 2001. 72(1-3): p. 191-202. 
10. Lee, K.S., et al., Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric 
micelle formulation of paclitaxel, in patients with metastatic breast cancer. Breast Cancer 
Res Treat, 2008. 108(2): p. 241-50. 
11. Varela-Moreira, A., et al., Clinical application of polymeric micelles for the treatment of 
cancer. Materials Chemistry Frontiers, 2017. 1(8): p. 1485-1501. 
12. Oerlemans, C., et al., Polymeric micelles in anticancer therapy: targeting, imaging and 
triggered release. Pharm Res, 2010. 27(12): p. 2569-89. 
  180 
13. Houdaihed, L., J.C. Evans, and C. Allen, Overcoming the Road Blocks: Advancement of 
Block Copolymer Micelles for Cancer Therapy in the Clinic. Mol Pharm, 2017. 14(8): p. 
2503-2517. 
14. Ranade, A.A., et al., Clinical and economic implications of the use of nanoparticle 
paclitaxel (Nanoxel) in India. Ann Oncol, 2013. 24 Suppl 5: p. v6-12. 
15. Lee, S.W., et al., Development of docetaxel-loaded intravenous formulation, Nanoxel-PM 
using polymer-based delivery system. J Control Release, 2011. 155(2): p. 262-71. 
16. Madaan, A., et al., Efficiency and mechanism of intracellular paclitaxel delivery by novel 
nanopolymer-based tumor-targeted delivery system, Nanoxel(TM). Clin Transl Oncol, 
2013. 15(1): p. 26-32. 
17. Chu, B., et al., Synthesis, characterization and drug loading property of Monomethoxy-
Poly(ethylene glycol)-Poly(epsilon-caprolactone)-Poly(D,L-lactide) (MPEG-PCLA) 
copolymers. Sci Rep, 2016. 6: p. 34069. 
18. Oasmia. Oasmia Pharmaceutical Announces Positive Overall Survival Results from Phase 
III Study of Paclical/Apealea for Treatment of Ovarian Cancer. Overall Survival data from 
the Phase III study meets endpoint and demonstrates non-inferiority favoring 
Paclical/Apealea; will form basis for application seeking marketing approval in the United 
States anticipated for the end of 2016/2017. 2016  [cited 2016 04-27]; Available from: 
https://oasmia.com/en/press-release/oasmia-pharmaceutical-announces-positive-overall-
survival-results-phase-iii-study-paclicalapealea-treatment-ovarian-cancer/. 
19. Bernabeu, E., et al., Paclitaxel: What has been done and the challenges remain ahead. Int 
J Pharm, 2017. 526(1-2): p. 474-495. 
20. Hamaguchi, T., et al., NK105, a paclitaxel-incorporating micellar nanoparticle 
formulation, can extend in vivo antitumour activity and reduce the neurotoxicity of 
paclitaxel. Br J Cancer, 2005. 92(7): p. 1240-6. 
21. Kato, K., et al., Phase II study of NK105, a paclitaxel-incorporating micellar nanoparticle, 
for previously treated advanced or recurrent gastric cancer. Invest New Drugs, 2012. 
30(4): p. 1621-7. 
22. Bertrand, N., et al., Cancer nanotechnology: the impact of passive and active targeting in 
the era of modern cancer biology. Adv Drug Deliv Rev, 2014. 66: p. 2-25. 
23. Shi, J., et al., Self-assembled targeted nanoparticles: evolution of technologies and bench 
to bedside translation. Acc Chem Res, 2011. 44(10): p. 1123-34. 
  181 
24. Robinson, M.B., et al., Extracellular heat shock protein 70: a critical component for 
motoneuron survival. J Neurosci, 2005. 25(42): p. 9735-45. 
25. Patlak, C.S. and R.G. Blasberg, Graphical evaluation of blood-to-brain transfer constants 
from multiple-time uptake data. Generalizations. J Cereb Blood Flow Metab, 1985. 5(4): 
p. 584-90. 
26. Hu, Q., et al., Complete regression of breast tumour with a single dose of docetaxel-
entrapped core-cross-linked polymeric micelles. Biomaterials, 2015. 53: p. 370-8. 
27. A Study of CriPec Docetaxel Given to Patients with Solid Tumours (NAPOLY).  [cited 2017 
Apr. 14]; Available from: https://clinicaltrials.gov/ct2/show/NCT02442531. 
28. Nishiyama, N., et al., Novel cisplatin-incorporated polymeric micelles can eradicate solid 
tumors in mice. Cancer Res, 2003. 63(24): p. 8977-83. 
29. Endo, K., et al., Tumor-targeted chemotherapy with the nanopolymer-based drug NC-6004 
for oral squamous cell carcinoma. Cancer Sci, 2013. 104(3): p. 369-74. 
30. Baba, M., et al., Micellization of cisplatin (NC-6004) reduces its ototoxicity in guinea pigs. 
J Control Release, 2012. 157(1): p. 112-7. 
31. Uchino, H., et al., Cisplatin-incorporating polymeric micelles (NC-6004) can reduce 
nephrotoxicity and neurotoxicity of cisplatin in rats. Br J Cancer, 2005. 93(6): p. 678-87. 
32. Doi, T., et al., NC-6004 Phase I study in combination with gemcitabine for advanced solid 
tumors and population PK/PD analysis. Cancer Chemother Pharmacol, 2017. 79(3): p. 
569-578. 
33. Cabral, H., N. Nishiyama, and K. Kataoka, Optimization of (1,2-diamino-
cyclohexane)platinum(II)-loaded polymeric micelles directed to improved tumor targeting 
and enhanced antitumor activity. J Control Release, 2007. 121(3): p. 146-55. 
34. Cabral, H., et al., Preparation and biological properties of dichloro(1,2-
diaminocyclohexane)platinum(II) (DACHPt)-loaded polymeric micelles. J Control Release, 
2005. 101(1-3): p. 223-32. 
35. Matsumura, Y., et al., Phase I clinical trial and pharmacokinetic evaluation of NK911, a 
micelle-encapsulated doxorubicin. Br J Cancer, 2004. 91(10): p. 1775-81. 
36. Alakhov, V., et al., Block copolymer-based formulation of doxorubicin. From cell screen 
to clinical trials. Colloids and Surfaces B: Biointerfaces, 1999. 16(1): p. 113-134. 
  182 
37. Danson, S., et al., Phase I dose escalation and pharmacokinetic study of pluronic polymer-
bound doxorubicin (SP1049C) in patients with advanced cancer. Br J Cancer, 2004. 90(11): 
p. 2085-91. 
38. Valle, J.W., et al., A phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting 
pluronics, in patients with advanced adenocarcinoma of the esophagus and 
gastroesophageal junction. Invest New Drugs, 2011. 29(5): p. 1029-37. 
39. Koizumi, F., et al., Novel SN-38-incorporating polymeric micelles, NK012, eradicate 
vascular endothelial growth factor-secreting bulky tumors. Cancer Res, 2006. 66(20): p. 
10048-56. 
40. Matsumura, Y., Preclinical and clinical studies of NK012, an SN-38-incorporating 
polymeric micelles, which is designed based on EPR effect. Adv Drug Deliv Rev, 2011. 
63(3): p. 184-92. 
41. Nakajima, T.E., et al., Synergistic antitumor activity of the novel SN-38-incorporating 
polymeric micelles, NK012, combined with 5-fluorouracil in a mouse model of colorectal 
cancer, as compared with that of irinotecan plus 5-fluorouracil. Int J Cancer, 2008. 122(9): 
p. 2148-53. 
42. Bae, Y., et al., Preparation and biological characterization of polymeric micelle drug 
carriers with intracellular pH-triggered drug release property: tumor permeability, 
controlled subcellular drug distribution, and enhanced in vivo antitumor efficacy. 
Bioconjug Chem, 2005. 16(1): p. 122-30. 
43. Bonfante, V., et al., Preliminary clinical experience with 4-epidoxorubicin in advanced 
human neoplasia. Recent Results Cancer Res, 1980. 74: p. 192-9. 
44. Gluck, S., The expanding role of epirubicin in the treatment of breast cancer. Cancer 
Control, 2002. 9(2 Suppl): p. 16-27. 
45. Harada, M., et al., Improved anti-tumor activity of stabilized anthracycline polymeric 
micelle formulation, NC-6300. Cancer Sci, 2011. 102(1): p. 192-9. 
46. Kato, Y., et al., Acidic extracellular microenvironment and cancer. Cancer Cell Int, 2013. 
13(1): p. 89. 
47. Takahashi, A., et al., NC-6300, an epirubicin-incorporating micelle, extends the antitumor 
effect and reduces the cardiotoxicity of epirubicin. Cancer Sci, 2013. 104(7): p. 920-5. 
  183 
48. Yamamoto, Y., et al., Enhanced antitumor effect of anti-tissue factor antibody-conjugated 
epirubicin-incorporating micelles in xenograft models. Cancer Sci, 2015. 106(5): p. 627-
34. 
49. Matsumura, Y., The drug discovery by nanomedicine and its clinical experience. Jpn J Clin 
Oncol, 2014. 44(6): p. 515-25. 
50. Sakai-Kato, K., et al., General considerations regarding the in vitro and in vivo properties 
of block copolymer micelle products and their evaluation. J Control Release, 2015. 210: p. 
76-83. 
51. van Gaal, E. and D. Crommelin, Polymeric Micelles. 2015. 11-76. 
52. Torchilin, V.P., Micellar nanocarriers: pharmaceutical perspectives. Pharm Res, 2007. 
24(1): p. 1-16. 
53. Adams, M.L., A. Lavasanifar, and G.S. Kwon, Amphiphilic block copolymers for drug 
delivery. J Pharm Sci, 2003. 92(7): p. 1343-55. 
54. Allen, C., D. Maysinger, and A. Eisenberg, Nano-engineering block copolymer aggregates 
for drug delivery. Colloids and Surfaces B: Biointerfaces, 1999. 16(1): p. 3-27. 
55. Weiss, R.B., et al., Hypersensitivity reactions from taxol. J Clin Oncol, 1990. 8(7): p. 1263-
8. 
56. Kloover, J.S., et al., Fatal outcome of a hypersensitivity reaction to paclitaxel: a critical 
review of premedication regimens. Br J Cancer, 2004. 90(2): p. 304-5. 
57. Rijcken, C.J., et al., Hydrolysable core-crosslinked thermosensitive polymeric micelles: 
synthesis, characterisation and in vivo studies. Biomaterials, 2007. 28(36): p. 5581-93. 
58. Nakanishi, T., et al., Development of the polymer micelle carrier system for doxorubicin. J 
Control Release, 2001. 74(1-3): p. 295-302. 
59. Maeda, H., Toward a full understanding of the EPR effect in primary and metastatic tumors 
as well as issues related to its heterogeneity. Adv Drug Deliv Rev, 2015. 91: p. 3-6. 
60. Kwon, G.S. and T. Okano, Polymeric micelles as new drug carriers. Advanced Drug 
Delivery Reviews, 1996. 21(2): p. 107-116. 
61. Tang, Y., et al., Solubilization and controlled release of a hydrophobic drug using novel 
micelle-forming ABC triblock copolymers. Biomacromolecules, 2003. 4(6): p. 1636-45. 
  184 
62. Bertrand, N. and J.C. Leroux, The journey of a drug-carrier in the body: an anatomo-
physiological perspective. J Control Release, 2012. 161(2): p. 152-63. 
63. Lammers, T., Improving the efficacy of combined modality anticancer therapy using 
HPMA copolymer-based nanomedicine formulations. Adv Drug Deliv Rev, 2010. 62(2): 
p. 203-30. 
64. Heppner, G.H., Tumor heterogeneity. Cancer Res, 1984. 44(6): p. 2259-65. 
65. Hanahan, D. and R.A. Weinberg, Hallmarks of cancer: the next generation. Cell, 2011. 
144(5): p. 646-74. 
66. Hanahan, D. and R.A. Weinberg, The hallmarks of cancer. Cell, 2000. 100(1): p. 57-70. 
67. Hainaut, P. and A. Plymoth, Targeting the hallmarks of cancer: towards a rational 
approach to next-generation cancer therapy. Curr Opin Oncol, 2013. 25(1): p. 50-1. 
68. Burrell, R.A., et al., The causes and consequences of genetic heterogeneity in cancer 
evolution. Nature, 2013. 501(7467): p. 338-45. 
69. Guarneri, V. and P.F. Conte, The curability of breast cancer and the treatment of advanced 
disease. Eur J Nucl Med Mol Imaging, 2004. 31 Suppl 1: p. S149-61. 
70. Cho, H., et al., Polymeric micelles for multi-drug delivery in cancer. AAPS PharmSciTech, 
2015. 16(1): p. 10-20. 
71. Chou, T.C., Drug combination studies and their synergy quantification using the Chou-
Talalay method. Cancer Res, 2010. 70(2): p. 440-6. 
72. Chou, T.C. and P. Talalay, Quantitative analysis of dose-effect relationships: the combined 
effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul, 1984. 22: p. 27-55. 
73. Chou, T.C. and P. Talalay, Generalized equations for the analysis of inhibitions of 
Michaelis-Menten and higher-order kinetic systems with two or more mutually exclusive 
and nonexclusive inhibitors. Eur J Biochem, 1981. 115(1): p. 207-16. 
74. Weiss, A., et al., A streamlined search technology for identification of synergistic drug 
combinations. Sci Rep, 2015. 5: p. 14508. 
75. Cho, H., T.C. Lai, and G.S. Kwon, Poly(ethylene glycol)-block-poly(epsilon-caprolactone) 
micelles for combination drug delivery: evaluation of paclitaxel, cyclopamine and 
gossypol in intraperitoneal xenograft models of ovarian cancer. J Control Release, 2013. 
166(1): p. 1-9. 
  185 
76. Hasenstein, J.R., et al., Antitumor activity of Triolimus: a novel multidrug-loaded micelle 
containing Paclitaxel, Rapamycin, and 17-AAG. Mol Cancer Ther, 2012. 11(10): p. 2233-
42. 
77. Shin, H.C., et al., A 3-in-1 polymeric micelle nanocontainer for poorly water-soluble drugs. 
Mol Pharm, 2011. 8(4): p. 1257-65. 
78. Shin, M., et al., Donor morbidity including biliary complications in living-donor liver 
transplantation: single-center analysis of 827 cases. Transplantation, 2012. 93(9): p. 942-
8. 
79. Bae, Y., et al., Mixed pH-sensitive polymeric micelles for combination drug delivery. 
Pharm Res, 2010. 27(11): p. 2421-32. 
80. Duncan, R., Polymer conjugates as anticancer nanomedicines. Nat Rev Cancer, 2006. 6(9): 
p. 688-701. 
81. Greco, F. and M.J. Vicent, Combination therapy: opportunities and challenges for 
polymer-drug conjugates as anticancer nanomedicines. Adv Drug Deliv Rev, 2009. 61(13): 
p. 1203-13. 
82. Na, H.S., et al., Combination antitumor effects of micelle-loaded anticancer drugs in a CT-
26 murine colorectal carcinoma model. Int J Pharm, 2010. 383(1-2): p. 192-200. 
83. Wang, H., et al., Enhanced anti-tumor efficacy by co-delivery of doxorubicin and paclitaxel 
with amphiphilic methoxy PEG-PLGA copolymer nanoparticles. Biomaterials, 2011. 
32(32): p. 8281-90. 
84. Chitkara, D., et al., Micellar delivery of cyclopamine and gefitinib for treating pancreatic 
cancer. Mol Pharm, 2012. 9(8): p. 2350-7. 
85. Katragadda, U., et al., Multi-drug delivery to tumor cells via micellar nanocarriers. Int J 
Pharm, 2011. 419(1-2): p. 281-6. 
86. Desale, S.S., et al., Biodegradable hybrid polymer micelles for combination drug therapy 
in ovarian cancer. J Control Release, 2013. 171(3): p. 339-48. 
87. Jang, S.H., et al., Drug delivery and transport to solid tumors. Pharm Res, 2003. 20(9): p. 
1337-50. 
88. Lu, D., et al., Tumor priming enhances delivery and efficacy of nanomedicines. J 
Pharmacol Exp Ther, 2007. 322(1): p. 80-8. 
  186 
89. Truong, N.P., et al., The importance of nanoparticle shape in cancer drug delivery. Expert 
Opin Drug Deliv, 2015. 12(1): p. 129-42. 
90. Lee, S.E., et al., Paclitaxel nanosuspensions for targeted chemotherapy - nanosuspension 
preparation, characterization, and use. Pharm Dev Technol, 2014. 19(4): p. 438-53. 
91. Mitragotri, S., In drug delivery, shape does matter. Pharm Res, 2009. 26(1): p. 232-4. 
92. Christian, D.A., et al., Flexible filaments for in vivo imaging and delivery: persistent 
circulation of filomicelles opens the dosage window for sustained tumor shrinkage. Mol 
Pharm, 2009. 6(5): p. 1343-52. 
93. Bouzas, V., et al., Nontoxic impact of PEG-coated gold nanospheres on functional 
pulmonary surfactant-secreting alveolar type II cells. Nanotoxicology, 2014. 8(8): p. 813-
23. 
94. Geng, Y., et al., Shape effects of filaments versus spherical particles in flow and drug 
delivery. Nat Nanotechnol, 2007. 2(4): p. 249-55. 
95. Gabizon, A., H. Shmeeda, and Y. Barenholz, Pharmacokinetics of pegylated liposomal 
Doxorubicin: review of animal and human studies. Clin Pharmacokinet, 2003. 42(5): p. 
419-36. 
96. Gentile, F., et al., The effect of shape on the margination dynamics of non-neutrally buoyant 
particles in two-dimensional shear flows. J Biomech, 2008. 41(10): p. 2312-8. 
97. Lee, S.Y., M. Ferrari, and P. Decuzzi, Shaping nano-/micro-particles for enhanced 
vascular interaction in laminar flows. Nanotechnology, 2009. 20(49): p. 495101. 
98. MacDonald, I.C., E.E. Schmidt, and A.C. Groom, The high splenic hematocrit: a 
rheological consequence of red cell flow through the reticular meshwork. Microvasc Res, 
1991. 42(1): p. 60-76. 
99. Zhou, Z., et al., Linear-dendritic drug conjugates forming long-circulating nanorods for 
cancer-drug delivery. Biomaterials, 2013. 34(22): p. 5722-35. 
100. Kim, Y., et al., Polymeric worm micelles as nano-carriers for drug delivery. 
Nanotechnology, 2005. 16(7): p. S484-91. 
101. Shukla, A.K., et al., Visualization of arrestin recruitment by a G-protein-coupled receptor. 
Nature, 2014. 512(7513): p. 218-222. 
  187 
102. Daum, N., et al., Novel approaches for drug delivery systems in nanomedicine: effects of 
particle design and shape. Wiley Interdiscip Rev Nanomed Nanobiotechnol, 2012. 4(1): p. 
52-65. 
103. Caldorera-Moore, M., et al., Designer nanoparticles: incorporating size, shape and 
triggered release into nanoscale drug carriers. Expert Opin Drug Deliv, 2010. 7(4): p. 
479-95. 
104. Liu, Z., et al., In vivo biodistribution and highly efficient tumour targeting of carbon 
nanotubes in mice. Nat Nanotechnol, 2007. 2(1): p. 47-52. 
105. Arnida, et al., Geometry and surface characteristics of gold nanoparticles influence their 
biodistribution and uptake by macrophages. European Journal of Pharmaceutics and 
Biopharmaceutics, 2011. 77(3): p. 417-423. 
106. Akiyama, Y., et al., Conversion of rod-shaped gold nanoparticles to spherical forms and 
their effect on biodistribution in tumor-bearing mice. Nanoscale Res Lett, 2012. 7(1): p. 
565. 
107. Black, K.C., et al., Radioactive 198Au-doped nanostructures with different shapes for in 
vivo analyses of their biodistribution, tumor uptake, and intratumoral distribution. ACS 
Nano, 2014. 8(5): p. 4385-94. 
108. Chauhan, V.P., et al., Fluorescent nanorods and nanospheres for real-time in vivo probing 
of nanoparticle shape-dependent tumor penetration. Angew Chem Int Ed Engl, 2011. 
50(48): p. 11417-20. 
109. Hu, X., et al., Polyprodrug amphiphiles: hierarchical assemblies for shape-regulated 
cellular internalization, trafficking, and drug delivery. J Am Chem Soc, 2013. 135(46): p. 
17617-29. 
110. Champion, J.A. and S. Mitragotri, Shape induced inhibition of phagocytosis of polymer 
particles. Pharm Res, 2009. 26(1): p. 244-9. 
111. Zhang, Y., et al., Permission to enter cell by shape: nanodisk vs nanosphere. ACS Appl 
Mater Interfaces, 2012. 4(8): p. 4099-105. 
112. Dalhaimer, P., et al., Targeted worm micelles. Biomacromolecules, 2004. 5(5): p. 1714-9. 
113. Champion, J.A. and S. Mitragotri, Role of target geometry in phagocytosis. Proc Natl Acad 
Sci U S A, 2006. 103(13): p. 4930-4. 
  188 
114. Yoo, J.W., N. Doshi, and S. Mitragotri, Endocytosis and Intracellular Distribution of 
PLGA Particles in Endothelial Cells: Effect of Particle Geometry. Macromol Rapid 
Commun, 2010. 31(2): p. 142-8. 
115. Kolhar, P., N. Doshi, and S. Mitragotri, Polymer nanoneedle-mediated intracellular drug 
delivery. Small, 2011. 7(14): p. 2094-100. 
116. Alkilany, A.M., S.E. Lohse, and C.J. Murphy, The gold standard: gold nanoparticle 
libraries to understand the nano-bio interface. Acc Chem Res, 2013. 46(3): p. 650-61. 
117. Tsai, C.P., et al., High-contrast paramagnetic fluorescent mesoporous silica nanorods as 
a multifunctional cell-imaging probe. Small, 2008. 4(2): p. 186-91. 
118. Zhao, X., et al., Cytotoxicity of hydroxyapatite nanoparticles is shape and cell dependent. 
Arch Toxicol, 2013. 87(6): p. 1037-52. 
119. Oh, W.K., et al., Shape-dependent cytotoxicity and proinflammatory response of poly(3,4-
ethylenedioxythiophene) nanomaterials. Small, 2010. 6(7): p. 872-9. 
120. Oltra, N.S., et al., Filomicelles in nanomedicine - from flexible, fragmentable, and ligand-
targetable drug carrier designs to combination therapy for brain tumors. Journal of 
Materials Chemistry B, 2013. 1(39): p. 5177-5185. 
121. Chen, T., et al., A strategy in the design of micellar shape for cancer therapy. Adv Healthc 
Mater, 2012. 1(2): p. 214-24. 
122. Karagoz, B., C. Boyer, and T.P. Davis, Simultaneous polymerization-induced self-
assembly (PISA) and guest molecule encapsulation. Macromol Rapid Commun, 2014. 
35(4): p. 417-21. 
123. Karagoz, B., et al., Polymerization-Induced Self-Assembly (PISA) - control over the 
morphology of nanoparticles for drug delivery applications. Polymer Chemistry, 2014. 
5(2): p. 350-355. 
124. Huang, X., et al., Cancer cell imaging and photothermal therapy in the near-infrared 
region by using gold nanorods. J Am Chem Soc, 2006. 128(6): p. 2115-20. 
125. Chu, K.S., et al., Plasma, tumor and tissue pharmacokinetics of Docetaxel delivered via 
nanoparticles of different sizes and shapes in mice bearing SKOV-3 human ovarian 
carcinoma xenograft. Nanomedicine, 2013. 9(5): p. 686-93. 
126. overview of clinical trials available via [cited 2010 01-27]; Available from: 
http://www.clinicaltrials.org/. 
  189 
127. Saif, M.W., et al., Phase II clinical trial of paclitaxel loaded polymeric micelle in patients 
with advanced pancreatic cancer. Cancer Invest, 2010. 28(2): p. 186-94. 
128. Kim, D.W., et al., Multicenter phase II trial of Genexol-PM, a novel Cremophor-free, 
polymeric micelle formulation of paclitaxel, with cisplatin in patients with advanced non-
small-cell lung cancer. Ann Oncol, 2007. 18(12): p. 2009-14. 
129. Hamaguchi, T., et al., A phase I and pharmacokinetic study of NK105, a paclitaxel-
incorporating micellar nanoparticle formulation. British Journal of Cancer, 2007. 97(2): 
p. 170-176. 
130. Matsumura, Y., Poly (amino acid) micelle nanocarriers in preclinical and clinical studies. 
Adv Drug Deliv Rev, 2008. 60(8): p. 899-914. 
131. Khayat, D., E.C. Antoine, and D. Coeffic, Taxol in the management of cancers of the breast 
and the ovary. Cancer Invest, 2000. 18(3): p. 242-60. 
132. Rowinsky, E.K. and R.C. Donehower, Paclitaxel (taxol). N Engl J Med, 1995. 332(15): p. 
1004-14. 
133. Caldas, C. and W.P. McGuire, 3rd, Paclitaxel (Taxol) therapy in ovarian carcinoma. 
Semin Oncol, 1993. 20(4 Suppl 3): p. 50-5. 
134. Tamura, T., et al., Phase I study of paclitaxel by three-hour infusion: hypotension just after 
infusion is one of the major dose-limiting toxicities. Jpn J Cancer Res, 1995. 86(12): p. 
1203-9. 
135. Matsumura, Y., Polymeric micellar delivery systems in oncology. Jpn J Clin Oncol, 2008. 
38(12): p. 793-802. 
136. Wilson, R.H., R. Plummer, and J. Adam, Phase I and pharmacokinetic study of NC-6004, 
a new platinum entity of cisplatin-conjugated polymer forming micelles. Vol. 26. 2008. 
137. Matsumura, Y. and K. Kataoka, Preclinical and clinical studies of anticancer agent-
incorporating polymer micelles. Cancer Sci, 2009. 100(4): p. 572-9. 
138. Sutton, D., et al., Functionalized micellar systems for cancer targeted drug delivery. Pharm 
Res, 2007. 24(6): p. 1029-46. 
139. Supratek Pharm Inc. Pipepline available via.  [cited 2009 10-12]; Available from: 
http://www.sopratek.com/. 
  190 
140. Ledford, H., Bankruptcy filing worries developers of nanoparticle cancer drugs. Nature, 
2016. 533(7603): p. 304-5. 
141. Von Hoff, D.D., et al., Phase I Study of PSMA-Targeted Docetaxel-Containing 
Nanoparticle BIND-014 in Patients with Advanced Solid Tumors. Clin Cancer Res, 2016. 
22(13): p. 3157-63. 
142. Rafi, M., et al., Polymeric micelles incorporating (1,2-diaminocyclohexane)platinum (II) 
suppress the growth of orthotopic scirrhous gastric tumors and their lymph node 
metastasis. J Control Release, 2012. 159(2): p. 189-96. 
143. Talelli, M., et al., Intrinsically active nanobody-modified polymeric micelles for tumor-
targeted combination therapy. Biomaterials, 2013. 34(4): p. 1255-60. 
144. Wani, M.C., et al., Plant antitumor agents. VI. The isolation and structure of taxol, a novel 
antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc, 1971. 93(9): p. 
2325-7. 
145. Zhang, Z., L. Mei, and S.S. Feng, Paclitaxel drug delivery systems. Expert Opin Drug Deliv, 
2013. 10(3): p. 325-40. 
146. Zasadil, L.M., et al., Cytotoxicity of paclitaxel in breast cancer is due to chromosome 
missegregation on multipolar spindles. Sci Transl Med, 2014. 6(229): p. 229ra43. 
147. Liggins, R.T., W.L. Hunter, and H.M. Burt, Solid-state characterization of paclitaxel. J 
Pharm Sci, 1997. 86(12): p. 1458-63. 
148. Brouwer, E., et al., Measurement of fraction unbound paclitaxel in human plasma. Drug 
Metab Dispos, 2000. 28(10): p. 1141-5. 
149. Sparreboom, A., et al., Nonlinear pharmacokinetics of paclitaxel in mice results from the 
pharmaceutical vehicle Cremophor EL. Cancer Res, 1996. 56(9): p. 2112-5. 
150. Yamamoto, Y., I. Kawano, and H. Iwase, Nab-paclitaxel for the treatment of breast cancer: 
efficacy, safety, and approval. OncoTargets and therapy, 2011. 4: p. 123-136. 
151. Sparreboom, A., et al., Comparative preclinical and clinical pharmacokinetics of a 
cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel 
formulated in Cremophor (Taxol). Clin Cancer Res, 2005. 11(11): p. 4136-43. 
152. Rugo, H.S.B., W. T.; Moreno-Aspitia, A.; Lyss, A. P.; Cirrincione, C.; Mayer, E. L.; 
Naughton, M.; Layman, R. M.; Carey, L. A.; and Somer, R. A. . in ASCO Annual Meeting 
Proceedings. 2012. 
  191 
153. Schulz, A., et al., Drug-induced morphology switch in drug delivery systems based on 
poly(2-oxazoline)s. ACS Nano, 2014. 8(3): p. 2686-96. 
154. Khandare, J., et al., Structure-biocompatibility relationship of dendritic polyglycerol 
derivatives. Biomaterials, 2010. 31(15): p. 4268-77. 
155. Senthil, M., et al., A shortened activated partial thromboplastin time predicts the risk of 
catheter-associated venous thrombosis in cancer patients. Thromb Res, 2014. 134(1): p. 
165-8. 
156. Hawkins, M.J., P. Soon-Shiong, and N. Desai, Protein nanoparticles as drug carriers in 
clinical medicine. Adv Drug Deliv Rev, 2008. 60(8): p. 876-85. 
157. Luxenhofer, R., et al., Structure-property relationship in cytotoxicity and cell uptake of 
poly(2-oxazoline) amphiphiles. J Control Release, 2011. 153(1): p. 73-82. 
158. Luxenhofer, R., et al., Poly(2-oxazoline)s as Polymer Therapeutics. Macromolecular rapid 
communications, 2012. 33(19): p. 1613-1631. 
159. Kierstead, P.H., et al., The effect of polymer backbone chemistry on the induction of the 
accelerated blood clearance in polymer modified liposomes. J Control Release, 2015. 213: 
p. 1-9. 
160. He, Z., et al., Poly(2-oxazoline) based micelles with high capacity for 3rd generation 
taxoids: preparation, in vitro and in vivo evaluation. J Control Release, 2015. 208: p. 67-
75. 
161. Chen, Y., et al., Comparative assessment of the stability of nonfouling poly(2-methyl-2-
oxazoline) and poly(ethylene glycol) surface films: an in vitro cell culture study. 
Biointerphases, 2014. 9(3): p. 031003. 
162. He, Z., et al., A Low Protein Binding Cationic Poly(2-oxazoline) as Non-Viral Vector. 
Macromol Biosci, 2015. 15(7): p. 1004-20. 
163. Ulbricht, J., R. Jordan, and R. Luxenhofer, On the biodegradability of polyethylene glycol, 
polypeptoids and poly(2-oxazoline)s. Biomaterials, 2014. 35(17): p. 4848-61. 
164. Bauer, M., et al., In vitro hemocompatibility and cytotoxicity study of poly(2-methyl-2-
oxazoline) for biomedical applications. Journal of Polymer Science Part A: Polymer 
Chemistry, 2013. 51(8): p. 1816-1821. 
165. Eskow Jaunarajs, K.L., et al., Rotigotine polyoxazoline conjugate SER-214 provides robust 
and sustained antiparkinsonian benefit. Mov Disord, 2013. 28(12): p. 1675-82. 
  192 
166. Kyluik-Price, D.L., L. Li, and M.D. Scott, Comparative efficacy of blood cell 
immunocamouflage by membrane grafting of methoxypoly(ethylene glycol) and 
polyethyloxazoline. Biomaterials, 2014. 35(1): p. 412-22. 
167. Tong, J., et al., Conjugates of superoxide dismutase 1 with amphiphilic poly(2-oxazoline) 
block copolymers for enhanced brain delivery: synthesis, characterization and evaluation 
in vitro and in vivo. Mol Pharm, 2013. 10(1): p. 360-77. 
168. Zhang, N., et al., Tailored poly(2-oxazoline) polymer brushes to control protein adsorption 
and cell adhesion. Macromol Biosci, 2012. 12(7): p. 926-36. 
169. Gaertner, F.C., et al., Synthesis, biodistribution and excretion of radiolabeled poly(2-alkyl-
2-oxazoline)s. Journal of Controlled Release, 2007. 119(3): p. 291-300. 
170. Shi, Y., et al., Complete Regression of Xenograft Tumors upon Targeted Delivery of 
Paclitaxel via Pi-Pi Stacking Stabilized Polymeric Micelles. ACS Nano, 2015. 9(4): p. 
3740-52. 
171. Leonessa, F., et al., MDA435/LCC6 and MDA435/LCC6MDR1: ascites models of human 
breast cancer. Br J Cancer, 1996. 73(2): p. 154-61. 
172. Prat, A., et al., Phenotypic and molecular characterization of the claudin-low intrinsic 
subtype of breast cancer. Breast Cancer Res, 2010. 12(5): p. R68. 
173. Herschkowitz, J.I., et al., Comparative oncogenomics identifies breast tumors enriched in 
functional tumor-initiating cells. Proc Natl Acad Sci U S A, 2012. 109(8): p. 2778-83. 
174. Usary, J., et al., Predicting drug responsiveness in human cancers using genetically 
engineered mice. Clin Cancer Res, 2013. 19(17): p. 4889-99. 
175. Haakensen, V.D., et al., Gene expression profiles of breast biopsies from healthy women 
identify a group with claudin-low features. BMC Med Genomics, 2011. 4: p. 77. 
176. Song, G., et al., Effects of tumor microenvironment heterogeneity on nanoparticle 
disposition and efficacy in breast cancer tumor models. Clin Cancer Res, 2014. 20(23): p. 
6083-95. 
177. Cabral, H., et al., Accumulation of sub-100 nm polymeric micelles in poorly permeable 
tumours depends on size. Nat Nanotechnol, 2011. 6(12): p. 815-23. 
178. Woodle, M.C., C.M. Engbers, and S. Zalipsky, New amphipatic polymer-lipid conjugates 
forming long-circulating reticuloendothelial system-evading liposomes. Bioconjug Chem, 
1994. 5(6): p. 493-6. 
  193 
179. Viegas, T.X., et al., Polyoxazoline: chemistry, properties, and applications in drug delivery. 
Bioconjug Chem, 2011. 22(5): p. 976-86. 
180. Seo, Y., et al., Poly(2-oxazoline) block copolymer based formulations of taxanes: effect of 
copolymer and drug structure, concentration, and environmental factors. Polymers for 
Advanced Technologies, 2015. 26(7): p. 837-850. 
181. Miao, L., et al., Nanoparticles with Precise Ratiometric Co-Loading and Co-Delivery of 
Gemcitabine Monophosphate and Cisplatin for Treatment of Bladder Cancer. Adv Funct 
Mater, 2014. 24(42): p. 6601-6611. 
182. Kalemkerian, G.P., et al., Small cell lung cancer. J Natl Compr Canc Netw, 2013. 11(1): 
p. 78-98. 
183. Chan, B.A. and J.I.G. Coward, Chemotherapy advances in small-cell lung cancer. Journal 
of Thoracic Disease, 2013. 5(Suppl 5): p. S565-S578. 
184. Chou, T.C., Theoretical basis, experimental design, and computerized simulation of 
synergism and antagonism in drug combination studies. Pharmacol Rev, 2006. 58(3): p. 
621-81. 
185. Miura, Y., et al., Cyclic RGD-linked polymeric micelles for targeted delivery of platinum 
anticancer drugs to glioblastoma through the blood-brain tumor barrier. ACS Nano, 2013. 
7(10): p. 8583-92. 
186. Dhar, S., et al., Targeted delivery of cisplatin to prostate cancer cells by aptamer 
functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles. Proc Natl Acad Sci U S A, 2008. 
105(45): p. 17356-61. 
187. Giandomenico, C.M., et al., Carboxylation of Kinetically Inert Platinum(IV) Hydroxy 
Complexes. An Entr.acte.ee into Orally Active Platinum(IV) Antitumor Agents. Inorg Chem, 
1995. 34(5): p. 1015-21. 
188. Barnes, K.R., A. Kutikov, and S.J. Lippard, Synthesis, characterization, and cytotoxicity 
of a series of estrogen-tethered platinum(IV) complexes. Chem Biol, 2004. 11(4): p. 557-
64. 
189. McEvoy, G.K.e., American Hospital Formulary Service - Drug Information 92. Bethesda, 
MD: American Society of Hospital Pharmacists, Inc.,, 1992: p. p. 524. 
190. Tee, A.R. and C.G. Proud, DNA-damaging agents cause inactivation of translational 
regulators linked to mTOR signalling. Oncogene, 2000. 19(26): p. 3021-31. 
  194 
191. Johnson, S.W., et al., Increased platinum-DNA damage tolerance is associated with 
cisplatin resistance and cross-resistance to various chemotherapeutic agents in unrelated 
human ovarian cancer cell lines. Cancer Res, 1997. 57(5): p. 850-6. 
192. Tian, J., et al., Nanoparticle delivery of chemotherapy combination regimen improves the 
therapeutic efficacy in mouse models of lung cancer. Nanomedicine, 2017. 13(3): p. 1301-
1307. 
193. Pillai, R.N. and T.K. Owonikoko, Small Cell Lung Cancer: Therapies and Targets. 
Seminars in oncology, 2014. 41(1): p. 133-142. 
194. Montecucco, A., F. Zanetta, and G. Biamonti, Molecular mechanisms of etoposide. EXCLI 
Journal, 2015. 14: p. 95-108. 
195. Arnida, et al., Geometry and surface characteristics of gold nanoparticles influence their 
biodistribution and uptake by macrophages. Eur J Pharm Biopharm, 2011. 77(3): p. 417-
23. 
196. Mullner, M., et al., Size and rigidity of cylindrical polymer brushes dictate long circulating 
properties in vivo. ACS Nano, 2015. 9(2): p. 1294-304. 
197. Geng, Y.A.N., et al., Shape effects of filaments versus spherical particles in flow and drug 
delivery. Nature nanotechnology, 2007. 2(4): p. 249-255. 
198. Nair, P.R., et al., Filomicelles from aromatic diblock copolymers increase paclitaxel-
induced tumor cell death and aneuploidy compared with aliphatic copolymers. 
Nanomedicine, 2016. 11(12): p. 1551-1569. 
199. Ozols, R.F., Advanced ovarian cancer: a clinical update on first-line treatment, recurrent 
disease, and new agents. J Natl Compr Canc Netw, 2004. 2 Suppl 2: p. S60-73. 
200. Rhee, E.J., H.S. Jeong, and S.S. Lee, Efficacy of Combination Chemotherapy with 
Paclitaxel and Cisplatin in Patients with Advanced Non-Small Cell Lung Cancer. Cancer 
Res Treat, 2002. 34(1): p. 28-33. 
201. Schiff, P.B., J. Fant, and S.B. Horwitz, Promotion of microtubule assembly in vitro by taxol. 
Nature, 1979. 277(5698): p. 665-7. 
202. Florea, A.M. and D. Busselberg, Cisplatin as an anti-tumor drug: cellular mechanisms of 
activity, drug resistance and induced side effects. Cancers (Basel), 2011. 3(1): p. 1351-71. 
203. Siddik, Z.H., Cisplatin: mode of cytotoxic action and molecular basis of resistance. 
Oncogene, 2003. 22(47): p. 7265-79. 
  195 
204. Hall, M.D., et al., Say no to DMSO: dimethylsulfoxide inactivates cisplatin, carboplatin, 
and other platinum complexes. Cancer Res, 2014. 74(14): p. 3913-22. 
205. Lancet, J.E., et al., Final results of a phase III randomized trial of CPX-351 versus 7+ 3 in 
older patients with newly diagnosed high risk (secondary) AML. 2016, American Society 
of Clinical Oncology. 
206. Qin, M., et al., Overcoming cancer multidrug resistance by codelivery of doxorubicin and 
verapamil with hydrogel nanoparticles. Macromol Biosci, 2014. 14(8): p. 1106-15. 
207. Ma, L., M. Kohli, and A. Smith, Nanoparticles for combination drug therapy. ACS Nano, 
2013. 7(11): p. 9518-25. 
208. Luxenhofer, R., et al., Poly(2-oxazoline)s as polymer therapeutics. Macromol Rapid 
Commun, 2012. 33(19): p. 1613-31. 
209. Y. Han, Z.H., A. Schulz, T.K. Bronich, R. Jordan, R. Luxenhofer, A.V. Kabanov,, 
Synergistic combinations of multiple chemotherapeutic agents in high capacity poly(2-
oxazoline) micelles. Mol. Pharm., 2012. 9 (2012) 2302-2313. 
210. He, Z., et al., A High Capacity Polymeric Micelle of Paclitaxel: Implication of High Dose 
Drug Therapy to Safety and In Vivo Anti-Cancer Activity. Biomaterials, 2016. 
211. Rosati, G., et al., A phase II study of paclitaxel/cisplatin combination in patients with 
metastatic breast cancer refractory to anthracycline-based chemotherapy. Tumori, 2000. 
86(3): p. 207-10. 
212. Paal, K., J. Muller, and L. Hegedus, High affinity binding of paclitaxel to human serum 
albumin. Eur J Biochem, 2001. 268(7): p. 2187-91. 
213. Miele, E., et al., Albumin-bound formulation of paclitaxel (Abraxane ABI-007) in the 
treatment of breast cancer. Int J Nanomedicine, 2009. 4: p. 99-105. 
 
